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1.1  Introduction 
Biological systems are continuously exchanging messages with their environment, both 
chemical and electrical in nature 1. The biological effects that result from interactions 
between biomacromolecules and small molecules, hormones, co-factors and ligands are 
based on physical contacts between the interactors and specific interaction between two 
or more molecules which requests molecular recognition 2. Molecular recognition, thus, 
plays pivotal roles in all biological systems as it is involved in essential elements of life 
affecting metabolism, cellular signaling, immune responses, etc. For example, enzymes 
which catalyze chemical reactions in biological systems do so by bringing their substrates 
in close proximity within the active site so that reactions can be accelerated by lowering 
the activation energy 3-5. 
The genome of unicellular S. cerevisiae has currently been estimated to consist of 5,858 
genes and it was concluded that in an average yeast cell the number of proteins, i.e. the 
gene products, would amount to approximately 42 million 6. It is legitimate to reason that in 
all organisms, and the more so in more complex multicellular organism like humans, the 
wide range of molecules present in eukaryotic cells must possess unique features that 
permit recognition which, consequently, leads to specific interactions. In other words, in 
order to achieve sanity in a living system consisting of some millions of molecules, there 
must be certain features or defined properties of these molecules that cause them to 
differentiate and recognize their interacting partners and then bind to them, once a 
matching recognition pattern is revealed. 
All of the different classes of biomacromolecules express recognition patterns, including 
protein – carbohydrate ligand systems 7 and DNA / RNA − protein assemblies (e.g. DNA 
and the zinc-finger protein assembly) 8,9, to name only a few. All these molecular 
interactions are innately encoded in the molecule´s structure which by itself is encoded in 
the genome, and recognition motifs are thereby reliably provided to the organism by simply 
expressing and/or producing the respective biomolecules.  
 
1.1.1 Molecular recognition in biomacromolecules 
Whereas “recognition” has been proposed to apply to both, inter- and intramolecular 
phenomena, alternative terminologies such as “host-guest chemistry”, “supramolecular 
chemistry”, and “self-assembly” are limited to intermolecular processes; the first two by 
definition and the third by convention 2.  
 
The Three-Dimensional Force Code 
The interaction between macromolecules like proteins in general, and between antibodies 
and antigens in particular, can be described at various structural levels (Table 1). The 
specific binding of proteins to other proteins does not generally rely on all the amino acids 
located at the contact interface (paratope – epitope in case of antibody recognition), but on 
a limited set of atoms of some of the key amino acid residues of the epitope or the 
paratope. In order for molecular recognition of their cognate partners, specific atoms on 
binding interfaces must become part of a “three-dimensional force code” (not to be 
confused with the “three dimensional N-body code” 10). The three-dimensional force code 
to which is referred to in this thesis is situated or stored as hotspot(s) on the surface of the 
interacting biomacromolecules, such as proteins. The atoms which constitute the three-
dimensional force code are therefore to be elucidated in order to understand their altruistic 
nature and ultimately to obtain detailed knowledge on molecular recognition.  
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The three-dimensional force code is what determines which molecule or set of molecules 
is being recognized and bound to e.g. by a given protein. Moreover, the three dimensional 
force code not only defines specificity but also determines how strong interactions 
between binding partners shall be. General forces that keep molecules in physical contact 
upon molecular recognition occur mainly through hydrogen bonds, ionic forces, Van der 
Waals forces as well as by hydrophobic effects between the respective surface atoms. In 
other words, the three dimensional force code serves as the “eye” with which a molecule 
“sees” and simultaneously as the “hand” with which it holds on or clings to its binders. 
 




donor  acceptor 
domain b) antibody´s VL and VH (Ab)  antigen (Ag) 
sub-domain paratope (para)  epitope (epi) 
peptide complementarity determining regions 
(CDR) 
 complex determining peptides 
(CDP) 
residue specificity determining residues 
(SDR) 
 specificity determining positions 
(SDP) 
atom force donors and/or receptors  
(FDR) 
 force depending patches  
(FDP) 
a) exemplified on antibody – antigen pairs 
b) equals the molecular level in single domain proteins 
 
In case of antibody - antigen interaction the three dimensional force code which is located 
within the antibody´s paratope defines both, the antibody´s specificity and its affinity. The 
paratope on the antibody molecule, i.e. the region that recognizes and permits antigen 
binding to occur is also called antigen binding site 11. Within an antibody molecule, the six 
hypervariable loops, termed the complementarity determining regions (CDRs), are widely 
accepted as being the most responsible for antigen recognition. They together form the 
paratope. Even though the term specificity determining residues (SDRs) has been 
previously used in some cases to refer to key amino acid residues that determine the 
specificity of an antibody12-14, specificity determining residues (SDRs) 15,16 as well as 
specificity determining positions (SDPs) 17,18 have been used interchangeably to refer to 
the amino acid residues that are very important for molecular binding specificity of a 
protein 15-19. For improving clarity, the two terms are differentiated in this thesis, such that 
when speaking of specificity determining residues (SDRs) amino acid residues which are 
located on the antibody surface are addressed, whereas the term specificity determining 
positions (SDPs) shall be reserved to describe regions of the antigen´s epitope. To zoom 
in further, the set of atoms of the specificity determining residues (SDRs) on the antibody 
molecule which make intimate contacts with the antigen surface and, in addition, supply 
binding forces are described as those atoms that function as force donors and/or force 
receptors (FDRs). 
The antigens which are recognized and bound by antibodies vary widely in both their 
chemical and physical properties, such as in size, hydrophilicity / hydrophobicity, sugar or 
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amino acid composition, etc. 20. Typical antigens encountered by antibodies can be 
proteins, such as receptors which are expressed on cell surfaces, carbohydrates on 
bacterial and viral cell surfaces, hormones, chemical compounds, or nucleic acid 
structures 21-24. The area / region on an antigen molecule that interacts or binds with an 
antibody is known as the “antigenic determinant” or the epitope 25. In analogy to CDRs on 
antibodies, the respective peptides that are included in the antigen´s epitope are named 
complex determining peptides (CDPs). The different arrangements of complex determining 
peptides (CDPs) on the antigen surface that one can distinguish, allows to subdivide 
epitopes into different classes (Fig. 1). As previously summarized 25, epitopes may be 










However, defining epitope subclasses, i.e the complex determining peptides (CDPs) along 
a proteins´s higher order structural elements 26, may perhaps be preferable. It is suggested 
to consider a “consecutive epitope” as an epitope which consists of one CDP that solely 
comprises primary structure elements (i). In analogy, a “hybrid” epitope also consists of 
one CDP which, however, is kept in position by secondary structure motifs like alpha 
helices (ii). At last, an “assembled” epitope consists of more than one CDP and is 
constructed by the tertiary structure of the antigen (iii).  
Finally, the set of atoms within the antigens complex determining peptides (CDPs) are 
then termed, again in analogy to the respective atoms on the antibody´s CDRs “force 
depending patches (FDPs)”. Their positioning in space is predetermined by the protein 
surface which itself is defined by the protein fold that results as predetermined higher order 
structure which is formed by the amino acid sequence which finally is encoded in the 
respective genome. FDPs are typically identified by X-ray crystallography or by NMR as 
being in contact with atoms of the antibody in such distances which are consistent with 
those from known bond structures, e.g. hydrogen bonds have a typical length of ca. 3 - 4 Å 
in proteins 27,28. FDPs have in some cases been termed “structural epitopes” 11.  
 
1.1.2 The humoral immune system 
The humoral immune system involves macromolecules which are found in extracellular 
spaces of the body, and is largely mediated by secreted immunoglobulins (antibodies) of 
the B cells and/or the plasma cells 29. Complement proteins and certain antimicrobial 







Fig. 1 The three dimensional epitope structures on a protein antigen molecule surface. 
A primary structure motif defines a “consecutive” epitope (i, red), a secondary structure 
motif determines a “hybrid” epitope (ii, green), and a tertiary structure motif is needed 




aspect of humoral immunity that involves antibodies is often referred to as antibody - 
mediated immune response. Antibodies (also named immunoglobulins) are glycoproteins 
naturally amplified in response to invading foreign particles such as bacteria, viruses, and 
other microorganisms 31,32. As many of the bacteria that cause infections multiply in the 
extracellular space, and most intracellular pathogens spread by moving from cell to cell 
through extracellular fluids, the extracellular spaces are protected by the humoral immune 
response during a microbial attack 29.  
One must remember that even before an individual´s immune system comes into contact 
with a foreign particle (antigen), the B cells of the immune system is capable of producing 
enormous repertoires of antibodies 29,33. The antibodies, which are part of the humoral 
immune system, are generated to potentially recognize a plethora of antigens beforehand. 
One must keep in mind though, that just like any other cellular protein, antibodies are 
encoded by genes. The final genes responsible for encoding antibodies are assembled on 
the DNA-level from separate gene segments during B cell development 33. This irreversible 
process ensures that an individual can generate a sufficiently diverse repertoire of 
antibodies to react with the numerous toxic and pathogenic organisms present in the 
environment. The joining of antibody gene segments before they are transcribed, as well 
as the assembly of heavy and light chains during antibody formation has been described in 
several papers and textbooks in detail 33-36.  
During B cell development in the bone marrow, the antibody molecules are at first 
embedded into the B cell membrane as receptors and then in a slightly different form are 
later produced as secreted molecules 37. Depending on the strength and duration of the B 
cell antigen receptor (BCR) signaling, upon antigen binding, the BCRs may or may not 
require co-stimulatory signals for B cell activation to proliferate and differentiate into either 
memory cells or antibody-secreting effector cells 37. By this, only those B cells that 
encounter an antigen to which their receptor binds will be activated to proliferate and 
differentiate into effector cells. In sum, quite to the contrary of other protein – protein 
interactions, antibody − antigen recognition 38 is based on a learning system. The immunity 
developed as a result of this learning system, known as the clonal selection theory, is a 
central principle in adaptive immunity 39.  
 
1.1.3 Structure – function correlation of binding sites on immunoglobulin G 
Antibodies play a critical role in the immune system’s defense against infection and 
disease 21,32. There are five classes of antibodies known to occur in mammals (IgG, IgA, 
IgM, IgE and IgD) 40,41. Subclasses of IgG and IgA are also known to exist 40,42. In human 
serum, the abundances as well as biological effects of the various classes and subclasses 
of antibodies vary widely 40,41 but they ultimately mediate specific biologic functions that 
are essential for responding to pathogens. In practice they are distinguished by 
immunoanalytical assays in which specific antibodies are applied. Once B lymphocytes 
have matured into plasma cells, each cell clone produces antibody molecules with a 
unique antigen binding site 43. 
IgG is the most abundant class of antibody in serum as it constitutes about 75% of the 
antibody in serum 29,39. The four subclasses of IgG known to exist in humans are IgG1, 
IgG2, IgG3, and IgG4, with relative amounts of ca. 60%, 25%, 10%, and 5% respectively 
in normal serum 42. The molecular mass of an IgG molecule is approx. 150 kDa, and it is 
composed of a pair of two different kinds of polypeptide chains. One, of ca. 50 kDa in 
mass, is termed the heavy chain or H chain, and the other, of ca: 25 kDa in mass, is 
termed the light chain or L chain. Each IgG molecule consists of two heavy chains and two 
light chains (Fig. 2). The two heavy chains are linked to each other by disulfide bridges 
and each heavy chain is linked to a light chain by a disulfide bridge as well as by non-
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covalent interactions to form the arms of a Y-shaped antibody molecule. In any given 
immunoglobulin G molecule, the two heavy chains and the two light chains are identical, 
giving an antibody molecule two identical antigen-binding sites. This implies that an IgG 















The amino acid composition of IgG heavy and light chains show that each chain consists 
of a series of similar, although not identical, sequences, each ca. 110 amino acids long 
and each of these repeats corresponds to a discrete, compactly folded region of protein 
structure known as a protein domain 29,42. An important feature revealed by comparing the 
amino acid sequences is that the amino-terminal sequences of both the heavy and light 
chains vary widely between different antibodies. Thus, the variability in amino acid 
sequence is limited to the residues located in the variable domains (VL and VH). The 
remaining domains are constant between IgG chains of the same subclass. 
The variable domains of the heavy and light chains (VH and VL, respectively) together 
make up the variable region (V of Fv domains) of the antibody and confer on an IgG the 
ability to bind a specific antigen, whereas the constant domains (C domains) of the heavy 
chain (CH1, CH2 and CH3) and light chain (CL) make up the C regions. The Fab is 
composed of two variable domains (VH in the heavy chain and VL in the light chain) and 
two constant domains (CH1 and CL). Two additional domains, CH2 and CH3 of both of the 
heavy chains compose the Fc region which is responsible for mediating the biological 
activity of the IgG molecule 29. 
The most widely studied immunoglobulin class, the IgG class, has found a broad variety of 
applications including treatment of numerous autoimmune diseases and cancer 44-46. 
Consequent to the clinical and biotechnological applications of IgGs, a variety of strategies 
are currently available for improving the manufacturability of IgG on a large scale either by 
recombinant DNA technology or hybridoma techniques 47. Moreover, as reagents, 
antibodies have varying applications in disease diagnostics and biotechnological assays 
due to their striking specificities in recognizing their cognate antigens 48-50. The principle 
underlying the different kinds of molecular recognition patterns is utilized also in a variety 
of other biotechnological applications, such as the purification 51-53 and immobilization of 
biomolecules 54,55, labeling of proteins 56,57, targeting approaches in therapeutics 58-60, and 
design of molecular probes for disease diagnosis 61,62. Although various bio-recognition 
elements such as lectins 63, aptamers 64, enzymes 65,66 exist as well, antibodies, have 
 
Fig.2 Schematic representation of an IgG molecule. Domains are shown 
as boxes (orange and pink: variable domains; green: constant domains) 
which are connected by disulfide bonds (red lines) and linker regions 
(green lines). Each light chain is composed of two domains (VL and CL), 





particularly and widely been used as molecular recognition elements in a variety of 
biotechnology platforms due to their exquisite specificities for their cognate antigens 67.  
 
Paratope - Epitope interactions  
The VH and VL domains of an IgG combine in a non-covalent manner to form the Fv, also 
known as the variable domain which harbors the paratope 68 (Fig. 3). The variable loops of 
β-strands, three on each of the VL and VH domains, referred to as the complementarity 
determining regions (CDRs), are responsible for binding to the antigen 69. In essence, 
each of the two arms of the Y shaped antibody monomer is tipped with a paratope, which 
consists of residues originating from most or all the complementarity determining regions 
11. The partial surface of the antigen to which the paratope binds is called an epitope or 
antigenic determinant 11,25,68. The ability of antigen structures to be recognized and bound 












IgGs are not only responsible for binding to diverse antigens via paratope - epitope 
interaction but also bind to the various effector molecules to which their constant regions 
(Fc domains) engage 71, thereby mediating diverse effector activities through the various 
classes of Fc receptors (FcRs) 72.  
 
Ligatope – Efcetope interactions 
Fc receptors (FcRs) are protein molecules found on a variety of immune cells including 
macrophages, neutrophils, monocytes, eosinophils, and lymphocytes of the innate immune 
system (natural killer cells) or adaptive immune system (e.g., B cells) 73-76. Several classes 
of FcRs exist. They are classified based on the type of antibody that they recognize and 
bind 77. For instance, FcRs that bind the most predominant class of antibody, IgG, are 
called Fc-gamma receptors (FcγR), those that bind IgA are called Fc-alpha receptors 
(FcαR) and those that bind IgE are called Fc-epsilon receptors (FcεR). The recently 
identified FcR found to bind to IgM was also named FcµR 78. Subtypes of receptors are 
also denoted by capital Roman numerals, such as: FcγRI, II and III (numerals are in the 
order of affinity for IgG) 77. Although the FcRs can consist of up to several hundreds of 
amino acids, only a set of few amino acid residues are in contact with the antibody Fc at 
the binding interface 79,80; another example for realization of the three-dimensional force 
code.  
 
Fig.3 Schematic representation of an antibody molecule showing its antigen 







Interaction between Fc receptors on phagocytic cells and antibodies play a critical role in 
both innate and adaptive immune responses 73,81. Various immune responses are 
mediated through FcR-antibody recognition 73. The most common is the activation of 
phagocytes such as macrophages to ingest and kill IgG-decorated pathogens by a 
process known as phagocytosis 82. Another common process involving Fc receptors is the 
so-called antibody-dependent cell-mediated cytotoxicity (ADCC), where FcγRIII receptors 
on the surface of natural killer (NK) cells stimulate the NK cells to release cytotoxic 
molecules from their granules to kill antibody-covered target cells 76,83.  
FcRs recognize and bind to antibodies that are attached to the surfaces of microbes or 
microbe infected cells and activate these cells to eliminate microbial pathogens. Since the 
antibody functions as a ligand in the antibody-FcR recognition, the term “ligatope” may be 
used to appropriately describe the specific area on the antibody that recognizes and binds 
to the FcR (Fig. 3). The restricted area on the FcR that makes contact with the ligatope of 
the antibody could therefore be named an efcetope (efce; Fc and topos; place). The 
capacity of antigenic determinants or structures to induce cellular and humoral immune 
responses is termed immunogenicity 70.  
In recent years, much has been learned about the structural details of the interaction 
between various kinds of FcRs and IgG Fc parts using predominantly X-ray 
crystallography 79,84,85. From crystallographic studies, the FcγRIII has been shown to bind 
between the two CH2 regions of Fc part of IgG1 and make contact with residues in the 
hinge region 79,86. The total buried surface area on both CH2 domains upon FcγRIII-IgG-Fc 
complex formation was estimated to be 895 Å2 suggesting that only a few residues are 
involved in the binding interface 79. Additionally, some low affinity FcRs have been shown 
to bind to CH3 domains of IgG 
87. 
In light of the modern advancements in mass spectrometry, attempts have been made to 
understand and characterize ligatope - effcetope interactions by using mass spectrometry 
88-90. Studies on the interaction between a full length IgG1 and a human neonatal Fc 
receptor (FcRn) by hydrogen/deuterium exchange mass spectrometry (HDX-MS) showed 
that regions in the antibody Fc and the FcRn were protected from exchange upon complex 
formation- a result that was in good agreement with previous crystallographic studies of 
FcRn in complex with Fc fragment of IgG89. There is therefore no doubt that mass 
spectrometry can be used as an analytical tool to probe ligatope - efcetope interactions.  
 
Classotope, Idiotope, Allotope – Paratope interactions 
IgGs themselves can be antigenic 91-93. Thus, they can trigger the production of antibodies 
(anti-antibodies) in the appropriate recipient. For instance, injecting a patient with purified 
mouse derived IgG can cause very undesirable immune reactions 94 because the patient’s 
immune system recognizes the purified mouse IgG as foreign. It is also worth noting that 
the use of even humanized and fully human IgG as therapeutics may still carry some 
immunological risk 92. There is therefore untold need to elucidate structures on IgGs that 
make them immunogenic. 
Antibodies which are produced to recognize human antibodies enables their classification 
into isotypes, allotypes, and idiotypes 91,95 (Fig. 4) which is used to categorize antibodies 
into the five antibody classes (isotypes) - IgG, IgA, IgM, IgE and IgD and into subclasses, 
such as IgG1 through IgG4 40,95. The different heavy and light chain classes account for 
the isotypic variation in antibodies 40. Since the isotypic variation allows antibodies to be 
grouped broadly into their classes and sub-classes 96, regions on the antibody molecule 
that contain the isotypic markers may be referred to as “classotopes” (Fig. 4). 
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Allotypic variations are mostly known to occur in the constant region of H and L chains, but 
some have been found to appear in the framework residues of V regions 97-99. The region 
on an antibody molecule that defines the allotypic determinants of the antibody can 
therefore be termed as the allotope. Allotypic determinants (allotopes) are encoded by one 
allele (variation) of a given antibody gene and are present on the antibodies of some 












Although antibodies have been humanized to diminish the adverse effects of 
immunogenicity, the differences in allotope sequences still creates a potential for immune 
response from the patient to the antibody if the allotype of patient and antibody do not 
match 93. Consequently, the choice of allotype to select for a therapeutic antibody is 
difficult since allotypic distribution in humans is known to vary within and across ethnic 
groups 93,100. It therefore makes it imperative to develop novel methods that can be used to 
map the allotopes of antibodies to better understand immunogenicity arising from allotypic 
variations. 
Idiotypy has previously been coined to define the phenomenon where an antigenic 
determinant is found to be unique to particular antibody molecules of a given individual 91. 
Idiotopes (idiotypic determinants) are found in the V region near the antigen-binding site of 
the antibody molecule91 (Fig. 4). These determinants are common to antibodies exhibiting 
specificity for the same antigenic determinant and are therefore used to define the 
monoclonality of an antibody 96. Idiotopes are known to be individual-specific and each 
individual has as many different idiotypes as it has different antibodies. Of note, idiotopes 
of therapeutic antibodies may be responsible for triggering immune reactions in patients. 
 
Constatope – Cementotope interactions 
Apart from the fragment antigen binding (Fab) domains where cognate antigens bind to 
antibodies with high selectivity and specificity, the Fc regions of human immunoglobulins 
are also the primary recognition site for other proteins, such as the bacterial proteins, 
protein A (from Staphylococcus origin) and protein G (from Streptococcal origin).  
Protein G binds to the interface between the second and third heavy chain constant 
domains (CH2 and CH3) of Fc which is roughly the same binding site for protein A 
101. 
Since the amino acid residues of the fragment crystallizable (Fc) regions that serve as 
their primary recognition site are almost identical (constant regions), we name the area on 
the Fc where the proteins bind a constatope (Fig. 5). Due to the extremely high affinity with 
which protein G binds to the constatope on the Fc of the antibody, we call the area on the 
 
Fig.4 Schematic representation of an antibody molecule showing its classotope, 








protein G that makes contact with the constatope a cementotope. From X-ray 
crystallographic data and an NMR study, the interface between the Fc binding region 
(cementotope) of the protein G and that of the of the antibody (constatope) comprises of 
about 8-11 amino acid residues from the constatope in contact with about the same 












Although the binding of these bacterial proteins to the Fc part of IgGs have been widely 
applied for purification 103-105, immobilization 106 and affinity capturing 107 of antibodies in 
biotechnological assays, a major drawback of using the full length of these bacterial IgG 
binders is that their recognition profile may not be suitable for specific usages. When used 
as a ligand for affinity capturing of antibodies in immunoassays, the additional binding of 
the ligand to Fab regions of the antibodies can limit its application 108. In addition, the 
binding affinities of both protein A and protein G vary with different IgG subclasses 109-112. 
In spite of the aforementioned limitations, the tremendous importance of IgG Fc-binding 
proteins continues to stimulate research directed to improve their use as high affinity 
ligands 113. A prerequisite to designing ligands with enhanced specificities and affinities is 
a good understanding of their recognition motifs. Current understanding of their recognition 
sites through structural and functional studies has led to for example the design of artificial 
ligands that have high affinity for immunoglobulins, yet improved specificities 114,115. 
Recently, we reported the development of an electrospray ionization mass spectrometry-
based method by which thermodynamic properties of protein G-antibody interactions can 
be determined in the gas phase 116.  
At last, when constructing a “cementotope” as a part of an antibody´s heavy chain and 
simultaneously creating a “constatope” on a second heavy chain, the so tailored molecular 
recognition pattern and resulting specific interaction leads to novel designer antibodies, 
which then become bispecific antibodies. The engineering process has been coined “knob-
in-hole” 117,118, which involves creating a “knob” in the CH3 domain of an antibody and a 
“hole” in the CH3 domain of another antibody with a different specificity, thereby resulting in 
heterodimerization of the heavy chains of the two IgGs. Bispecific antibodies are IgG 
molecules which contain two different antigen binding sites. The design of such antibodies 
has largely been successful because of the sufficient understanding of the molecular 
recognition of IgG molecules. The emergence of bispecific antibodies 119-121 in the past 
years has developed into a promising field of research and for novel antibody based 
biotherapies. 
 







Carvotope – Meditope interactions 
A unique binding site for a small peptide in the center of the Fab cavity of cetuximab, a 
chimeric, anti-epidermal growth factor receptor monoclonal antibody was identified via 
diffraction studies and because of the position of the binding interface (Fig. 6), the peptide 
was named “meditope” (medius, middle; topos, place) 122. Structural analysis using X-ray 
crystallography showed that the meditope-binding site or “carvotope” on the Fab is not 
only distinct from the antibody’s antigen binding site (paratope) but also very distinct from 
the binding sites of other well established Fab binding proteins such as protein A, G, or L. 
The meditope-Fab recognition was found to involve all four domains of the Fab of 
cetuximab 122,123. The binding of the meditope to the carvotope of the antibody occurs via a 
noncovalent interaction that does not significantly disrupt the antibody’s ability to bind to its 
target antigen 59,122. A meditope can therefore be defined as any small peptide that 
specifically binds to a unique site located in the center of a cavity formed by the light and 
heavy chains of an antibody and does not interfere with antigen binding affinity, specificity 
and stability.  
In order to better understand the specificity of the meditope-Fab recognition and also to 
test whether this recognition could be expanded to other monoclonal antibodies, the 
meditope binding site of cetuximab has been grafted onto other monoclonal antibodies by 
the so called “SnAP” technology (Site specific novel Antibody Platform) 59. The core 
technique in this strategy is the generation of meditope-enabled antibodies by site-specific 
carving which is made possible because the cetuximab carvotope-meditope recognition 
has been studied in details. This novel strategy has enabled antibody-drug conjugates 
(ADCs) to be customized for variety of applications in diagnostics, therapeutic delivery and 












In general, the “Lego®-like” cave sites are created on Fab regions of a monoclonal 
antibody (mAb) by replacing a few amino acid residues using antibody engineering. These 
cave sites, termed as “meditope-binding site” or “carvotopes” of the antibody is then able 
to recognize and bind specifically to its cognate meditope without the need for a covalent 
chemical conjugation. Thus, by adjusting and optimizing engineered meditope-enabled 
antibodies, a stable non-covalent, yet site-specific conjugation can be accomplished. 
Considering the tremendous potential ADCs promise in the treatment of cancer 125-127, 
efforts have been made to design site-specific ADCs with high homogeneity 128,129 with the 
aim of identifying which conjugate species produce the most desirable pharmacological 
properties and also to aid accurate characterization of ADCs throughout all phases of 
discovery 130. Whereas creating ADCs by chemical conjugation of a cytotoxin to a mAb 
 







(typically involving lysines, reduced cysteines, or sugars on the mAb) has generally been 
reported to yield heterogeneous mixtures which can adversely affect the specificity and 
stability of the mAb and alter its bio-distribution 131-133, the use of meditope-enabled 
antibodies has been shown to be advantageous as it results in homogeneous ADC 
products with a predictable drug-to-antibody ratio (DAR).  
An in-depth understanding of the molecular recognition of meditope-carvotope interactions 
has led to efforts to improve binding affinity by altering the cyclization and side chains of 
the meditope 123,134. For example, to increase the affinity of the interaction between a cyclic 
12-residue meditope which binds to a carvotope on the cetuximab Fab, extension of the 
side chain of Arg8 in the meditope by carboxyethylarginine substituition increased the half-
life of the complex by three folds compared to the unmodified meditope 135. 
 
The concept of Darthotopes and Jeditopes  
As the lack of appropriate definitions and precise nomenclature has led to somewhat 
ambiguous terminologies in the past, the systematic and practical nomenclature that is 
suggested here (Table 2) intends to help reduce confusion in the field of molecular 
recognition investigations. For example, although an epitope is widely accepted as the 
region on an antigen molecule that makes contact with the paratope of an antibody, this 
definition had been abandoned when the region on an Fc receptor that binds to the Fc part 
of an antibody had been termed an epitope as well 80. 
Unambiguous verbalization of the components of a bipolar concept of inverse 
complementarity, which clearly characterizes the most prominent characteristics of 
molecular recognition based on a three dimensional force code is required. Motivated by 
the instantly recognized and easy to capture analogy of a “yin and yang” concept that 
every student knows from the famous Star Wars movies, the recognition motifs on the 
antibody shall be termed the darthotopes (“darth” and topos: place) and the oppositely 
corresponding set of amino acids, peptides or surface regions on the antigen which bind to 
the antibody shall be defined as the jeditopes (“jedi” and topos: place). Thus, a darthotope 
is the set of amino acids or the restricted area on the IgG that forms its three dimensional 
force code responsible for recognition. By this definition, the amino acid residues in an 
IgG’s darthotope are considered to be required for bringing balance to the force code 
situated on the antigen surface.  
 
Table 2. List of darthotope - jeditope pairs in antibody - antigen recognition. 
darthotopes jeditopes 




a) classotopes, allotopes, and idiotopes are epitopes. 
 
From an IgG molecule’s perspective, it recognizes a certain force code regardless of which 
molecule this force resides on. This implies that if atoms of amino acids of different and 
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unrelated protein antigens share a similar force code that can be recognized by an IgG 
molecule, chances are that the IgG will to some degree bind to these “unrelated” antigens 
136. Deciphering and learning into details about these recognition motifs and their force 
codes will thus arguably help to answer the problem of cross reactivities observed with 
antibody interactions as well as will help to broaden their applicability in life sciences.  
 
1.2 Objectives 
With the advent of therapeutic antibodies for treatment of patients, there is a huge demand 
for antibody characterization, both structurally and functionally. As the most specific 
property of an antibody is arguably its ability to bind its antigen through paratope - epitope 
recognition, the two prime objectives of this thesis were to develop simple but accurate 
mass spectrometric methods that can be used (i) to identify epitopes of antigens as well as 
(ii) to estimate the strength of antibody – antigen binding.  
First, a mass spectrometric approach was developed that enabled rapid and accurate 
determination of epitope peptides: the “Intact Transition Epitope Mapping (ITEM)” method. 
This method is now renamed to “Intact Transition Epitope Mapping – One-step Non-
covalent force Exploitation (ITEM-ONE)” since it has been surpassed by our most recently 
developed method which is entitled “Intact Transition Epitope Mapping – Targeted High-
Energy Rupture of Extracted Epitopes (ITEM - THREE)”. Both methods make use of ion 
mobility mass spectrometry for rapid and accurate determination of antigen-derived 
peptides, the epitopes, that undergo specific in-solution interactions with an antibody of 
interest.  
Second, within this thesis was developed a mass spectrometry-based method by which 
protein complex stabilities in the gas phase can be estimated. Once an immune complex 
had been isolated and translated into the gas phase, its stability was readily checked in 
one step by applying special experimental conditions through which one directly 
determined “apparent energies of dissociation activation (EA
#
m0g)” of charged antibody-
protein complexes by application of the Rice Ramsperger Kassel Marcus - Quasi 
Equilibrium Theory (RRKM-QET). The example of choice in this thesis was the already 
established Immunoglobulin G Fc - protein G pair which according to our nomenclature 
resembles a “constatope - cementotope” recognition motif.  
All three methods, although developed with antibody – antigen pairs, can principally be 
used to study apparent gas phase dissociation energies and identify substructures of 
protein - protein interactions of all kinds of biomacromolecular complexes. Because mass 
spectrometry offers the advantages of speed and low sample consumptions the here 
developed methods can be applied for many bio-medical purposes, such as to investigate 
stabilities of any disease-related interaction of biomacromolecules, hence opening 
avenues to functional testing of targeted personalized medicine concepts. 
 
1.3 Methods 
1.3.1 Protein epitope mapping in the gas phase 
The most specific property of an antibody is arguably its ability to bind its cognate antigen 
in a unique fashion via precise paratope- epitope recognition. The experimental 
determination of antigenic determinants (epitopes), i.e. the region on the antigen that binds 
to the antibody, is of tremendous importance for antibody characterization. The relatively 
low amount of sample required for mass spectrometric epitope mapping makes it a 
method of choice. However, a major drawback to all the currently available experimental 
epitope mapping methods including mass spectrometric work-ups lies in the rather 
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sophisticated, but up to now unavoidable lengthy in-solution procedures. There is therefore 
an unmet need for rapid and accurate epitope mapping procedures. As a result, a method 
that facilitates in-solution handling is expected to generate a real breakthrough in routine 
epitope mapping. 
In this thesis the “Intact Transition Epitope Mapping” method (ITEM) has been developed 
and applied as an epitope mapping procedure that identifies the epitope peptide of an 
antibody of interest in a fast and easy fashion. In-solution handling is reduced to mixing of 
peptide and antibody solutions using native mass spectrometry compatible volatile 
solvents whose pH allow antibodies to maintain their property to bind their cognate 
antigens. The entire antibody - peptide mixtures are electro-sprayed directly into the mass 
spectrometer, the unbound peptides (UBPs) are separated from the immune-complexes in 
the gas phase in an ion mobility separation chamber. Next, the immune-complexes are 
dissociated via collision induced dissociation (CID) and the masses of the complex-
released peptides (CoRPs) are subsequently determined leading to unequivocal 
identification of epitopes in an easy to interpret “arrival time over m/z, atomz” plots. 
Using both epitope extraction and excision work-ups, we applied the ITEM method to 
rapidly and accurately identify the epitope of the anti-RA33 antibody from a crude digest of 
rhRA-33 and the His-tag epitope from recombinantly expressed protein G´e.  
For more information on protein epitope mapping in the gas phase see Chapter 1.4.1. 
 
1.3.2 Identification of epitope peptides from unknown antigens  
Information provided by results of epitope mapping experiments is extremely valuable in 
the process of antibody humanization, as well as in vaccine design. Mass spectrometric 
epitope mapping methods that identify epitopes at amino acid resolution are not only 
useful for identifying the regions on the antigens antibodies bind to but also are essential 
for identifying potential post-translational modifications on these regions and their effects 
on antibody recognition. Equally important is an epitope mapping method that allows 
scientist in life sciences to identify unknown antigens by first identifying the amino acid 
sequence of epitopes and with the aid of a protein database, identifying the antigen that 
contains the identified epitope.  
In this thesis, we thus present the development and application of “Intact Transition 
Epitope Mapping - Targeted High-energy Rupture of Extracted Epitopes” method (ITEM-
THREE) which allow identification of epitopes at amino acid resolution and subsequently 
identification of unknown antigens via a protein database search. 
To perform ITEM-THREE experiments, three electrospray-compatible solutions with 
neutral pH, in which the antibodies maintain their in-solution activities, are prepared. 
Solution 1 is either a mixture of epitope peptides in 200 mM ammonium acetate (we mixed 
seven synthetic peptides) or a proteolytic digest of an antigen. Solution 2 contains one 
antibody in 200 mM ammonium acetate (in our case antiRA33, antiTRIM21, antiHis-tag or 
antiTNFalpha antibody). Solution 3 is a mixture of solutions 1 and 2, in which the specific 
immune complexes form (molar ratios: 2.2 : 1). 
Without any purification steps solution 3 is then electrosprayed and the quadrupole 
analyzer is first used as a mass filter by setting it to block transmission of lower molecular 
weight ions (unbound peptides). The traversing antibody-peptide complexes are then 
dissociated in a first collision cell (TRAP) by increasing the collision cell voltage difference. 
The dissociated complexes then transit into the ion mobility separation chamber where 
they are separated according to their m/z, sizes and shapes. Finally, the collision cell 
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voltage difference in a second collision cell (TRANSFER) is also increased to cause 
fragmentation of the complex released peptides (CoRPs).   
The collision voltages in the two collision cells (TRAP AND TRANSFER) are raised in a 
stepwise manner (5-20V/step) and optimized for each experiment to ensure adequate 
dissociation of the antibody - peptide complex and subsequent fragmentation of the 
complex released peptides. Appropriate control experiments using rituximab as a non-
specific antibody were also carried out. Also, we performed control experiments by 
individually electrospraying the antibody solutions and the peptide mixtures (digests) alone 
and following the procedure described above. The resulting spectra were processed with 
Masslynx software version 4.1. The processed data was submitted to a Mascot search 
against a protein sequence database search to obtain partial amino acid sequence of the 
extracted epitope peptide which then allows one to identify the amino acid sequence of the 
full length antigen through a database search. ITEM-THREE thus provides a means of 
direct identification of antigens from which the epitope peptide has been extracted. 
For more information on identification of epitopes from unknown antigens see Chapter 
1.4.2. 
 
1.3.3 Gas phase thermodynamic analysis of protein-protein complex dissociation 
Protein-protein complexes are characterized in solution by determining thermodynamic 
properties like dissociation constants (KD) and Gibbs free binding energies (ΔG
0
s) at 
equilibrium. Whereas methods to determine kinetic and/or thermodynamic properties of 
proteins and protein complexes in solution are well-established and broadly applied, 
approaches for studying such interactions in the gas phase are lacking. Electrospray mass 
spectrometry enables transfer of intact protein - protein complexes into the gas phase. 
Since in vacuo measurement of analyte molecules are free of intermolecular interactions 
with surrounding solvent spheres, it allows the energy of intramolecular and intermolecular 
forces to be studied independently from interference of the solvent environment. The 
dissociation of complexes in the gas phase is unidirectional and irreversible, hence not 
reaching equilibrium conditions but we applied the so-called Rice-Ramsperger-Kassel-
Marcus quasi-equilibrium theory which is based on a statistic model.  
We estimated apparent activation energies in the gas phase using three closely related 
protein-protein complexes consisting of Fc parts of immunoglobulins (IgG) and protein G´e 
(IgG-Fc*G´e; IgG-Fc*G´f , and IgG-Fc*G´g). Proteins G´e, G´f, and G´g as well as IgG-Fc 
were subjected to buffer exchange using 200 mM NH4OAc. Immune complexes were 
formed by individually mixing of IgG-Fc with slight molar excesses of proteins G´s (1.3 : 1 
molar ratios). Protein complexes (ca. 3 µl solution, each) were introduced into a Synapt 
G2S mass spectrometer via nanoelectrospray ionization. Non-complexed starting 
materials were separated from immune complexes by ion mobility separation. Upon ion 
mobility drift separation of the ionized intact complexes from excess of non-complexed 
constituent ions, dissociation of the complexes was induced by raising the transfer collision 
energy (TCE) in a stepwise manner to induce dissociation of the complexes via collision 
induced dissociation (CID).  
The ion intensities of the surviving complexes and dissociated complex constituents were 
recorded in a mass spectrum and were used to calculate apparent activation energies of 
dissociation in the gas phase (EA
#
m0g) and apparent gas phase dissociation constants 
(KD
#
m0g). Comparing the calculated KD
#
m0g values in the gas phase with those obtained 
from in-solution investigations, we were able to establish that the amino acid sequence of 
the IgG-binding domains of protein G´ plays a crucial role in high affinity binding between 
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protein G´ isoforms and IgG while neither the N-terminal nor the C-terminal flanking 
sequences were significantly influencing binding to IgG.  
For more information on determination of gas phase thermodynamic parameters of protein 
complexes see Chapter 1.4.3. 
 
1.4 Results 
The sections within this chapter are a compilation of the abstracts of the published work 
from this thesis. 
 
1.4.1 Intact Transition Epitope Mapping (ITEM) 
"Intact Transition Epitope Mapping" enables rapid and accurate determination of protein 
antigen-derived epitopes by either epitope extraction or epitope excision. Upon formation 
of the immune-complex in solution, the entire mixture is electro-sprayed to translate all 
constituents as protonated ions into the gas phase. There, ions from antibody-peptide 
complexes are separated from unbound peptide ions according to their masses, charges, 
and shapes either by ion mobility drift or by quadrupole ion filtering. Subsequently, 
immune-complexes are dissociated by collision induced fragmentation and the ion signals 
of the “complex-released peptides”, which in effect are the epitope peptides, are recorded 
in the time-of-flight analyzer of the mass spectrometer. Mixing of an antibody solution with 
a solution in which antigens or antigen-derived peptides are dissolved is, together with 
antigen proteolysis, the only required in-solution handling step. Simplicity of sample 
handling and speed of analysis together with very low sample consumption makes "Intact 
Transition Epitope Mapping" faster and easier to perform than any other experimental 
epitope mapping methods. 
For detailed information on epitope mapping using the ITEM method see Chapter 2.1. 
 
1.4.2 Intact Transition Epitope Mapping - Targeted High-Energy Rupture of 
Extracted Epitopes (ITEM-THREE) 
Epitope mapping, which is the identification of antigenic determinants, is essential for the 
design of novel antibody-based therapeutics and diagnostic tools. ITEM-THREE is a mass 
spectrometry-based epitope mapping method which is capable to identify epitopes on 
antigens upon generating an immune complex in electrospray-compatible solutions by 
adding an antibody of interest to a mixture of peptides from which at least one holds the 
antibody´s epitope. This mixture is nano-electrosprayed without purification. Identification 
of the epitope peptide is performed within a mass spectrometer which provides an ion 
mobility cell sandwiched in-between two collision cells and where this ion manipulation 
setup is flanked by a quadrupole mass analyzer on one side and a time-of-flight mass 
analyzer on the other side. In a step-wise fashion, immune-complex ions are separated 
from unbound peptide ions and dissociated to release epitope peptide ions. Immune 
complex-released peptide ions are separated from antibody ions and fragmented by 
collision induced dissociation. Epitope-containing peptide fragment ions are recorded and 
mass lists are submitted to unsupervised data base search thereby retrieving both, the 
amino acid sequence of the epitope peptide and the originating antigen. ITEM-THREE was 
developed with antiTRIM21 and antiRA33 antibodies for which the epitopes were known, 
subjecting them to mixtures of synthetic peptides of which one contained the respective 
epitope. ITEM-THREE was then successfully tested with an enzymatic digest of His-
tagged recombinant human β-actin and an antiHis-tag antibody, as well as with an 
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enzymatic digest of recombinant human TNFα and an antiTNFα antibody whose epitope 
was previously unknown. 
For detailed information on epitope mapping using the ITEM-THREE method see Chapter 
2.2. 
 
1.4.3 Determining Apparent Activation Energies of Protein Complex Dissociations 
in the Gas Phase by Electrospray Mass Spectrometry 
We have developed a method to determine apparent activation energies of dissociation for 
ionized protein-protein complexes in the gas phase using electrospray ionization mass 
spectrometry following the Rice-Ramsperger-Kassel-Marcus quasi-equilibrium theory. 
Protein-protein complexes were formed in solution, transferred into the gas phase and 
separated from excess free protein by ion mobility filtering. Afterwards, complex 
disassembly was initiated by collision induced dissociation with step-wise increasing 
energies. Relative intensities of ion signals were used to calculate apparent activation 
energies of dissociation in the gas phase by applying linear free energy relations. The 
method was developed using streptavidin tetramers. Experimentally determined apparent 
gas phase activation energies for dissociation (𝐸𝐴 𝑚0𝑔
# ) of complexes consisting of Fc parts 
from immunoglobulins (IgG-Fc) and three closely related protein G´ variants (IgG-
Fc•protein G´e, IgG-Fc•protein G´f, and IgGFc•protein G´g) show the same order of 
stabilities as can be inferred from their in-solution binding constants. Differences in 
stabilities between the protein-protein complexes correspond to single amino acid residue 
exchanges in the IgG-binding regions of the protein G´ variants. 
For detailed information on determination of gas phase apparent activation energies of 
protein complexes see Chapter 2.3. 
 
1.5 Discussion 
Mass spectrometry has been used more and more as an analytical tool to study molecular 
recognition of biomolecules and has been shown to have real advantages such as low 
sample consumption and speed over other available methods 25,137. Mass spectrometry-
based techniques have also been successfully used to identify epitopes of protein antigens 
25,137,138. Although typical lengths of investigated antigens using mass spectrometric 
methods (epitope excision and epitope extraction) have increased up to several 100 amino 
acids, experimentally determined epitope peptides have been shown to comprise of 10-15 
amino acid residues on average 25. Also, X-ray crystallographic studies of antibody–protein 
complexes have shown that the paratope–epitope interface involves a surface area of 
about 700-900 Å2 consisting of about 15-22 amino acid residues each, from both the 
antigen surface or the paratope 11,139. In some other reports, however, the epitope was 
denominated to consist of 8-12 amino acid residues 25. After applying the epitope mapping 
methods developed in this thesis to identify the epitope peptide of a previously unknown 
antigen (rhTNFα), the identified epitope consisted of 8 amino acid residues encompassing 
a surface area of ~680 Å2, which is on the low end of the average but consistent with 
previous results. 
Albeit structure-based methods (e.g. X-ray crystallography and NMR) have been 
successfully used to map epitopes of protein antigens even at atomic resolution; they are 
not always readily appropriate. For instance, the usually high amount of sample required, 
proteins which crystallize poorly, and the complex data analysis involved limit their 
application. The use of phage display peptide libraries have also been employed for 
mapping antibody epitopes 140-142. Typically, a phage library containing millions of random 
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peptides is used and the antibody whose epitope is to be identified is allowed to select and 
bind to peptides having reasonable affinity for their paratopes. From the consensus motifs 
observed in the multiple peptide sequences which bind to the antibody, the regions on the 
antigen containing the identified consensus motifs are matched as the epitope 141. In most 
cases of epitope mapping by phage display, a major computational challenge exists as the 
identified peptides may have no obvious similarity to any linear sequence on the antigen, 
thereby requesting for huge algorithmic task 143. Most in-solution epitope mapping 
procedures such as competition experiments 144, hydrogen/deuterium exchange (HDX) 145, 
fast photochemical oxidation of proteins (FPOP) 146 which use mass spectrometry as read 
out are usually met with drawbacks such as time consuming preparations, complex data 
analysis, high material consumption, just to mention but a few. Using our ITEM methods, 
one can easily overcome these challenges. 
The antigen-binding sites of many IgGs are known to cross-react with a variety of related 
but different antigenic determinants, making the antibody defense force even more 
formidable 33. Whilst antibody cross reactivity appears to be relevant for ensuring that the 
immune system fights against a myriad of infections, it has also been discussed to initiate 
autoimmune diseases by molecular mimicry 147. Moreover, in most biotechnological 
applications with antibodies, antibody cross reactivity often leads to poor reproducibility of 
results - a phenomenon known as the antibody reproducibility crisis 148. Consequently, an 
important question that remains to be answered is how cross-reactivities observed with 
antibody recognition can be estimated and whether engineered antibodies’ applicabilities 
can be broadened.  
In addition to identifying the epitope peptide by accurately determining the mass of the 
complex released peptides in ITEM-ONE 137, with ITEM-THREE 136, the experimentalist 
can obtain in a single experiment, amino acid sequence information of epitope peptide(s) 
and the originating antigen, thereby allowing possible cross-reactivities to be estimated 
by performing a BLAST search of the amino acid sequence of the identified epitope(s). 
Mass spectrometric epitope mapping, molecular modeling and site-directed mutagenesis 
studies on antibodies and protein antigens have also revealed that within an epitope, there 
is a subset of residues that contributed most of the free binding energy 106,149,150. Applying 
ITEM-THREE we were able to study the effect of single amino acid substitutions in epitope 
peptides 136.  
Whereas certain in-solution handling steps, such as trimming of the epitope by employing 
different enzymes can be performed equally well in MALDI-based epitope mapping 
methods as well as ITEM, with ITEM-ONE and ITEM-THREE, no antibody immobilization 
steps are required and therefore these newly developed methods drastically reduce the 
in-solution handling. As most currently available MALDI-MS based methods for epitope 
mapping 63,106,144 require immobilization of the antibody of interest on a protein A or protein 
G resin or on some kind of a substrate (e.g. beads or columns), there is the likely risk of 
non-specific adsorption of the antigen / epitope peptide to the surface of the substrate. The 
non-specific attachment of antigen / peptides onto the substrate may become a likely 
source of experimental artefacts if washing procedures are not effective enough, and 
therefore, appropriate control experiments become necessary - a procedure not 
mandatory in ITEM. The experimentalist thus does not only save time by using our newly 
developed epitope mapping methods described in this thesis, but also reduces sample 
consumption.  
Another important feature of ITEM-THREE is that, it enables one to check whether an 
antibody-epitope peptide complex has been formed. This is done by recording mass 
spectra with higher m/z range prior to dissociation of the complex. When using a MALDI 
MS-based method 144,151,152, the formation of the immune complex is not directly 
observable as upon addition of the matrix, mostly because of the acidic solution in which 
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the matrix is typically dissolved in, non-covalent complexes are typically destroyed. This 
lack of information may become particularly important when one has to distinguish non-
specific adsorption from specific paratope-epitope interactions. Whereas in ITEM-THREE 
only one source of non-specific interactions is present, i.e. peptides non-specifically 
attached to other sites of the antibody surface, in MALDI based methods, apart from other 
sites of the antibody being a source of non-specific attachment, the protein G or protein A 
substrate – or any other surface – could also result in non-specific attachments. 
Apart from characterizing antibodies by precisely identifying the epitopes, our studies on 
determining the gas phase activation energies required for dissociating protein-protein 
complexes open the field for investigating gas phase stabilities of protein-peptides and 
other protein complexes in general. As the molecular recognition and functions of proteins 
can be adversely altered by single amino acid substitutions 116, the method described in 
this thesis which allows gas phase stabilities of protein-protein complexes to be 
determined will pave a way for life scientists to elucidate the effect of amino acid 
exchanges in the binding strengths of protein complexes.  
The order of the gas phase dissociation energies for the different protein-protein 
complexes we studied matched to that from in-solution measurements very well 116. 
Conventionally, binding strengths of protein complexes are determined using in-solution 
methods like calorimetry 153,154, surface plasmon resonance 54,155, surface acoustic wave 
biosensor 156 etc. Apart from the high sample amounts required for these in-solution 
methods, they also do not generally provide any information about the stoichiometry and 
structural details of the interactors. By employing our gas phase procedure for determining 
the binding energies of protein-protein complexes 116, one is able to simultaneously obtain 
the stoichiometry of the interaction as well as some structural details of the interactors. 
Evidently, understanding the various molecular recognitions of IgG has enormous benefits 
in drug design. For example, a good understanding of ligatope-efcetope interactions could 
unveil strategies that will improve treatment of not only autoimmune diseases, but also 
graft versus host rejections. FcR–IgG-Fc interactions can be manipulated by mutagenesis 
at either the efcetope or ligatope to enhance the therapeutic efficacy of cytotoxic 
antibodies in neoplastic diseases 157-159, or to antagonize their ability to trigger effector 
responses as a means of treating IgG antibody-mediated autoimmune diseases 160,161. 
After identifying residues involved in ligatope-efcetope contacts, efcetope peptides can be 
synthesized and by competition experiments the ability of such peptides to block antibody-
receptor interactions can be explored. The success of a synthesized efcetope being able 
to block antibody Fc binding to an FcR could pave the way for designing new therapeutics 
to treat antibody-mediated autoinflammatory response in autoimmune diseases such as 
systemic erythematosus and rheumatoid arthritis 162,163. 
To conclude, the mass spectrometric methods which have been developed in this thesis 
will enhance our understanding of molecular recognition of not only antibodies, but could 
also be extended for elucidating, in general, the molecular recognitions involved in protein-
protein interactions. The methods will essentially provide a means of characterizing 
antibody recognition by providing precise information about their epitopes, thereby 
improving our current understanding of how antibody applications can be broadened. 
Moreover, the method that was developed to study gas phase binding energies of protein-
protein interactions can allow one to precisely examine the influences of amino acid 
substitutions on antibody recognition, therefore providing a means to better understand 
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Abstract. Intact transition epitope mapping (ITEM) enables rapid and accurate
determination of protein antigen-derived epitopes by either epitope extraction or
epitope excision. Upon formation of the antigen peptide-containing immune complex
in solution, the entire mixture is electrosprayed to translate all constituents as pro-
tonated ions into the gas phase. There, ions from antibody–peptide complexes are
separated from unbound peptide ions according to their masses, charges, and
shapes either by ion mobility drift or by quadrupole ion filtering. Subsequently,
immune complexes are dissociated by collision induced fragmentation and the ion
signals of the Bcomplex-released peptides,^ which in effect are the epitope peptides,
are recorded in the time-of-flight analyzer of the mass spectrometer. Mixing of an
antibody solution with a solution in which antigens or antigen-derived peptides are dissolved is, together with
antigen proteolysis, the only required in-solution handling step. Simplicity of sample handling and speed of
analysis together with very low sample consumption makes ITEM faster and easier to perform than other
experimental epitope mapping methods.
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Introduction
Antibodies are most relevant and indispensable tools foranalytical laboratory assays, such as enzyme linked im-
munosorbent assay (ELISA), Western blot, and immuno-
histochemistry [1–3], all of which are applied routinely in
numerous laboratories around the world. Antibodies contribute
a great share to disease diagnostics [4] with huge market values
[5]. In addition, antibodies have become of immense clinical
importance as diagnostic biomarkers [4], and with
BPersonalized Medicine^ concepts gaining momentum,
antibody-based therapeutics constitute the fastest growing class
of medication with increased sales volumes of billions of US$
[6–9]. Obviously, reliance on the functionality of an antibody
either as a therapeutic agent or as a bioanalytical reagent is
huge and the pitfalls that one might step into when an
antibody’s functionality has not been understood in detail have
been extensively discussed in high impact journals [5, 10, 11].
To increase reliability of such precious reagents, there is a
tremendous demand for antibody characterization, both struc-
turally and functionally.
Since the most specific property of an antibody is its capa-
bility to bind to its antigen in a unique fashion via precise
paratope-epitope recognition, experimental determination of
epitopes (i.e., partial surfaces on the antigen to which an
antibody binds) is of utmost importance for antibody charac-
terization. The two most important strategies for epitope map-
ping either apply methods for precise structural determinations
of antigen partial surfaces (X-ray diffraction, NMR) or make
use of functional methods that include competition assays
(ELISA, biosensors), antigen modification (H/D exchange,
chemical modification of side chains), proteolytic or chemical
antigen fragmentation, and synthetic peptides [12, 13]. The
bottleneck of all available experimental epitope mapping pro-
cedures lies in the rather sophisticated, but up to now unavoid-
able, multi-step in-solution handling procedures [14], leaving
an unmet need for rapid and reliable epitope mapping methods
[15, 16]. Facilitating in-solution handling is expected to gener-
ate a real breakthrough in routine epitope mapping.
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Upon its introduction, ion mobility mass spectrometry [17,
18] enjoys vastly growing interest and finds many new applica-
tions in studies on biomolecular structures and dynamics thanks
to an additional separation dimension in the gas phase according
to the ions’mobilities in a cell filled with a neutral gas [19–22].
Commercial systems have now become available in which such
ion mobility drift cells have been flanked by collision cells. The
latter enable gas-phase ion reactions and thereby give access to
deeper insights into protein structures and into protein–protein
complex properties [23–25].
In this paper, we present the development and application of
a fast and easy to apply epitope mapping method that identifies
the epitope peptide of an antibody of interest in a single exper-
iment. The intact transition epitope mapping (ITEM) procedure
makes use of (1) the determining property of an antibody (i.e., its
ability to strongly bind to its antigen), (2) the survival of the
intact immune-complex when transitioned into the gas phase,
(3) ion separation by ion mobility and/or quadrupole filtering,
(4) dissociation of the immune complex by collision induced
dissociation, and (5) time-of-flight analysis of the complex
constituents, all within the mass spectrometer.
Experimental
Preparation of Antibody and Antigen Solutions
Anti-hnRNP-A2/B1 mouse IgG2a (antiRA33; product no.
R4653, lot no. 044K4766; Sigma, St. Louis, MO, USA), anti-
His-tag mouse IgG1 (product no. MCA1396, batch no. 0309,
AbD Serotec, Oxford, UK), and anti-FLAG M2 mouse IgG1
(product no. F3165, lot no. 128H9200; Sigma, St. Louis, MO,
USA) monoclonal antibodies and recombinant human TNF
protein (rhTNFα) were subjected to buffer exchange using
Amicon Ultra centrifugal filters with cutoff 50 K (Millipore
Corporation, Ireland). The respective volumes of antibody and
antigen stock solutions (as delivered by suppliers) containing
50 μg of antibodies and antigen, were each loaded onto one filter
unit. The volumes on the filter units were filled up to 500 μL
with 200 mM ammonium acetate buffer (pH 7.1). Then, the
units were centrifuged for 10 min at 13,000 rpm. After centri-
fugation, 430 μL of 200 mM ammonium acetate buffer (pH 7.1)
was added on top of the residual volumes above the filters (ca.
70 μL) and centrifugation (10 min at 13,000 rpm) was repeated.
Refilling and centrifugation were repeated eight times. After
that, filter units were placed upside down into a new vial and
the retentates (ca. 50 μL volumes) were collected by centrifuga-
tion for 2 min at 4500 rpm. Such re-buffered antibody solutions
were directly used for preparation of antigen/peptide-antibody
mixtures. Aliquots (ca. 2 μg) were subjected to protein concen-
tration determinations with the fluorescence-based Qubit assay
(Invitrogen, Carlsbad, CA, USA). To prepare the Qubit working
solution, 1990 μL of Qubit buffer was mixed with 10 μL Qubit
reagent. Next, 190 μL of the Qubit working solution was mixed
with 10 μL of the three calibration standards (0, 200, and 400 ng/
μL). The mixtures were vortexed and incubated for 15 min and
after that they were used to calibrate the Qubit 2.0 fluorometer.
An antibody solution (ca. 2 μg of antibody) was mixed with the
Qubit working solution to reach a final volume of 200 μL, and
the mixture was incubated for 15 min. Then, raw fluorescence
values were measured and the concentration of the protein in the
assay tube was automatically calculated. Antibody solutions
were stored at –20 °C for future use.
In-Solution Peptide Mixture Preparation
A peptide mixture (solution 1) was generated by combining 10
μL of each of the following six peptide solutions (peptide
concentrations: 0.1 μg/μL, dissolved in 200 mM ammonium
acetate, pH 7.1): FLAG peptide, [M + H]+ 1013.39; angiotensin
II, [M + H]+ 1046.54; GPI tryptic peptide, [M + H]+ 1142.59;
TRIM21 tryptic peptide, [M + H]+ 2098.11 and [M + 2H]2+
1050.5; substance P, [M + H]+ 1347.74; and RA33 tryptic
peptide, [M + H]+ 1633.87 and [M + 2H]2+ 817.44. To 3 μL
of an antiFLAG M2 monoclonal antibody solution with a con-
centration of 1 μg/μL (6.7 μM) in 200 mM ammonium acetate
buffer, pH 7.1 (solution 2), was added 1.2 μL of the peptide
mixture (solution 1) to yield a molar ratio of the antiFLAG M2
antibody to the FLAG peptide of 1:1. The antibody-peptide
mixture (solution 3) was kept at room temperature and was
directly used for nanoESI-MS/MS and nanoESI-IMS-MS/MS
analysis, respectively.
Proteolysis of Antigen Proteins
The His-RA33 protein (Euroimmun, Luebeck, Germany; 50
μL, 0.48 μg/μL, dissolved in 8 M urea, 1 M sodium chloride,
50 mM sodium phosphate, pH 7.4), was subjected to in-
solution digestion with LysC (Roche Diagnostics GmbH,
Mannheim, Germany; reconstituted according to the manufac-
turer’s protocol) using an enzyme to substrate ratio of 1:50
(w/w). Digestion was performed at room temperature overnight
and subsequently at 37 °C for 6 h. The proteolytic peptide-
containing digestion mixture was desalted with RP-packed tips
(ZipTip C18 tips; Millipore, Billerica, MA, USA) loading 5 μL
portions onto one tip, which was reconstituted using 50%
ACN, and equilibrated using 0.1% TFA solution (pH 1.7).
Washing was performed twice using 10 μL of 0.1% TFA
solution (pH 1.7) each time and peptides were eluted with 5
μL 80% ACN/0.1% TFA solution (pH 1.7), each. Ten desalted
peptide portions (total volume 50 μL) were pooled and 10 μL
of 5 M BrCN solution in ACN was added and incubated at 25
°C in the dark for 20 h [26]. Protein G′e (Sigma, St. Louis, MO,
USA; 50 μL, 1 μg/μL, dissolved in 100 mM ammonium
bicarbonate, pH 8), was subjected to in-solution digestion with
trypsin (Promega, Madison, WI, USA, reconstituted according
to the manufacturer’s protocol) using an enzyme to substrate
ratio of 1:20 (w/w). Digestion was performed at 37 °C for 48 h.
The proteolytic peptide-containing digestion mixture (5 μL)
was loaded onto an RP-packed tip (ZipTip C18 tips, Millipore,
Billerica, MA, USA), which was reconstituted using 50%
ACN, and equilibrated using 0.1% TFA solution (pH 1.7).
Washing was performed twice using 10 μL of 0.1% TFA
solution (pH 1.7) each time, and peptides were eluted with 5
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μL of 80% ACN/0.1% TFA solution (pH 1.7) [27]. Peptide
mixtures were lyophilized using a SpeedVac concentrator
(Martin Christ GmbH, Osterode, Germany), re-solubilized in
10 μL of 200 mM ammonium acetate buffer, pH 7.1, and
stored at –20 °C for future use.
Preparation of Peptide-Antibody Mixtures
for Epitope Extraction
Synthetic RA33 epitope peptide (MAARPHSIDGRVVEP-NH2;
Peptides&Elephants, Potsdam, Germany) and synthetic FLAG
peptide (DYKDDDDK; Thermo Fisher Scientific GmbH, Ulm,
Germany) were each dissolved in 200 mM ammonium acetate
buffer (pH 7.1) to obtain concentrations of 0.01 μg/μL (6.1 μM
and 9.8 μM, respectively). AntiRA33 and anti-FLAGM2mono-
clonal antibodies with concentrations of 1 μg/μL (6.7 μM each,
in 200 mM ammonium acetate buffer, pH 7.1) were mixed with
each of the peptide solutions to yield molar ratios of 1:1. To the
peptide mixture (10 μL) that derived from LysC/BrCN digestion
of His-tag-containing RA33 protein was added 1 μL of synthetic
RA33 epitope peptide (0.1 μg/μL) solution. To 1 μL of this
peptide mixture were added 3 μL of antiRA33 antibody solution
(1 μg/μL). To the peptide solution derived from tryptic digestion
of protein G´e (5 μL) were added 5 μL of antiHis-tag antibody
solution (1 μg/μL) yielding in a molar ratio of ca. 1:14 between
antiHis-tag antibody and His-tag carrying peptide. All antibody-
peptide mixtures were prepared at room temperature and directly
used for nano-ESI-IMS-MS/MS analysis. Excesses of the pre-
pared mixtures were stored at +4 °C for a maximum 1 wk.
Preparation of Antigen-Antibody Mixtures
and Proteolysis of Immune Complexes for Epitope
Excision
Five μL of rhTNFα (0. 36 μg/μL; 92 pmol) in 200 mM ammo-
nium acetate buffer (pH 7.1) was mixed with 10 μL of anti-His-
tag antibody (0.68 μg/μL; 46 pmol) in 200 mM ammonium
acetate buffer (pH 7.1), and the immune complex mixture was
incubated overnight at room temperature. Trypsin (Promega,
Madison, WI, USA) was first reconstituted in 3 mM HCl with
a concentration of 1 μg/μL (stock solution). From this, a work-
ing solution with a trypsin concentration of 2 ng/μL was pre-
pared with 200 mM ammonium acetate buffer (pH 7.0). Next, 1
μL of trypsin working solution was added to the immune
complex mixture (generating a ratio of 100:1 between rhTNFα
and trypsin). After 10 min incubation, this mixture was directly
applied for nano-ESI-IMS-MS/MS analysis.
NanoESI-IMS-MS/MS Acquisition Conditions
Nano-ESI capillaries were prepared in-house from borosilicate
glass tubes of 1 mm outer diameter and 0.5 mm inner diameters
(Sutter Instrument, Novato, CA, USA) using a P-1000 Flaming/
Brown Micropipette Puller System (Sutter Instrument).
Capillaries were gold-coated using a sputter coater BalTec
SCD 004 (Bal-Tech, Balzers, Liechtenstein). For each measure-
ment, 3 μL of antibody-antigen/peptide mixtures was loaded
into nano-ESI capillaries using a microloader pipette tip
(Eppendorf, Hamburg, Germany). Nano-ESI-IMS-MS/MS
measurements were performed on a Synapt G2-S mass spec-
trometer (Waters MS-Technologies, Manchester, UK) equipped
with a traveling-wave ion mobility cell (TW-IMS). Stability of
arrival times and gas pressures of the instrument were checked
by performing 10 ESI-IMS-MS experiments, five of which were
performed on day 1 and 5 others after 2 days’ time. We used for
the 10 measurements the RA33 peptide (exp. molecular mass:
1632.879 ± 0.021 Da) and the FLAG peptide (exp. molecular
mass: 1012.402 ± 0.012 Da). The mean arrival time of the
doubly protonated RA33 peptide was 8.202 ± 0.115 ms and
that of the singly protonated FLAG peptide was 13.922 ± 0.090
ms. The IMS gas pressures during the measurement series were
3.256 ± 0.006 mbar and 3.254 ± 0.002 mbar, respectively. The
instrumental parameters were optimized as follows: source tem-
perature, 50 °C; source offset, 80 V; trap collision energy, 4 V;
trap gas flow, 10 mL/min; helium cell gas flow, 180 mL/min;
IMS gas flow, 102 mL/min; wave velocity, 650 m/s; wave
amplitude, 40 V. Purge gas was set to 600 L/h. EDC delay
coefficient of the instrument was 1.41. Capillary and sample
cone voltages were optimized for each measurement and were
varied between 1.3–2 kV and 60–150 V, respectively. Transfer
collision energy (TCE) was raised from 2 to 220 V in a stepwise
manner (20–30 V/step). Mass spectra were acquired in positive-
ion mode applying a mass window ofm/z 200–10,000. External
mass calibration was performed with 1 mg/mL sodium iodide
dissolved in an isopropanol/water solution (50:50, v/v). Data
acquisition and processing were performed with the MassLynx
software ver. 4.1 (Waters MS-Technologies, Manchester, UK)
and the DriftScope software ver. 2.4. CorelDraw X4 was used
for data visualization [28].
NanoESI-MS/MS Acquisition Conditions for ITEM
with Quadrupole Ion Filtering
The instrumental parameters were optimized as follows: source
temperature, 50 °C; source offset, 150 V; capillary voltage, 1.8
V; cone voltage, 150 V; trap collision energy, 4 V; and purge
gas, 600 L/h. Transfer collision energy (TCE) was set to either
2 or 220 V for low and high fragmenting conditions, respec-
tively. To record peptide ion signals at low TCE, the quadru-
pole profile was set to Bauto^ which corresponds to dwelling at
250 m/z for 25% of the scan time, and then using 75% of the
scan time to ramp up to 6640 m/z. For suppressing the ions in
the low m/z range the quadrupole profile was manually set to:
M1 = 4000 with dwell time of 25% and ramp time of 25%; M2
= 5000 with dwell time of 25% and ramp time of 25%; M3 =
6000. All times are given in % of the mass window scan time.
Mass spectra were acquired in positive-ion mode applying a
mass window of m/z 200–8000. External mass calibration was
performed with 1 mg/mL sodium iodide dissolved in an
isopropanol/water solution (50:50, v/v). Data acquisition and
processingwas performedwith theMassLynx software ver. 4.1
(Waters MS-Technologies, Manchester, UK). CorelDraw X4
was used for data visualization [28].
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Results
Method Development
The ITEM method was developed using synthetic peptides
(Table 1) in conjunction with commercially available mono-
clonal antibodies. In each case, three solutions were prepared
and subsequently analyzed. Solution 1 contained just the pep-
tide(s), solution 2 contained the antibody, and solution 3 was a
mixture of solutions 1 and 2.
Key operation for determining a peptide as an epitope was
to compare the electro-sprayed peptides’ and antibodies’ ion
abundances and their arrival-times from the mixtures (solution
3) after passing the ions through an ion filtering device, such as
an ionmobility drift cell or a quadrupole, and upon exposing all
those ions that passed the ion filter (i.e., the unbound peptides,
the free antibodies, and the immune complexes) to different
collision energies in the subsequently aligned collision cell
(transfer cell energy; TCE). Two transfer cell energy conditions
were chosen for comparisons: low collision induced dissocia-
tion (CID) conditions (2 V TCE), and high CID conditions
(220 V or 120 V TCE). With ion mobility separation ion
signals were recorded and displayed as arrival-time versus
mass-over-charge plots (AToMZ plots), i.e., digital images in
which the ions’ different intensities are represented by grey-
scaled pixels. Analysis of peptides (solutions 1) and antibodies
(solutions 2) alone is not needed for epitope identification but
was performed for comparisons and controls.
In the first experiment, the FLAG peptide was dissolved in
200mM ammonium acetate buffer (solution 1) fromwhich it was
electro-sprayed. The protonated peptide ion was allowed to travel
through the ion mobility drift cell, and was exposed to 2 V TCE
(i.e., conditions that did not cause excessive fragmentation). The
resultingmass spectrum showed a singly charged ion signal of the
peptide, referred to as unbound peptide (UBP), atm/z 1013.4 and
its sodium adduct atm/z 1035.4 (Figure 1a). These FLAG peptide
ion signals were observed with arrival times of 13.3 ms in the
AToMZ plot (solid line circle in Figure 1b). They were accom-
panied by a few rather low-intensity fragment ions, forming a
diagonal trend line in the AToMZ plot on which all singly
charged ions were lined up. When the collision energy in the
transfer cell of the mass spectrometer was elevated to 220VTCE,
the ion signals of the intact FLAGpeptide completely disappeared
because under these conditions the peptide was entirely
fragmented. As a result of harsh fragmentation conditions, no
resolved ion fragments were observed in the AToMZ plot; in-
stead, fragment ion signals were found in a Bcloud^ with lowm/z
values (at the very left of the m/z scale), all with arrival times of
their precursors, i.e., ca. 13.3 ms (Figure 1c).
When the mixture consisting of the anti-FLAG M2 antibody
and the synthetic FLAG peptide (solution 3) was electro-sprayed
and ions passed through the ion mobility drift cell and were
subjected to 2 V TCE, the resulting mass spectrum and
AToMZ plot (low mass range) resembled the one from solution
1 at low TCE (Figure 1f). By contrast, when solution 3 was
exposed to high collision energy (220 V TCE), a singly charged
ion signal at m/z 1013.4 for the protonated FLAG peptide was
observed in the AToMZ plot (dotted circle in Figure 1g).
Strikingly, the arrival time of the FLAG peptide ion was now
18.8 ms, which corresponds to the arrival time of the multiply
charged antibody or its fragments (Figure 2). Of note, the other
singly charged ion in this spectrum at m/z 810.40 could not be
assigned to any of the ion signals from solution 1 and, therefore,
was assumed as being an antibody-derived fragment.
This later arrival time of the FLAG peptide ion is explained
by the formation of the noncovalent immune complex in-
solution and, upon transition into the gas phase, its migration
through the ion mobility cell as Bcargo^ of the antibody follow-
ed by release of the intact FLAG peptide from the antibody,
referred to as complex-released peptide (CoRP). Dissociation of
the complex is caused by the high collision energy in the transfer
cell. For comparison, electro-spraying the antibody solution
(solution 2), multiply charged ion signals were recorded with
arrival times of 18.6 ms (Supplementary Table S1). From this
result, two main features of CoRPs are deduced that allow
distinguishing them fromUBPs in the peptide-antibodymixture:
1. CoRPs survive the peptide fragmenting conditions in the
transfer cell.
2. CoRPs possess arrival times that match the drift times of the
antibody ions.
As the ion mobility arrival-time shift of CoRPs in compar-
ison to UBPs is one of the two important features that ITEM
takes into account, the epitope peptide ion to be identified by
this method must be fast enough to provide an observable
arrival-time difference when comparing UBP and CoRP ion
Table 1. Antibody-Binding Peptides
Peptide name Amino acid sequence a Charge [n] [M + nH]n+ (calcd) m/z (exp.)
FLAG tag DYKDDDDK 1+ 1013.4 1013.4
RA33 epitope MAARPHSIDGRVVEP 1+ 1633.8 1633.8
2+ 817.4 817.4
His-tag GSSHHHHHHSSGLVPR 1+ 1768.8 1768.9
(protein G´e 2+ 884.9 884.9
and TNFα) 3+ 590.3 590.3
IgG-Fc-binding QYANDNGVDGEWTYDDATK 1+ 2161.9 2161.9
(protein G´e) 2+ 1081.5 1081.4
pQYANDNGVDGEWTYDDATK 1+ 2144.9 2144.9
a pQ = pyroglutamic acid
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signals in the AToMZ plots. This has been true for the fairly
small FLAG peptide (8 amino acid residues in length).
By contrast, the singly charged ion signal of the 15 amino
acid residue long RA33 epitope peptide that is recognized by
the anti-RA33 antibody [26] migrates with similar arrival times
as do the multiply charged ions from the antibody. Yet, the
doubly charged peptide ion signal provides the telltale distinc-
tive shift in arrival times in the AToMZ plots. More details on
our studies with longer peptides as well as with quadrupole ion
filtering or with non-epitope peptide–antibody interactions can
be found in sections I–III of the Supplementary Results. In
general, in our experiments we observed that the chance that a
doubly protonated ion was produced as the most abundant ion
by the ESI process – as opposed to the singly protonated ion –
increased with the length of the peptide. As only longer pep-
tides with single charges would cause the problem of arival
time overlapping with the antibodies’ arrival times, the double-
charging effect of Blonger^ peptides automatically resolves the
problem of potential ambiguity (see Supplementary Results,
section I).
To test whether the experimental settings for ITEM are
effective enough to clearly identify epitopes from samples with
high complexity, we generated a peptide mixture by proteolytic
digestion of full-length proteins. The peptide mixture (solution
1) was obtained by digesting the His-RA33 protein with LysC
through which rather long peptides were created. These were
further cleaved chemically by BrCN into smaller peptides.
Although this procedure producedmany peptides with ion signals
in the mass range between m/z 500 and 1200 (ca. 40 ion signals
were recorded with adequate intensities; cf. Supplementary
Figure S1a), the Bnative^ epitope peptide was not among them.
This observation is consistent with previous findings [26] that
place the His-RA33 protein into the group of difficult to digest
proteins. Therefore, the synthetic RA33 epitope peptide, resem-
bling the partial amino acid sequence aa78-92 of the His-RA33
protein (underlined partial sequence in Supplementary
Figure S1b), was spiked into the mixture (solution 1).
Upon electro-spraying solution 1 and after passing all ions
through the ion mobility cell and when 2 V TCE was applied,
the RA33 epitope peptide was observed as doubly charged
UBP ion withm/z 817.4 in the ESI-MS spectrum of the peptide
mixture (Figure 3 and Table 1). In the AToMZ plots of solu-
tions 1 and/or 3, the doubly charged UBP ion signal of the
RA33 epitope peptide was observed along the drift-time trend
line of the doubly charged peptides with an arrival time of
8.2 ms (Figure 3b).
By contrast, when ion mobility-separated ions from solution
3 were exposed to 220 V TCE, the only singly and doubly
Figure 1. NanoESI mass spectra and AToMZ plots from the FLAG
epitope peptide. (a), (b) Ion signals from solution 1 at low TCE (2 V), and
(c), (d) at high TCE (220V). (e), (f) Ion signals fromFLAGepitope peptide
in the presence of antiFLAGM2 antibody (solution 3) at low TCE (2 V),
and (g), (h) at high TCE (220 V). Solvent: 200 mM ammonium acetate,
pH 7.1. UBP positions are marked with orange solid line
circles; CoRP positions with red dotted line circles. Charge
states of selected UBPs and CoRPs are given. Trend lines of
ions are emphasized by orange and light red lines. For m/z
values of selected ion signals see Table 1
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charged ion signals in the AToMZ plot were CoRPs from the
RA33 epitope peptide (dotted circles in Figure 3c). Consistent
with previous observations, the arrival time of the doubly
charged RA33CoRP (i.e., the epitope peptide) was now shifted
to 18.7 ms and corresponded with the arrival time of the ions
from the antibody (Figure 4).
Of note, the accuracy of determination of the RA33 epitope
peptide in this experiment was 18 ppm (the experimentally
determined mass of the epitope peptide was 1633.8654, which
agrees well with the theoretical mass of 1633.8359). This find-
ing highlights the ITEM feature of determining the epitope
peptide mass with isotopic resolution and high mass accuracy
because at lowm/z range monoisotopic masses of CoRPs can be
determined very precisely. Conversely, in the high m/z range of
the mass spectrum of solution 3, three ion series were observed
for the antibody and the immune complexes with molecular
masses of 150,019.3 ± 72.5 Da, 151,640.3 ± 42.3 Da, and
153,273.1 ± 48.7 Da with average mass differences of
1621.0 Da and 1632.9 Da, respectively (Figure 5).
Hence, when using the experimentally determined masses
of the immune complexes to calculate the epitope peptide mass
directly from the ESI mass spectra, the accuracy with which the
RA33 epitope peptide (Mr 1633.8359) was determined was
7871 ppm and 573 ppm, respectively. Obviously, subtracting
experimentally determined masses of the antibody from the
masses of the immune complexes leads to rather imprecise
determination of the epitope peptide mass, independent of the
mass spectrometer performance. The primary reason for the
poor resolution of around 160 (FWHM) at this mass range is
due to the mean peak widths of the antibody/immune complex
ion signals, which were between 25 and 30 Th, caused mostly
by antibody heterogeneity.
The observations on AToMZ plot resolutions and inspec-
tions of m/z traces prompted us to investigate alternative quad-
rupole ion filtering as an approach within the ITEM method
(see Supplementary Results, section II). In contrast to quadru-
pole ion filtering, which functions like an off-switch with
respect to transmission of low m/z ions from the ESI source,
ion mobility filtering spreads out the ions that are produced in
the ESI source on a traveling time scale and allows adding an
extra dimension to the mass spectrum. This feature enables to
display the data as two-dimensional plots, termed AToMZ
plots, and affords instant identification of an ion signal as
deriving from a UBP or a CoRP without ambiguity.
Figure 2. NanoESI mass spectrum and AToMZ plot of
antiFLAG antibody. (a), (b) Ion signals from solution 2 at high
TCE (220 V). Solvent: 200 mM ammonium acetate, pH 7.1.
Selected multiply charged ion signals from the intact antibody
and its fragments and/or contaminants are labeled (cf. Supple-
mentary Table S1)
Figure 3. NanoESI mass spectra and AToMZ plots from the
His-RA33 peptides from in-solution digestion in the presence of
antiRA33 antibody. (a), (b) Ion signals from solution 3 at low TCE
(2 V), and (c), (d) at high TCE (220 V). Solvent: 200 mM ammo-
nium acetate, pH 7.1. UBP positions are marked with orange
solid line circles, CoRP positions with red dotted line circles.
Charge states of selected UBPs andCoRPs are given. Contrast
enhanced region is boxed;magnification factor is given. Form/z
values of selected ion signals see Table 1
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Application Examples
Epitope extraction We first applied the ITEM method to
identify the His-tag epitope from recombinant protein G´e by
epitope extraction. Protein G´e is a commercial protein [27]
from which 25 assignable peptide ion signals with adequate
intensities were produced by tryptic digestion (cf.
Supplementary Figure S2a), yielding 100% sequence coverage.
The complex peptide mixture containing the His-tag carrying
peptide served as solution 1. Solution 3 consisted of solution 1 to
which an antiHis-tag antibody (solution 2) was added. When
solution 3 was electrosprayed and ions were ion mobility sepa-
rated and exposed to 2 V TCE, the His-tag peptide was recorded
in the AToMZ plot as doubly and triply charged ion signals at
m/z 884.9 andm/z 590.3 with arrival times of 8.2 ms and 5.8 ms,
respectively (solid line circles in Figure 6; Table 1).
Electrospraying solution 3, separating all ions in the ion
mobility cell, and exposing the ions to 120 V TCE afforded
in the AToMZ plot singly charged ion signals for the His-tag
peptide at m/z 1768.9 (Table 1) but now with 21.5 ms arrival
time (dashed line circle in Figure 6c), which matched the
arrival time of the antibody ions and their respective fragment
ions (Supplementary Figure S3). This characteristic change in
position in the AToMZ plots qualified the His-tag peptide ions
as CoRPs, i.e., identified the peptide as epitope (underlined
partial sequence in Supplementary Figure S2b).
Interestingly, another peptide ion signal that survived frag-
mentation when 120 V TCE was applied was found at m/z
1535.6. It was assigned to the partial sequence aa17-31 from
protein G´e (cf. Supplementary Figure S2). However, the po-
sition of this ion signal in the AToMZ plots did not match the
arrival time of the antibody, indicating that it was not a CoRP
but survived fragmentation, at least partially, because of its
stability. Of note, in all spectra from the antiHis-tag antibody
(solution 2), rather strong ion signals within the mass range of
m/z 2000 and 4000 at arrival times above 12 ms were observed
from which molecular masses of ca. 38 kDa were calculated
(Supplementary Table S1). As these ion signals were present in
the AToMZ plots at both low TCE (data not shown) and high
TCE (Supplementary Figure S3), they were assigned as un-
known contaminants. Owing to their multiple charge states,
they did not interfere with assignment of epitope peptide ions
as the latter typically were doubly or singly protonated.
Even more intriguing was that in addition to the His-tag
carrying epitope peptide, two more closely spaced, singly
charged peptide ion signals with m/z 2144.9 and 2161.9 and
with arrival times of 24.2 ms each, were recorded in the
AToMZ plots when solution 3 was investigated with high
CID conditions (120 V TCE). As the arrival times of these
two ions matched those of the antibody (dashed squares in
Figure 6c), their positions in the AToMZ plots marked them
as CoRPs as well. The ion signal atm/z 2161.9 was assigned to
the identical partial amino acid sequences aa77-95 and/or
aa147-165 of protein G´e (dashed lines in Supplementary
Figure S2b), and the ion signal at m/z 2144.9 was regarded as
a deamination product therefrom (Table 1). The latter was most
likely produced by CID from the N-terminal Q residue [29] of
this peptide. Reexamination of the AToMZ plot from solution
3 with 2 V TCE revealed the presence of the respective doubly
charged peptide ion at m/z 1081.4 with 9.8 ms arrival time
(solid line rectangle in Figure 6b; the ion signal is marked with
B#^ in Supplementary Figure S2a). From X-ray crystallogra-
phy data it is known that protein G´e binds strongly to Fc parts
of antibodies [30] and the region of protein G´e that makes
contact with the antibodies encompasses the partial amino acid
sequences aa77-95 and/or aa147-165 [31]. Hence, our ITEM
result stands in full agreement with crystal structure analyses.
Figure 4. NanoESI mass spectrum and AToMZ plot of
antiRA33 antibody. (a), (b) Ion signals from solution 2 at high
TCE (220 V). Solvent: 200 mM ammonium acetate, pH 7.1.
Selected multiply charged ion signals from the intact antibody
and its fragments and/or contaminants are labeled (cf. Supple-
mentary Table S1)
Figure 5. NanoESI mass spectrum of the mixture of antiRA33
antibody and RA33 epitope peptide at 2 V TCE. Solvent:
200mM ammonium acetate, pH 7.1. The 1:2 (antibody:epitope)
mixture shows ion signals belonging to the antibody (series Ba^)
and to the immune complexes in which one epitope peptide
(series Bb^) and two epitope peptides (series Bc^) were bound,
respectively. Selected charge states and m/z values are
indicated
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More specific investigations on antibody-protein G binding can
be found in the Supplementary Results (section III).
Epitope Excision For epitope excision, we first prepared
solution 3 by mixing rhTNFα (as a full-length antigen) with
the antiHis-tag antibody and subjected this immune complex-
containing mixture to enzymatic digestion with trypsin. All
solvent mixing was done using 200 mM ammonium acetate
buffer (pH 7). Then, following the standard ITEM procedure,
we electrosprayed the resulting peptide and protein mixture as a
whole and exposed the ion mobility-separated ions first to low
(2 V TCE) and second to high (200 V TCE) fragmentation
conditions. When solution 3 was subjected to 2 V TCE
(Figure 7b, c, and Supplementary Figure S4), a few peptide
ion signals, which were formed upon digestion of the antigen
with trypsin, were observed in the low m/z range of the mass
spectrum, all with less than 15 ms arrival times. The His-tag-
carrying peptide was found as a doubly charged ion signal at
m/z 884.89 with an arrival time of 7.95 ms. The presence of the
Figure 6. NanoESI mass spectra and AToMZ plots from the
protein G´e peptides derived from in-solution digestion. (a), (b)
Ion signals from digest peptide mixture in the presence of
antiHis-tag antibody (solution 3) at low TCE (2 V), and (c), (d)
at high TCE (120 V). Solvent: 200 mM ammonium acetate, pH
7.1. UBP positions are marked with orange solid line circles and
yellow squares; CoRP positions with red dotted line circles and
dark yellow dotted squares. The blue arrow points to a non-
fragmenting peptide. Charge states of selected UBPs and
CoRPs are given. Trend lines of ions are emphasized by orange
and light red lines. Contrast-enhanced region is boxed; magni-
fication factor is given. For m/z values of selected ion signals
see Table 1
Figure 7. NanoESI mass spectra and AToMZ plots from the
rhTNFα peptides derived from epitope excision. (a), (b) Ion
signals from digest peptide mixture in the presence of the
antiHis-tag antibody (solution 3) at low TCE (2 V), and (c), (d)
at high TCE (120 V). Solvent: 200 mM ammonium acetate, pH
7.1. UBP positions are marked with orange solid line circles;
CoRP positions with red dotted line circles. Charge states of
selected UBPs and CoRPs are given. Trend line of ions is
emphasized by an orange line. Contrast enhanced region is
boxed; magnification factor is given. Form/z values of selected
ion signals see Table 1
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unbound His-tag peptide in this mixture can be explained by
the fact that rhTNFα is a trimer, potentially leaving some of the
His-tag peptides inaccessible to the antibody.
When the ion mobility-separated ions from solution 3 were
exposed to high TCE voltage, unbound peptides were
fragmented and the only nonfragmented ion signal that could
be attributed to the antigen was that of the doubly charged His-
tag-carrying peptide at m/z 884.88. But now its arrival time of
21.4 ms matched that of the antibody (Figure 7c). Again, the
antiHis-Tag antibody was prone to degradation when exposed
to high TCE voltage, producing many multiply charged and
some singly charged fragment ions (cf. Supplementary
Table S1). The fact that the peptide with m/z 884.88 survived
high TCE conditions and possessed an arrival time like that of
the anti-His-tag antibody proves that this peptide is a CoRP
and, consequently, the epitope peptide.
Discussion
We have developed the ITEM method to provide a facile and
routinely applicable procedure to rapidly determine antigen-
derived epitopes of an antibody of interest using both epitope
extraction and epitope excision. These two epitope mapping
methods have proven to be well applicable to identify assem-
bled (conformational, discontinuous) as well as sequential (lin-
ear, continuous) epitopes [14, 32] by mass spectrometry, and
typically afford peptide masses as read-outs by which the
epitopes are defined. It has been proven that higher-order
structured peptides are able to bind to antibodies. Peptides of
a certain length (ca. 6–10 amino acids and more) are known to
be able to adopt higher order structures such as alpha-helices in
solution [19, 33, 34], and peptides are known to be able to bind
to antibodies (or other binding partners) via a mechanism that is
called Binduced fit^ [35]. For instance, withWestern blotting as
well as with so-called peptide chips, one is able to identify
epitopes [26, 36] independent of the fact that by applying these
methods the structures that are bound by the antibodies are
taken out of the context of their highly structured Bnatively
folded^ antigen proteins. Despite not knowing the precise
structure of the bound amino acids in an immune complex,
the experimentally determined epitope is sufficiently encoded
by the peptide that contains the partial structure which is
recognized by the antibody. Hence, the identified CoRPs re-
flect the epitope peptides with high accuracy.
Our ITEM approach, in fact, follows the same step-wise
experimental sequence as was developed for in-solution epi-
tope mapping methods, yet without immobilization of the
antibody and/or the immune complex. Instead, after in-
solution formation of the specific antibody–peptide complex,
a transition of this complex into the gas phase is induced
together with all other constituents in that mixture. Sample
preparation for ITEM has, thus, been minimized to the gener-
ation of antigen/peptide-antibody mixtures using volatile
buffers. The demand on purity for both the antigen/peptide
solution (solution 1) and the antibody solution (solution 2) is
rather moderate. With nanospray capillaries, the consumed
volume in one experiment is ca. 3–5 μL and the amount of
required peptide and antibody is in the low pmol range for
each. In our hands, as long as a suitable electrospray was
obtained from the mixture (solution 3) the epitope mapping
experiment was successful.
Already during the desolvation step, electrospray conditions
can be selected such that weakly bound molecules and nonspe-
cifically bound Bstickier^ peptides are efficiently removed
from the specific immune complex while antibody–epitope
interactions are not broken; they are typically very strong with
KD values of around 10 nM [32]. Therefore, the traditional
Bwashing step^ that is implemented to remove nonspecific or
unbound mixture components occurs predominantly in the
transition step from solution to the gas phase in the source
and to a lesser extent within the ion mobility drift cell.
BElution^ of the epitope peptide from the immune complex is
achieved by efficient collision induced dissociation in the
transfer cell (or the collision cell). Simultaneously, peptides
that are not bound to the antibody (UBPs) but that passed the
ion filter are efficiently fragmented under the applied CID
conditions. After these simultaneous gas-phase processes,
which are equivalent to Bwashing^ and Belution^, only a few
peptides survived, resulting in just a few ion signals (i.e., spots
in an AToMZ plot) which, therefore, are easy to interpret.
It turned out that the harshness of both the electrospray and
the gas-phase dissociation conditions were to be fine-tuned to
match the individual stabilities of all constituents of the sprayed
mixture, including those of the antibodies [37], the peptides,
and the contaminants in order to obtain good signal intensities
(signal to noise values) and to simultaneously avoid generation
of too many Ab-derived fragment ion signals. In cases when
milder collision energy regimens in the transfer cell were
selected for successful ITEM analysis (e.g., 120 V as opposed
to 220 V), some fairly stable UBPs may survive unfragmented.
However, they can be easily identified by comparing their
arrival times with the arrival times of the antibody ion signals
(from solution 3) and by the absence of arrival time shifts.
Of note, since CoRP ions are not produced by the ESI
process in the source region of the mass spectrometer, they
receive/retain their protons (charges) from the antibody–epi-
tope complexes during CID in the transfer cell. Thus, in prin-
ciple it may be possible that neutral CoRPs are obtained by
CID, which would not be detectable in the mass spectrometer
and, therefore, ITEMmight be limited. Yet a number of studies
have shown that via CID an asymmetric distribution of charges
on the dissociated components occurs [38] in which the smaller
of the two complex partners takes the relatively larger numbers
of protons upon dissociation. This stands in agreement with our
observations that showed that the CoRPs were either singly or
doubly protonated upon dissociation of the immune complex.
Also, the fact that ionization of CoRPs is not taking place in the
ESI source makes them free from so-called Bmatrix effects^
where peptides from a more or less complex mixture are
competing for the available protons under the respective
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solution ionization conditions. Therefore, ion yields which are
observed for peptides that are ionized from complex peptide
mixtures are not decisive for the abundance by which the
epitope peptide ion signals will be observed by the ITEM
method. For comparison, high resolution structure analysis
techniques, such as X-ray diffraction [39, 40] or NMR [41] of
immune complexes, also suffer from limitations like high ma-
terial demands, time-consuming preparations, and molecular
size restrictions [42].
In addition to alternative ion filtering methods like ion
mobility and quadrupole separation that can be applied with
ITEM, there are several mass spectrometric methods that have
found application for gas-phase fragmentation of protein–pro-
tein complexes. Black-body infrared dissociation (BIRD)
seems one potential alternative for fragmentation of
noncovalent peptide–protein bonds. Yet BIRD is so far not
routinely available with commercial mass spectrometers [43,
44]. The closest alternative to CID breakage of noncovalent
bonds in the gas phase seems to be surface induced dissociation
(SID) [45, 46]. However, it was reported that in SID experi-
ments, charge distribution is more symmetric and charges are
distributed proportionally to the masses of dissociated constit-
uents [47].
In summary, ITEM is very powerful and allows the direct
identification of an epitope as in-solution handling is reduced to
mixing of antigen/epitope peptide and antibody solutions.
Since suitable mass spectrometry equipment has become avail-
able, our ITEM method seems to be easily adaptable by mass
spectrometry laboratories around the world.
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Section I (larger peptides) 
To test whether larger peptides with more than ten amino acids in length, i.e. with arrival times 
longer than 20 ms of the singly protonated ions, could be subjected to ITEM, again three 
solutions were prepared. Solution 1 consisted of the RA33 epitope peptide and solution 3 was a 
mix of the RA33 epitope peptide with the antiRA33 antibody (solution 2). Using solution 1 for 
electro-spraying, singly and doubly charged ion signals of the RA33 epitope peptide with m/z 
817.4 and m/z 1,633.8 (Table 1), and arrival times of 8.8 ms and 20.4 ms, respectively, were 
observed in the AToMZ plot as the major ion signals (solid line circles in Figure S5b) when 2 V 
TCE was applied. These ion signals were accompanied by low intensity fragment ion signals. 
As expected, the doubly charged ion signal was dominant. The mass spectrum of solution 2 at 
high TCE showed the multiply charged ions of the antibody as well as some multiply charged 
fragment ions (Figure 4; Table S1). When solution 3, consisting of a mixture of the RA33 
epitope peptide (solution 1) and the anti-hnRNP-A2/B1 antibody (solution 2), was electro-
sprayed and the ions passed through the ion mobility drift cell and were exposed to 220 V TCE, 
the corresponding AToMZ plot exhibited ion signals of the singly and doubly protonated RA33 
epitope peptide. Yet, in contrast to the results from solution 1, both ion signals were observed 
with arrival times of 19.5 ms (Figure S5c), matching with the arrival times of the ion signals of 
the antibody and its fragments. The overlaying antibody fragment ions did not interfere with 
epitope peptide assignment because multiply charged ions can easily be distinguished from 




Although at the moment the graphical means for visualization of AToMZ plots are somewhat low 
in resolution on the m/z scale, the assignment of an ion signal as UBP and/or CoRP was in all 
investigated cases unambiguous. The shift of arrival time of the epitope peptide could be 
tracked instantly by comparing AToMZ plots of solutions 3. Yet, if higher resolution on the m/z 
scale was needed, one can independently consult the m/z trace of the underlying data. 
Similarly, in case higher resolution on the arrival time scale was needed, one can plot the arrival 
time trace of an ion of interest and determine its intensity maximum using standard peak 
analysis software. But even without arrival time differences of longer epitope peptides, as in the 
case of the intact RA33 epitope peptide, the appearance of the singly charged ion signal under 
the selected high TCE conditions is indicative for the peptide to be derived from the immune-
complex, i.e. being a CoRP, since the respective UBP would be completely fragmented under 




Section II (quadrupole filtering) 
Quadrupole filtering was performed using a mixture of six synthetic peptides (solution 1), one of 
which was the Flag epitope peptide. Solution 3 was obtained by adding the antiFLAG M2 
antibody (solution 2) and was subjected to mass spectrometric analysis (Figure S6). TCE was 
kept at 2 V and the quadrupole filter was set to full transmission, i.e. all ions traversed the 
quadrupole, for recording all the ions from the peptide mixture (Figure S6a). Five ion signals 
were observed with different intensities. Then, the quadrupole was tuned to suppress all peptide 
ions in the low m/z range between m/z 500 and m/z 3000 (Figure S6b). Under these conditions 
only the ions of the antibody and of the immune complexes, respectively, were observed in the 




When TCE voltage was set to 200 V ion signals appeared again in the low m/z range. Since ion 
transmission from the ESI source was completely blocked, these low m/z ions must originate 
from the dissociated immune complex. We observed a singly charged ion signal of the epitope 
peptide at m/z 1013.40 together with fragment ion signals from the antibody, most of which 
were multiply charged (Figure S6c). The 7+ to 10+ ions signals indicated the presence of the 
light chain of the antibody with a molecular mass of 24215.84 ± 1.23 Da. Another fragment with 
a molecular mass of 13444.73 ± 0.89 Da was represented by 9+ and 6+ charged ion signals 
(Table S1). Of note, the other singly charged ion in this spectrum at m/z 810.40 could not be 
assigned to any of the peptides from solution 1 and, therefore, was assumed as being an 
antibody-derived fragment as well. 
 
The matching ion mobility filtering experiment with the exact same peptide mixture (solution 1) 
showed upon electro-spraying solution 3 and after passing all ions through the ion mobility cell 
and when 2 V TCE was applied, the FLAG epitope peptide as singly charged UBP ion with m/z 
1013.4 and an arrival time of 13.3 ms in the AToMZ plot; located along the arrival time trend line 




By contrast, when ion mobility separated ions from solution 3 were exposed to 220 V TCE the 
only singly charged ion signal in the AToMZ plot was a CoRP from the FLAG epitope peptide 
(dotted circle in Figure S7c). Consistent with previous observations, the arrival time of the singly 
charged FLAG CoRP, i.e. the epitope peptide, was now shifted to 18.8 ms and corresponded 





Section III (non-epitope peptide – antibody interactions) 
More specific investigations on antibody – protein G binding have been conducted to prove that 
the appearance of the peptides of solution 3 with ion signals at m/z 2,161.9 and m/z 2,144.9, 
both at 24.2 ms arrival time, was in fact reflecting a specific non-covalent in-solution bonding of 
this peptide to the Fc part of IgG. We performed an additional ITEM experiment using the 
antiFLAG M2 antibody (solution 2). As solution 1 we again applied the peptide mixture that was 
derived from tryptic digestion of protein G´e. As expected, the AToMZ plot from solution 3, i.e. 
the mixture of solutions 1 and 2, showed at 2 V TCE (Figure S8b) the presence of the Fc 
binding peptide of protein G´e that is indicated by the doubly charged ion at m/z 1,081.4 and 9.8 




When examining solution 3 at high TCE, the only singly charged CoRP ion signal was recorded 
in the AToMZ plot at m/z at 2,144.9 and 24.0 ms arrival time (Figure 8c), proving that the 
peptides with partial sequences aa77-95 and/or aa147-165 from protein G´e had been bound to 
the Fc part of the antiFLAG M2 antibody in-solution. Again, the explanation is that the in-solution 
complex between the protein G´e-derived peptide and the antiFLAG M2 antibody had been 
transitioned into the gas phase, had been separated from the UBPs of the protein G´e digest by 
ion mobility, and had been dissociated in the transfer cell under high fragmenting conditions. 
This finding, in fact, expands the applicability of our ITEM method for probing antigen-antibody, 
i.e. epitope-paratope interactions, to also other specific and stable in-solution protein-peptide 
interactions. The fact that the antiHis-tag antibody recognized the His-tag peptide from the 
protein G´e-derived peptide mixture as its epitope whereas the antiFlag M2 antibody, which can 
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Table S1: Antibody and fragment ions in nanoESI-MS/MS spectra and AToMZ plots of solutions 
2 at high TCE. 
 
antibody 
charge states of  
ion series 
arrival times [ms] exp. masses [Da] 
antiHis-tag 
a) 
27+ – 23+ 21.5 148,889.97 ± 19.25 
 14+ – 11+ >12 37,833.15 ± 240.86 
antiRA33 
b) 
28+ – 24+ 18.7 149,723.07 ± 54.94 
 8+ – 10+ 18.7 24,279.42 ± 11.07 
 9+ – 6+ 18.7 13,207.11 ± 1.16 
antiFLAG M2 
b) 
28+ – 24+ 18.6 148,430.43 ± 76.68 
 7+ – 10+ 18.6 24,215.84 ± 1.23 
 9+ – 6+ 18.6 13,444.73 ± 0.89 
a) 120 V TCE 






Figure S1: NanoESI mass spectrum of peptide mixture after in-solution digestion of His-RA33 
antigen and amino acid sequence. (a) Ion signals from solution 1 at low TCE (2 V). Solvent: 200 
mM ammonium acetate, pH 7.1. Selected ion signals are labeled with m/z values. Amino acid 
sequence ranges are indicated in parentheses. : RA33 epitope peptide. Sequence coverage: 
35 %. (b) Amino acid sequence of His-RA33 in single letter code. The epitope sequence for the 





Figure S2: NanoESI mass spectrum of peptide mixture after in-solution digestion of protein G´e 
antigen and amino acid sequence. (a) Ion signals from solution 1 at low TCE (2 V). Solvent: 200 
mM ammonium acetate, pH 7.1. Selected ion signals are labeled with m/z values. Amino acid 
sequence ranges are indicated in parentheses. : His-tag epitope peptide. #: peptides that bind 
to the Fc part of an IgG1 antibody. Sequence coverage: 100 %. (b) Amino acid sequence of 
protein G´e in single letter code. The epitope sequence for the antiHis-tag antibody (solid line) 






Figure S3: NanoESI mass spectrum and AToMZ plot of antiHis-tag antibody. (a,b) Ion signals 
from solution 2 at high TCE (120 V). Solvent: 200 mM ammonium acetate, pH 7.1.Selected 
multiply charged ion signals from the intact antibody and its fragments and/or contaminants are 






Figure S4: NanoESI mass spectrum of peptide mixture after in-solution digestion (epitope 
excision) of the immune complex consisting of the rhTNFα antigen and the anti-His-tag 
antibody. (a) Ion signals from solution 3 at low TCE (2 V). Solvent: 200 mM ammonium acetate, 
pH 7.1. Ion signals are labeled with m/z values. Amino acid sequence ranges are indicated in 
parentheses. : His-tag epitope peptide. (b) Amino acid sequence of rhTNFα in single letter 






Figure S5: NanoESI mass spectra and AToMZ plots from the RA33 epitope peptide. (a,b) Ion 
signals from solution 3 at low TCE (2 V) and (c,d) at high TCE (220 V). Solvent: 200 mM 
ammonium acetate, pH 7.1. UBP positions are marked with orange solid line circles, CoRP 
positions with red dotted line circles. Charge states of selected UBPs and CoRPs are given. 
Trend lines of ions are emphasized by orange and light red lines. For m/z values of selected ion 





Figure S6: NanoESI mass spectra of a synthetic peptide mixture and the anti-FLAG M2 
antibody. Ion signals from solution 1 (a) at low TCE (2 V). Ion signals from solution 3 (b) at low 
TCE (2 V) and (c) at high TCE (220 V). Solvent: 200 mM ammonium acetate, pH 7.1. The 
quadrupole profile in (a) was set to fully transmit all ions, in (b) and (c) it was set to block 
transmission of ions below m/z 3000. Selected ion signals are labeled with m/z values and 






Figure S7: NanoESI mass spectra and AToMZ plots from the synthetic peptide mixture that 
includes the FLAG epitope peptide. (a,b) Ion signals from solution 3, i.e. in the presence of the 
antiFLAG antibody, at low TCE (2 V) and (c,d) at high TCE (220 V). Solvent: 200 mM 
ammonium acetate, pH 7.1. UBP positions are marked with orange solid line circles; CoRP 
positions with red dotted line circles. Charge states of selected UBPs and CoRPs are given. 
Trend lines of ions are emphasized by orange and light red lines. For m/z values of selected ion 





Figure S8: NanoESI mass spectra and AToMZ plots from the protein G´e peptides from in-
solution digestion in the presence of antiFLAG-M2 antibody. (a,b) Ion signals from solution 3 at 
low TCE (2 V) and (c,d) at high TCE (220 V). Solvent: 200 mM ammonium acetate, pH 7.1. 
UBP positions are marked with orange solid line circles, CoRP positions with red dotted line 
circles. Charge states of selected UBPs and CoRPs are given. Contrast enhanced region is 
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epitope mapping. Sample con-
sumption is minimized and in-
solution handling reduced to
mixing of antibody and antigen
peptide solutions. After immune
complex formation in solution,
epitope mapping is performed in
the gas phase using the mass
spectrometer for sophisticated
ion manipulation and filtering.
Because amino acid sequence
information is obtained from the
epitope peptide, unknown anti-
gens can be identified. Knowing
the epitope broadens the appli-
cation of antibodies to unspeci-




• Multiplex epitope mapping/antigenic determinant identification in the gas phase.
• Intact transition and controlled dissociation of immune complexes by MS.
• Simultaneous identification and amino acid sequence determination of epitopes.
• Simplified in-solution sample handling because of ion manipulation and filtering by MS.
•
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Epitope mapping, which is the identification of antigenic
determinants, is essential for the design of novel anti-
body-based therapeutics and diagnostic tools. ITEM-
THREE is a mass spectrometry-based epitope mapping
method that can identify epitopes on antigens upon gen-
erating an immune complex in electrospray-compatible
solutions by adding an antibody of interest to a mixture of
peptides from which at least one holds the antibodys
epitope. This mixture is nano-electrosprayed without pu-
rification. Identification of the epitope peptide is per-
formed within a mass spectrometer that provides an ion
mobility cell sandwiched in-between two collision cells
and where this ion manipulation setup is flanked by a
quadrupole mass analyzer on one side and a time-of-flight
mass analyzer on the other side. In a stepwise fashion,
immune-complex ions are separated from unbound pep-
tide ions and dissociated to release epitope peptide ions.
Immune complex-released peptide ions are separated
from antibody ions and fragmented by collision induced
dissociation. Epitope-containing peptide fragment ions
are recorded, and mass lists are submitted to unsuper-
vised data base search thereby retrieving both, the amino
acid sequence of the epitope peptide and the originating
antigen. ITEM-THREE was developed with antiTRIM21
and antiRA33 antibodies for which the epitopes were
known, subjecting them to mixtures of synthetic peptides
of which one contained the respective epitope. ITEM-
THREE was then successfully tested with an enzymatic
digest of His-tagged recombinant human -actin and an
antiHis-tag antibody, as well as with an enzymatic digest
of recombinant human TNF and an antiTNF antibody
whose epitope was previously unknown. Molecular &
Cellular Proteomics 18: 2–14, 2019. DOI: 10.1074/mcp.
RA119.001429.
The identification of epitopes or antigenic determinants is
essential for the design of novel antibody-based therapeutics
and vaccines (1–4). With current personalized medicine con-
cepts (4, 5), epitope mapping, i.e. accurate identification of
antigenic determinants (epitopes) of protein antigens (6–8), is
very useful in the design of novel antibody-based diagnostic
tools, particularly for companion diagnostics (9, 10). Although
structure-based methods, such as X-ray crystallography (11,
12) and NMR (13, 14) have been regarded as “gold standard”
to map epitopes because they achieve atomic resolution, they
are not always readily applicable because a given antigen-
antibody pair may lie beyond the scope of either or both of
these methods, e.g. when the immune complex is not crys-
tallizable or is too large for NMR (15, 16). One great disad-
vantage of X-ray crystallography and NMR is that both require
rather large sample amounts (17, 18).
By contrast, the relatively low amounts of samples required
(19) and the rapidity (6) by which mass spectrometric epitope
mapping is executed is of great advantage in this respect (20).
Chemical cross-linking mass spectrometry (21, 22), hydro-
gen/deuterium exchange (HDX)1 mass spectrometry (23) and
mass spectrometric methods that employ chemical modifica-
tion on proteins, such as Fast Photochemical Oxidation of
Proteins (FPOP) (24, 25) or chemical modification of surface
exposed residues (26, 27) have been applied in epitope map-
ping experiments (28) and in determinations of protein - pro-
tein interaction sites in general (29), but their application may
be limited when rather demanding chemistries are involved,
or when performing such experiments becomes laborious,
and/or requires sophisticated laboratory equipment (20, 30).
Significant advances in epitope mapping protocols/methods
have been reached with the two most commonly used mass
spectrometric methods: epitope extraction and epitope
excision (20, 31, 32). These techniques have matured either
through automation of solution handling procedures (33) or by
minimizing in-solution handling, i.e. avoiding immobilization
procedures and other chemical reactions (6, 34).
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Advanced mass spectrometer designs have led to in-
creased flexibility by coupling various ion filtering devices with
different mass analyzers, and have opened new opportunities
for performing ion reactions, such as CID and SID (19, 35–39)
in the gas phase and/or laser irradiation and UV irradiation of
ions, respectively (36, 40, 41). The availability of mass spec-
trometers equipped with ion-mobility separation chambers
provide an additional dimension for the separation of ions
based on not only their m/z values but also on their shapes
and sizes (42–44). This new generation of mass spectrom-
eters led to the development of fast and easy to apply
epitope mapping methods by which epitope peptides of an
antibody of interest can be identified in a relatively simple
and robust fashion (6, 20). Based on our gas phase epitope
mapping strategy, termed ITEM-ONE (6), where epitopes of
known antigens have been identified by precisely determin-
ing the mass of the extracted epitope peptide, we have now
advanced to ITEM-THREE, where mass spectrometric
amino acid sequencing of unknown epitope peptides is
performed to identify an antigenic determinant on an anti-
gen surface.
MATERIALS AND METHODS
Proteins and Peptides—Mouse antiRA33 antibody (monoclonal an-
ti-hnRNP-A2/B1; clone DP3B3 lot: 044K4766) was obtained from
Sigma-Aldrich (Steinheim, Germany). Rabbit antiTRIM21 antibody
(polyclonal anti-52kDa Ro/SSA antibody; sc-20960 lot: F0503) raised
against amino acids 141–280 of TRIM21 (52kDa Ro/SSA) of human
origin was obtained from Santa Cruz Biotechnology, Inc. (Heidelberg,
Germany). Mouse antiHis-tag antibody (monoclonal antibody MCA
1396; Batch no. 0309) was supplied by Bio-Rad, (Munich, Germany)
and mouse antiTNF antibody (monoclonal antibody; catalogue no.
MA5-23720) was produced by ThermoFisher Scientific GmbH (Ulm,
Germany). Recombinant human TNF alpha (rhTNF) was a gift from
Prof. Harald Illges, Hochschule Bonn-Rhein-Sieg University of Ap-
plied Sciences, Germany. Actin, cytoplasmic 1 recombinant protein
was purchased from GenWay Biotech (Catalogue no. 10-288-
23014F, San Diego, CA). RA33 peptide (MAARPHSIDGRVVEP-NH2),
GPI peptide (ALKPYSPGGPR), Angiotensin II (DRVYIHPF), TRIM21A
peptide (LQELEKDEREQLRILGE), TRIM21B peptide (LQPLEKDE-
REQLRILGE) and TRIM21C peptide (LQELEKDEPEQLRILGE) were
synthesized by Peptides and Elephants GmbH (Potsdam, Ger-
many). The synthetic FLAG peptide (DYKDDDDK; article no.
020015) was obtained from ThermoFisher Scientific GmbH and
sequencing grade, modified trypsin was obtained from Promega
Corporation (Madison, WI).
Preparation of the Synthetic Peptide Mixture Solution (Solution
1)—A mixture of equimolar concentrations of seven synthetic
peptides (10 M each; GPI peptide, FLAG peptide, Angiotensin II,
TRIM21A peptide, TRIM21B peptide, TRIM21C peptide, and RA33
peptide) was prepared by dissolving the appropriate amounts of the
individual lyophilized peptide powders in freshly prepared 200 mM
ammonium acetate, pH 7.1 and mixing the appropriate volumes. The
peptide mixture-containing solution was shock-frozen and kept at
20 °C until either mass spectrometric analysis or immune complex
formation were performed.
Tryptic Digestion of Recombinant Human Beta Actin (Solution 1)—
Recombinant human beta actin (rhactin) was digested with trypsin
(26, 34, 45) using a modified Filter Aided Sample Preparation (FASP)
protocol. To 10 l of 200 mM DTT, dissolved in 0.1 M Tris/HCl
containing 8 M urea was added 20 l of rhactin solution (protein
concentration 1 g/l). This mixture was incubated at 37 °C for 30
min. Then, this solution was transferred into an equilibrated 30K
Amicon centrifugal filter (equilibration with 1% formic acid according
to protocol (46)) and 170 l of 8 M urea in 0.1 M Tris/HCl, pH 8.5, were
added and centrifuged at 13,000 rpm for 15 min. After discarding the
filtrate, 150 l of 8 M urea in 0.1 M Tris/HCl, pH 8.5, were added to the
retentate in the filter unit and centrifuged again at 13,000 rpm for 15
min. A further wash of the retentate was done by adding 100 l of
8 M urea in 0.1 M Tris/HCl, pH 8.5, to the filter unit and centrifuging at
13,000 rpm for 12 min. The filtrates were discarded and the retentate
was further washed for three times, first by adding 100 l, then 75 l,
and lastly 50 l of 50 mM ammonium bicarbonate solution, pH 8.6,
and each time centrifugation was performed at 13,000 rpm for 10 min,
12,000 rpm for 8 min, and 12,000 rpm for 6 min, respectively. After the
three washings, the filter unit containing the retentate (ca. 5 l) was
transferred into a new collection tube. A volume of 35 l of 11.42
ng/l of trypsin in 50 mM ammonium bicarbonate, pH 8.6, was added
to the protein that was dissolved in the solution on the filter unit to
obtain an enzyme/substrate ratio of 1:50 (w/w). The mixture was
incubated at room temperature in a wet chamber for 16 h and then
centrifuged at 8000 rpm for 5 min and at 12,000 rpm for 3 min. Next,
a volume of 40 l of 10 mM ammonium bicarbonate, pH 8.6, and a
further amount of 4 l of 0.1 g/l trypsin solution (composition see
above) was added and incubated at 37 °C for 2 h. Finally, the mixture
was centrifuged at 12,000 rpm for 8 min and the filtrate (ca. 80 l),
which contained the tryptic peptides, was collected for further anal-
ysis. The peptide concentration of the solution was determined using
the Qubit® 2.0 Fluorometer (Carlsbad, CA), following described pro-
cedures (6, 47). Aliquots (10 l, each), were shock-frozen and kept at
20 °C until either mass spectrometric analysis or immune complex
formation were performed.
Tryptic Digestion of Recombinant Human TNF Alpha (Solution 1)—
Tryptic digestion of recombinant human TNF alpha (26, 34, 45)
(rhTNF, 1 g/l) was performed by adding 15 l of the rhTNF
dissolved in 200 mM ammonium acetate, pH 7.1, to 32 l of trypsin
solution (9.4 ng/l in 4.8 mM Tris/HCl with 5 mM DTT) to yield an
enzyme/substrate ratio of 1:50 (w/w). This mixture was incubated at
37 °C for 20 h. The resulting tryptic peptide solution was divided into
nine aliquots, each of which contained a volume of 5 l. Each aliquot
was desalted by loading the entire 5 l volume onto one C18 ZipTip
Pipette Tip (Merck Millipore Ltd, Tullagreen, Carrigtwohill, Co. Cork,
Ireland) that had been wetted with a mixture of deionized H2O/ACN
(50:50, v/v). Equilibration and washing solutions consisted of 1%
HCOOH in deionized H2O; two times 10 l were used for each step.
The affinity-bound peptides were eluted into 5 l of 1% HCOOH in
H2O : 1% HCOOH in ACN (50:50, v/v) (46, 48). Next, all nine
desalted portions of the tryptic peptide-containing solutions were
pooled to obtain a total volume of 45 l. This solution was aliquoted
into 10 l volumes, shock-frozen and kept at 20 °C until either
mass spectrometric analysis or immune complex formation were
performed.
Preparation of Antibody Solutions (Solution 2)—As described pre-
viously (6), a volume of 30 l of 0.8 g/l of antiRA33 antibody
solution was loaded onto a 50K Amicon centrifugal filter (Merck
Millipore Ltd, Tullagreen, Carrigtwohill, Co. Cork, Ireland) and 470 l
of 200 mM ammonium acetate, pH 7.1, was added. The resulting
1 The abbreviations used are: HDX, hydrogen deuterium exchange;
Nano-ESI, nano-electrospray ionization; IMS, ion mobility separation;
ToF, time of flight; CID, collision induced dissociation; CV, collision
cell voltage difference; UBPs, unbound peptide ions; CoRPs, com-
plex-released peptide ions; BLAST, basic local alignment search tool.
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solution was centrifuged at 13,000 rpm for 10 min for eight times.
Each time the filtrates were discarded and 470 l of 200 mM ammo-
nium acetate, pH 7.1, were added to the retentates. After the last
centrifugation the filter units were inverted and placed into new tubes
and centrifuged at 4500 rpm for 5 min to collect the retentates of ca.
20 l antibody solution in each case. Protein concentrations were
determined using the Qubit® 2.0 Fluorometer following described
procedures (6). Similarly, 100 l of 0.2 g/l of antiTRIM21 antibody
solution, 20 l of 1.0 g/l antiHis-tag antibody solution, and 40 l of
0.5 g/l of antiTNF antibody solution, which were all obtained from
suppliers in PBS buffer, were buffer exchanged into 200 mM ammo-
nium acetate buffer, pH 7.1.
Preparation of Immune Complex-containing Solutions (Solution
3)—For immune complex formation, a final concentration of ca. 0.2
g/l of each antibody-containing solution (solution 2) was prepared
by diluting the solutions obtained from the buffer exchange with 200
mM ammonium acetate, pH 7.1. Solutions 3 were binary mixtures of
one Solution 1 with one Solution 2 to obtain the molar ratios of 2.2:1
(epitope peptide/antibody) in each of Solutions 3. Immune complex-
containing mixtures (Solutions 3) were incubated at room temperature
for at least 1 h.
NanoESI-IMS-MS/MS Instrument Settings and Spray Needle Prep-
aration—NanoESI-IMS-MS/MS measurements were carried out in
positive ion mode on a quadrupole ion-mobility separation time-of-
flight mass spectrometer (Synapt G2-S, Waters MS-Technologies,
Manchester, United Kingdom) as described (6). The m/z range 200–
8000 of the time-of-flight analyzer was calibrated externally using a 1
mg/ml sodium iodide solution dissolved in an isopropanol/water mix-
ture (50:50, v/v). Measurements were performed with the following
instrumental settings; source temperature, 50 °C; capillary voltage,
1.60–1.90 kV; source offset, 80–100 V; sample cone voltage, 90–120
V; TRAP cell gas flow, 6.0 ml/min; cone gas flow, 100 liters/h. Gas
controls were set to automatic as follows: TRAP cell gas flow, 2.0
ml/min; helium cell gas flow, 180 ml/min; IMS cell gas flow, 90 ml/min.
IMS wave velocity and wave height were manually set to 650 m/s and
40 V, respectively. Start wave height and end wave height were also
optimized with 30–35 V and 20–25 V, respectively, for each experi-
ment to obtain adequate ion mobility separation. Pusher width and
pusher cycle times were both set to automatic. Scan duration of 1.0 s
and inter scan delay of 0.015 s were set for both IMS and MS
measurements. Reflectron grid, flight tube and reflectron voltages
were 1.46 kV, 10.00 kV and 3.78 kV, respectively, and detector
sensitivity was set to normal. Pressure settings within the various
parts of the mass spectrometer were as follows: TRAP cell, 2.2 
102 mbar; Helium cell, 1.35  103 mbar; IMS cell, 3.5  100
mbar; TRANSFER cell, 2.6  102 mbar; ToF analyzer, 8.0  107
mbar. Spray needles were prepared in-house from borosilicate glass
tubes of 1 mm outer and 0.5 mm inner diameters with a P-1000
Flaming/BrownTM Micropipette Puller System (Sutter Instruments,
Novato, CA, USA) followed by gold coating, applying the Sputter
Coater SCD 005 (BAL-TEC Inc., Balzers, Liechtenstein) (6, 47).
NanoESI-IMS-MS/MS Measurements for Epitope Mapping—To
perform ITEM-THREE experiments, solutions 3 (ca. 3 l, each) were
loaded into spray needles with the aid of 20 l microloader pipette
tips (Eppendorf AG, Hamburg, Germany) and were electrosprayed
without any purification. In the mass spectrometer, the quadrupole
analyzer was first used to block transmission of lower molecular
weight ions (filter off ions below m/z 5000) by manually setting the
quadrupole appropriately (6). The epitope peptide-antibody com-
plexes were able to transit the quadrupole intact. Next, dissociation of
the epitope peptide-antibody complexes in the TRAP cell (first colli-
sion cell) was achieved by increasing the collision cell voltage differ-
ence (CV) to between 50 and 80 V. The collision voltage differences
in the TRAP cell were raised in a stepwise manner (5–20 V/step) and
were so optimized for each experiment to ensure adequate dissoci-
ation of the antibody - peptide complex with minimal antibody frag-
mentation. The dissociated complex constituents then entered the ion
mobility chamber where they were separated according to their m/z
values, sizes and shapes. Finally, the collision cell voltage differences
(CV) in the TRANSFER cell (second collision cell) were also in-
creased to 40–70 V to cause enough fragmentation of the complex
released peptides (CoRPs). Again, the collision voltage differences in
the TRANSFER cell were raised in a stepwise manner (5–20 V/step) to
adjust optimized peptide ion fragmentation conditions for each ex-
periment. Both ion mobility raw data (arrival time of ions) and mass
spectral raw data were collected and stored using MassLynx software
4.1 (Waters MS-Technologies). The mass spectrometry data have
been deposited in the PRIDE database (49).
Mascot Database Search with MS/MS Fragment Ions—After se-
lecting the arrival time of the released epitope peptide ion, raw data
from an MS/MS spectrum were de-convoluted and de-isotoped and
then converted into peak lists using the MaxEnt3 algorithm on the
MassLynx version 4.1 software. The peak list was then saved as a
SEQUEST file (*.DTA) that was then uploaded onto the Mascot (Matrix
Science Ltd., London, UK) search engine (50, 51), using the UniProt
database (release 2018_06) that contained 557,713 sequences and
an “amended UniProt” database that was generated to contain the
amino acid sequences of the recombinant antigens in addition to all
the amino acid sequence entries of the UniProt database (release
2018_06). The search parameters were set as follows: taxonomy, all
entries; enzyme, none or trypsin (where tryptic digests were used),
and up to 1 missed cleavage was allowed. Fixed modifications,
carbamidomethylation of cysteine, and variable modifications, dicar-
bamidomethylation of lysine, were selected where necessary. Peptide
mass tolerance and MS/MS ion mass tolerance were both set to 0.3
Da. Threshold ion scores were used in accepting the individual spec-
tra. The ion scores above these thresholds indicated amino acid
sequence with significant homology to the sequence entries from the
data base.
NCBI BLAST of Identified Epitope Peptides—The amino acid se-
quence of the first hit from the Mascot search (epitope peptide) was
submitted to an NCBI BLAST search using the following parameters:
database, Uniprot (release 2018_06); organisms, all; max target se-
quence, 250; expect threshold, 2000; matrix PAM50 (52).
RESULTS
Method Development—
Immune Complex Formation and Epitope Identification for
the antiRA33 Antibody—On electrospraying a peptide mixture
that consists of seven synthetic peptides dissolved in aque-
ous ammonium acetate (solution 1) and operating the mass
spectrometer in positive ion and ion mobility separation
modes, the arrival times of the peptide ions at the end of the
ion mobility separation chamber were recorded between 4 ms
and 14 ms, respectively. The mass spectrum showed all ion
signals from this arrival time regime as mainly singly and
doubly charged ion signals within the mass range between
m/z 300 and m/z 1600 (Fig. 1A–1B). In addition, fragment ions
from the FLAG peptide and the GPI peptide were recorded as
well (supplemental Table S1), despite low voltage differences
(ca. 2 V to 4 V) in both, the TRAP cell that is the first collision
cell located behind the quadrupole but in front of the ion
mobility separation chamber, and the TRANSFER cell, which
is the second collision cell, located behind the ion mobility
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separation chamber but in front of the ToF analyzer. As ex-
pected, in later arrival time regimes, i.e. above 16 ms, the
mass spectrum of this peptide mixture did not show any ion
signals (supplemental Fig. S1A–S1B).
Adding the antiRA33 antibody (solution 2) to the synthetic
peptide mixture (solution 1) produced solution 3 in which
formation of the immune complex occurred, consisting of
RA33 epitope peptide and antiRA33 antibody. Electrospray-
ing solution 3 and setting the quadrupole to block transmis-
sion of ions with m/z values below m/z 5000, only the intact
immune complex ions as well as free antibody ions were able
to traverse the quadrupole ion filter. The high molecular
weight components of solution 3 produced multiply charged
ions, ranging from 24 to 30 charge states, which all ap-
peared abovem/z 5000 (supplemental Fig. S1C–S1D, cf. sup-
plemental Table S3). All these multiply charged ion signals
were recorded with arrival times between 16 ms and 22 ms at
the end of the ion mobility separation chamber (Fig. 1C). On
looking at the arrival time regime where the unbound peptide
ions (UBPs) were expected to reach the end of the ion mobility
separation chamber (4 ms to 14 ms), there appeared no
peptide ion signals within the mass range of m/z 300 to m/z
1600 (Fig. 1D).
However, when higher collision cell voltage differences (50
V) were applied in the TRAP cell, collision of the immune
complex ions with argon gas atoms caused dissociation of
singly and/or doubly charged peptide ions from the multiply
charged immune complex ions. The complex-released pep-
tide ions (CoRPs) were detected with arrival times of around
13 ms and the corresponding arrival time-matched mass
spectrum showed doubly charged ions at m/z 817.48 and at
m/z 825.48 for the RA33 epitope peptide and its oxygenated
product, both with mass accuracies of 61 ppm (Fig. 1E–1F).
Obviously, after intact transition into the gas phase, the re-
spective multiply charged immune complex ions traversed the
quadrupole mass filter while the quadrupole effectively
blocked transmission of all UBPs (Fig. 1C–1D).
Next, the collision cell voltage difference in the TRANSFER
cell was increased to 60 V to fragment (rupture) the CoRPs,
which had been generated in the TRAP cell. Thus, at high
collision cell voltage differences in both the TRAP cell (50 V)
and the TRANSFER cell (60 V) fragment ions of the RA33
epitope peptide were recorded with the same arrival times
(ca. 13 ms) as the precursor CoRP ions (Fig. 1H). Additionally,
when high collision cell voltage differences in both collision
cells are applied, multiply charged antibody fragment ions
FIG. 1. Mass spectrometric dissociation of the RA33 epitope peptide – antiRA33 antibody complex and amino acid sequence
determination of the complex-released peptide by mass spectrometric fragmentation. Ion mobility arrival time plots of A, Solution 1, C,
and E, Solution 3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the
quadrupole are indicated at the right. B, D, and F, nanoESI mass spectra (low m/z range) of ions from selected arrival time ranges. Selected
m/z values are given and charge states are indicated in parentheses. For ion signal assignments see supplemental Table S1. G, Amino acid
sequence of the complex-released peptide (single letter code) as determined by the matched mass spectrometric fragment ions (fragment ion
types and numbers are indicated). The Uniprot protein ID of the peptide source protein (first hit) is shown. H, Pseudo mass spectrum (after
charge deconvolution and de-isotoping) of fragment ions derived by selecting arrival time of the complex-released peptide with m/z 817.48.
For ion signal assignments see supplemental Table S2.
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appeared at around m/z 2000 with arrival times similar to
those of the intact immune complex ions and/or the ions of
the free antibody (supplemental Fig. S1E–S1F).
After processing the raw data from the CoRP fragment ion
mass spectra by de-isotoping and deconvolution of charge
states, and after submitting the list of fragment ions to data
base search using the Mascot search engine, the best hit from
the search result reported the amino acid sequence of the
RA33 peptide (Fig. 1G). In addition to b-type and y-type ions,
some b-type and y-type ions that had lost ammonia were
identified as well (supplemental Table S2). The best hit re-
ported a score of 43 (threshold 34), indicating that the deter-
mined amino acid sequence had a significant homology to the
sequence entry from the data base. In addition to the amino
acid sequence the data base entry revealed the name of the
originating protein, hence the antigen.
Although the CoRPs, i.e. epitope peptides, which had been
generated in the TRAP cell could be identified with high mass
accuracies by comparing their monoisotopic masses to the
known masses of all the peptides in the peptide mixture
(solution 1), fragmenting the CoRP ions by increasing the
collision cell voltage difference in the TRANSFER cell enabled
experimental determination of the respective partial amino
acid sequence on data base search, thereby substantiating
epitope identification.
Immune Complex Formation and Epitope Identification for
the antiTRIM21 Antibody—To further test our ITEM-THREE
workflow an antiTRIM21 antibody (solution 2) was added to
the mixture of synthetic peptides (solution 1), thereby obtain-
ing TRIM21 epitope peptide - antiTRIM21 antibody com-
plexes in solution 3. As before, the arrival times of the peptide
ions at the end of the ion mobility separation chamber were
recorded between 4 ms and 14 ms, respectively. The mass
spectrum showed all ion signals from this arrival time regime
as mainly singly and doubly charged ion signals within the
mass range between m/z 300 and m/z 1600 (Fig. 2A–2B).
Again, and as expected, the mass spectrum of this peptide
mixture did not show any ion signals in later arrival time
regimes, i.e. above 16 ms (supplemental Fig. S2A–S2B).
Electrospraying solution 3 and setting the quadrupole to
block transmission of ions below m/z 5000, only the multiply
charged ions of the intact immune complex and of the free
antibody traversed the quadrupole and the ion mobility sep-
aration chamber with arrival times of between 19 ms and 28
ms (Fig. 2C). Like before, within the time regime at which the
peptides’ arrivals at the end of the ion mobility separation
FIG. 2. Mass spectrometric dissociation of the TRIM21 epitope peptide – antiTRIM21 antibody complex and amino acid sequence
determination of the complex-released peptides by mass spectrometric fragmentation. Ion mobility arrival time plots of A, Solution 1, C,
and E, Solution 3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the
quadrupole are indicated at the right. B, D, and F, nanoESI mass spectra (low m/z range) of ions from selected arrival time ranges. Selected
m/z values are given, and charge states are indicated in parentheses. For ion signal assignments see supplemental Table S1. G, Amino acid
sequence of the complex-released peptide (single letter code) as determined by the matched mass spectrometric fragment ions (fragment ion
types and numbers are indicated). The Uniprot protein ID of the peptide source protein (first hit) is shown. H, Pseudo mass spectrum (after
charge deconvolution and de-isotoping) of fragment ions derived by selecting arrival time of the complex-released peptide with m/z 1049.66.
The “ ” marks ions that belong to the peptide with ion signal at m/z 1033.64. For ion signal assignments see supplemental Tables S4 and S5.
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chamber were expected (4 ms to 14 ms), no peptide ion
signals were seen in the mass range belowm/z 1600 (Fig. 2D).
However, contrary to the case of antiRA33 antibody-RA33
epitope peptide complex, the mass spectrum that covered
the arrival time range of 19 ms to 28 ms of the TRIM21 epitope
peptide - antiTRIM21 antibody complex showed the presence
of unresolved antiTRIM21 antibody together with TRIM21
epitope peptide-antiTRIM21 antibody complex ion signals at
abovem/z 5000. Their charge states ranged from 23 to 28
(supplemental Fig. S2C–S2D, cf. supplemental Table S6). De-
spite the unresolved multiply charged ion signals, this result
repeatedly showed that the quadrupole was effectively filter-
ing off UBPs.
On raising the TRAP cell voltage difference to 80 V and
looking at the mass spectra that matched to the arrival times
of CoRPs, in this case approx. 8 ms (Fig. 2E–2F), there ap-
peared two doubly charged peptides, one atm/z 1049.66 and
one at m/z 1033.64. By comparing the monoisotopic masses
of these ions to the masses of the peptide ions that were
contained in the peptide mixture (solution 1), the ion signal at
m/z 1049.66 was assigned to the TRIM21A peptide with a
mass accuracy of 85 ppm. Likewise, the ion signal at m/z
1033.64 was assigned to the TRIM21B peptide with a mass
accuracy of 68 ppm (cf. supplemental Table S1). It is worth
noting that the TRIM21C peptide, which was a constituent of
the peptide mixture (solution 1) had not bound to the an-
tiTRIM21 antibody and, hence, did not show up as a CoRP
but remained a UBP.
When the TRANSFER cell voltage difference was increased
to 70 V, both doubly charged precursor CoRP ions were
simultaneously fragmented. The respective fragment ion
spectrum that corresponded to the arrival time of the doubly
charged precursor ions (ca. 8 ms) showed a mixture of the
fragment ions. On performing data base search with the de-
convoluted and de-isotoped fragment mass list, only the
TRIM21A peptide sequence was reported as best hit with a
score of 46 (threshold 37; Fig. 2G–2H, cf. supplemental Table
S4), because only the wild type epitope peptide sequence
was included in the Uniprot database. The TRIM21B peptide
was identified (score 27; threshold 35) when repeating the
data base search and applying the amended Uniprot data-
base that contained the manually added amino acid sequence
with the respective amino acid exchange (Fig. 2H, cf. supple-
mental Table S5). For the TRIM21A peptide both, b-type and
y-type ions were assigned. Additionally, ion signals were ob-
served for b-type and y-type fragment ions that had lost
ammonia or water (supplemental Table S4). For the TRIM21B
peptide barely b-type ions with loss of ammonia or water were
seen (supplemental Table S5).
The mass spectra that were recorded at high collision cell
energies in both, the TRAP cell and the TRANSFER cell, and
selection of arrival times from 19 ms to 28 ms, where the
multiply charged ion signals of unresolved TRIM21 epitope
peptide - antiTRIM21 antibody immune complexes and free
antibody had appeared, showed in addition to these ion sig-
nals the presence of multiply charged antibody fragment ions
(supplemental Fig. S2E–S2F, cf. supplemental Table S6). To
unequivocally assign antibody fragment ion signals we per-
formed control experiments by individually electrospraying
the antibody solutions (solutions 2), one after the other, under
the same fragmentation conditions for comparisons (data not
shown).
Application Examples—
Immune Complex Formation and Epitope Identification for
the antiHis-tag Antibody—As a first application example, we
performed our ITEM-THREE method to identify a His-tag
epitope peptide from the 6-times histidine tagged recombi-
nant human beta actin (rhactin) using an antiHis-tag anti-
body. To generate solution 1 an in-solution tryptic digestion of
the His-tagged rhactin was performed. The arrival times of
the tryptic peptide ions from solution 1, after traversing the
quadrupole and the ion mobility separation chamber, ranged
from 4 ms to 14 ms when measured at low collision cell
voltage differences in both, the TRAP cell (4V) and the
TRANSFER cell (2V). The corresponding mass spectrum
showed ion signals below m/z 1600, which covered 55% of
the amino acid sequence of the full length rhactin (Fig.
3A–3B, cf. supplemental Fig. S5, supplemental Table S7).
However, none of the peptide masses from the mass spec-
trum could be assigned to the C-terminal tryptic peptide,
which contained the His-tag. In the mass range above m/z
5000, there were no ion signals present (supplemental Fig.
S4A–S4B).
The antiHis-tag antibody (solution 2) was added to solution
1 and the mixture (solution 3) was electrosprayed without any
further purification after an incubation period of 1 h at room
temperature. When analyzing solution 3 at low collision cell
voltage differences in both the TRAP cell and the TRANSFER
cell and with setting the quadrupole to block transmission of
UBPs, no ion signals appeared in the mass spectrum below
m/z 1600 (Fig. 3C–3D). In the mass range above m/z 5000
multiply charged ion signals of unresolved antiHis-tag anti-
body and His-tag peptide-anti-Histag antiHis-tag antibody
complex were recorded with charge states ranging from 22
to 27 (supplemental Fig. S4C–S4D, cf. supplemental Table
S10).
After raising the collision cell voltage difference to 50 V in
the TRAP cell, there appeared a doubly charged CoRP ion
signal at m/z 695.82 with an arrival time of around 11 ms (Fig.
3E–3F). Surprisingly, the mass of this ion signal did not match
to any of the predicted tryptic peptide masses from rhactin.
With an additional high collision cell voltage difference (40 V)
in the TRANSFER cell, we were able to obtain the fragment
ions of the corresponding CoRP, i.e. the peptide that was
pulled out by the antiHis-tag antibody, hence the epitope
containing peptide. After processing the ion signals from the
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fragment ion spectrum of the low m/z range and submitting
the mass list to Uniprot data base search using the Mascot
search engine, an assignment of the doubly charged CoRP
was obtained for a peptide with three histidine residues in a
row (Fig. 3G–3H), originating from Phospho-N-acetylmu-
ramoyl-pentapeptide-transferase (MRAY_PSYIN) from Psy-
chromonas ingrahamii (strain 37). The reported peptide se-
quence only provided 33% homology to the His-tag peptide
from rhactin that was used in the experiment. Although
the search engine reported a false positive hit (score 18), the
thereby suggested amino acid sequence indicated that the
epitope peptide indeed contained a set of consecutively ar-
ranged histidine residues. After including the amino acid se-
quence of the His-tagged rhactin into the amended Uniprot
database, we obtained the C-terminal peptide from rhactin
as chemically modified six histidine residue encompassing
peptide as best hit (score 22; threshold 23) for the fragmented
epitope peptide, i.e. the precursor ion at m/z 695.82. Of note,
the mass difference of 114.04 Da between the measured
and the theoretical masses of the tryptic His-tag peptide
KC(carb)FHHHHHH was assumed to be because of di-carb-
amidomethylation on the lysine K373 residue (supplemental
Fig. S3, cf. supplemental Table S9) in addition to carbam-
idomethylation of the cysteine C374 residue. Chemical mod-
ification on the K373 residue stands in agreement with shield-
ing this lysine residue from enzymatic cleavage; explaining the
“missed cleavage” at this amino acid residue (cf. supplemen-
tal Table S7).
At high collision cell energies in both the TRAP cell and the
TRANSFER cell, the mass spectrum of high m/z range (above
m/z 5000) with arrival times between 15 ms and 23 ms
showed multiply charged ion signals of intact antibody unre-
solved from immune complex ions together with antibody
fragments ions (supplemental Fig. S4E–S4F).
Immune Complex Formation and Epitope Identification for
the antiTNF Antibody—Because the ITEM-THREE method
successfully identified epitope peptides from either synthetic
peptide mixtures or from peptide mixtures originating from
digested antigen proteins when exposed to the respective
antibody, we applied our procedure to the identification of the
unknown epitope of an antiTNF antibody. Like before, solu-
tion 1 was generated by tryptic digestion of the protein, in this
case the trimeric recombinant human TNF (rhTNF). The
rhTNF tryptic peptides’ arrival times ranged from 4 ms to 12
ms and produced ion signals below m/z 1600 that covered
100% of the entire amino acid sequence of the full length
FIG. 3. Mass spectrometric dissociation of the His-tag epitope peptide – antiHis-tag antibody complex and amino acid sequence
determination of the complex-released peptide by mass spectrometric fragmentation. Ion mobility arrival time plots of A, Solution 1, C,
and E, Solution 3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the
quadrupole are indicated at the right. B, D, and F, nanoESI mass spectra (low m/z range) of ions from selected arrival time ranges. Selected
m/z values are given and charge states are indicated in parentheses. For ion signal assignments see supplemental Table S7. G, Amino acid
sequence of the complex-released peptide (single letter code) as determined by the matched mass spectrometric fragment ions (fragment ion
types and numbers are indicated). The Uniprot protein id of the peptide source protein (first hit) is shown. H, Pseudo mass spectrum (after
charge deconvolution and de-isotoping) of fragment ions derived by selecting arrival time of the complex-released peptide with m/z 695.82.
For ion signal assignments see supplemental Table S8.
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protein monomer (Fig. 4A–4B). After addition of the antiTNF
antibody (solution 2) and incubation for 1 h at room temper-
ature, solution 3 was electrosprayed. Setting the quadrupole
analyzer to block transmission of unbound peptide ions from
solution 3, there appeared no peptide ions in the lower mass
range (m/z below 1600) but in the higher mass range (m/z
above 5000) there appeared unresolved ion signals of
antiTNF antibody and rhTNF epitope peptide-antiTNF an-
tibody immune complexes with charge states ranging from
22 to 27 (Fig. 4C–4D and supplemental Fig. S7). Then, on
raising the TRAP cell voltage difference to 50 V, two singly
charged ion signals, one at m/z 857.60 and one at m/z 909.57
showed up with significant intensities in the corresponding
mass spectrum (Fig. 4E–4F). Albeit these two CoRPs over-
lapped with respect to their arrival times of approx. 11 ms,
they could be separately fragmented by applying different
TRANSFER cell voltage differences. A TRANSFER cell voltage
difference of 50 V was required to efficiently fragment the
precursor CoRP ion at m/z 857.60 whereas a TRANSFER cell
voltage difference of 55 V was needed to obtain high enough
yields of fragment ions of the precursor CoRP ion at m/z
909.57. Subsequent submission of the two different mass lists
from the processed fragment ion mass spectra to Uniprot
data base search revealed two amino acid sequences, VNLL-
SAIK for the CoRP with m/z 857.60 (score 14; threshold 26,
aa79–86) and IAVSYQTK for the CoRP withm/z 909.57 (score
35; threshold 26, aa87–94), respectively (Fig. 4G–4H and
supplemental Fig. S6, cf.supplemental Tables S12–S13). The
lower score for VNLLSAIK can be explained by the fact that at
the TRANSFER cell collision voltage of 50 V that was applied
to sufficiently fragment the precursor ion at m/z 857.60 some
rather high intensity fragments of the IAVSYQTK precursor
peptide were seen as well, now characterized as noise. Be-
cause unmatched ion signals generate a penalty in the Mas-
cot algorithm, the ion score for the amino acid sequence of
the target peptide is low. Interestingly, the two peptides are
located adjacent to each other in the amino acid sequence of
the rhTNF (supplemental Fig. S8).
To examine whether both peptides together form the
antiTNF antibody epitope or, alternatively, to decide which of
the two peptide contained the specific epitope, we compared
their hydrophobicity values and solvent accessible surface
areas (asa) using X-ray crystallographic data (1tnf.pdb). Our
computational investigations revealed that the amino acid
residues of the VNLLSAIK peptide (aa79–86) were highly
hydrophobic and only surface accessible when assuming the
FIG. 4. Mass spectrometric dissociation of the TNF epitope peptide – anti TNF antibody complex and amino acid sequence
determination of the complex-released peptide by mass spectrometric fragmentation. Ion mobility arrival time plots of A, Solution 1, C,
and E, Solution 3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the
quadrupole are indicated at the right. B, D, and F, nanoESI mass spectra (low m/z range) of ions from selected arrival time ranges. Selected
m/z values are given, and charge states are indicated in parentheses. For ion signal assignments see supplemental Table S11. G, Amino acid
sequence of the complex-released peptide (single letter code) as determined by the matched mass spectrometric fragment ions (fragment ion
types and numbers are indicated). The Uniprot protein id of the peptide source protein (first hit) is shown. H, Pseudo mass spectrum (after
charge deconvolution and de-isotoping) of fragment ions derived by selecting arrival time of the complex-released peptide with m/z 909.57.
For ion signal assignments see supplemental Table S12.
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presence of monomeric rhTNF. By contrast, the residues of
the IAVSYQTK peptide were highly surface accessible in both,
trimeric andmonomeric rhTNF. The IAVSYQTK peptide (aa87–
94) is rather hydrophilic as compared with the VNLLSAIK pep-
tide (supplemental Fig. S9).
From this comparison it can be concluded that on the
trimeric rhTNF the IAVSYQTK peptide is highly surface ex-
posed and, hence, is better accessible for antibody (paratope)
recognition than the VNLLSAIK peptide. On the other hand it
can be argued that the residues of VNLLSAIK are involved in
the trimerization interface of TNF and, consistent with the
three dimensional structure of TNF, only become surface
exposed on destroying the rhTNF trimer (Fig. 5). Thus, the
appearance of the VNLLSAIK peptide in the ITEM-THREE
experiment may be a result of nonspecific interaction of this
peptide to the antibody that could be attributed to its “stick-
iness” because of its many hydrophobic residues.
However, when in control experiments either rituximab or a
mouse monoclonal anti-actin antibody (solutions 2) was
added to the rhTNF tryptic peptide mixtures (solution 1) not
a single peptide was fished out by either of the two negative
control antibodies in ITEM-THREE (data not shown). Hence,
we are tempted to speculate that the antiTNF antibody may
not be monoclonal. If we were to assume that the commer-
cially available antiTNF antibody was in fact containing two
antibody clones, then, one might bind to the surface acces-
sible peptide (IAVSYQTK) as the “expected” epitope and the
other could bind to the “sticky” peptide (VNLLSAIK). In this
case both peptides fully satisfied the properties of epitope
peptides.
DISCUSSION
ITEM-THREE differs from MALDI MS-based epitope map-
ping methods (20, 53–55) in several aspects. Most currently
available MALDI-MS approaches for epitope mapping require
immobilization of the capturing antibody on a protein A (or
protein G) substrate or on some other sort of a substrate
(beads or columns) when chemically immobilized. Using a
substrate is usually associated with the risk of nonspecific
adsorption of the antigen/epitope peptide to its surface. Re-
spective control experiments that test for nonspecific adsorp-
tion of antigens and/or epitope peptides onto the substrate
material become mandatory, thereby doubling or tripling the
amount of antigen/epitope peptides to be consumed. In
ITEM-THREE one does not need to fix the capturing antibody
on any substrate and therefore a respective negative control
experiment with only substrate (bead or column surfaces,
protein A or protein G, etc.) is obsolete. Hence, with ITEM-
THREE sample consumption is reduced and the experiment-
ers time is saved as well. Perhaps more importantly, ITEM-
THREE allows one to check whether an antibody-epitope
peptide complex has been formed in the first place. This is
done by recording mass spectra with higher m/z range before
dissociation of the complex. Using a MALDI MS-based
method, the formation of the immune complex is not directly
observable as on addition of the matrix (mostly because of the
acidic solution in which the matrix is typically dissolved in),
immune complexes are destroyed.
Of note, in MALDI-MS-based methods, mass spectrometry
is applied “only” as a readout for the in-solution enzymatic/
chemical processing steps, whereas in ITEM-THREE the
mass spectrometers capabilities of ion manipulation and
sorting become part of the experimental process. For one, we
have observed that loosely (nonspecifically) attached pep-
tides can be “shaken off” from the antibody surface during
transition between the condensed and the gas phase by
adjusting desorption/ionization conditions. Stronger bound
epitope-containing peptides mostly survive this “cleansing”
step and are dissociated later by applying CID conditions in a
collision cell within the mass spectrometer. A comparable
“clean-up” effect within the ionization regime may be difficult
FIG. 5. 3D structure images of the human TNF protein trimer.
A, The cartoon display shows ribbons with backbone atom coordi-
nates. B, Display of vanderWaals surfaces. Monomer surfaces are
shown in different green shades. The epitope peptides surfaces on
each monomer (aa79 – aa86: IAVSYGTK) are displayed in red, the
adjacent peptides surfaces (aa87 – aa94: VNNLSAIK) in purple (cf.
supplemental Fig. S9).
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to achieve by applying a MALDI-based method, as dissocia-
tion of peptides is not controlled but forced by denaturation
of the antibody/immune complex under acidic matrix prepa-
ration conditions.
Also worth mentioning is the fact that dissociation of the
epitope-containing peptide from the antibody by CID gener-
ates the charged epitope peptide ions in an ionization process
that is completely different than that in an ionization source of
a mass spectrometer. In the ion source all analytes compete
for obtaining charge carriers (protons in positive ion mode)
and there is a selection taking place by which in general more
basic peptides become better ionized than less basic pep-
tides. In MALDI-MS ionization the “lucky survivor concept”
has found acceptance (56, 57). This in the end may have an
impact in the detection sensitivity because there is the risk
that some peptides simply may not ionize well and, hence
their ion signals are weak and, depending on the noise, may
be overlooked. By contrast, as has been amply described (6,
47, 58, 59) CID results in an asymmetric charge distribution
and the epitope-containing peptide, being the smaller partner
of the to be dissociated complex, receives at least one proton.
At least in our hands, ionization yields were not limiting de-
tection of the epitope peptides.
Further, additional in-solution handling steps, such as trim-
ming of the epitope by applying different enzymes (60) can be
done equally well in both of the two methods, MALDI-based
and ITEM-THREE, at least as long as the proteases that in
ITEM-THREE are to be added to one and the same sample
without purification are stable enough and not digest each
other faster than the time needed for trimming of the epitope
peptide. Another prerequisite for ITEM-THREE is that the
applied proteases should work in ammonium acetate buffer at
pH 7. Yet, also in MALDI-based epitope mapping methods,
during “trimming” the experimental conditions have to be kept
such that the immune complex is not destroyed, i.e. a pH
value of about neutral.
The fact that ITEM-THREE reveals partial amino acid se-
quences of epitope peptides as well as the respective protein
name of the antigen in one experiment, principally allows one
to identify unknown antigens of an antibody of interest in a
given protein extract. An example for the identification of an
unknown epitope amino acid sequence is presented by the
chemically modified His-tag containing C-terminal epitope
peptide, KCFHHHHHH, of rhactin that was found to be triply
carbamidomethylated. Both, the epitope peptide amino acid
sequence and the location of the modifications were clearly
identified by mass spectrometric fragmentation, thereby prov-
ing the versatility of ITEM-THREE. The observed double-car-
bamidomethylation at the lysine residue of the epitope pep-
tide is consistent with reports that have shown that lysine
residues might be modified by iodoacetamide, depending on
the lysine residues’ microenvironment (61, 62). In addition to
the highly abundant [M2H]2 ion at m/z 695.82 that was
released from the immune complex, we also observed ion
signals of two low-abundance doubly charged ion signals
(m/z 687.31 and 702.83) with mass differences of 17.04 Da
and 14.02 Da with respect to the epitope peptides mass
(Fig. 3F). The 17.04 Da likely was because of a loss of
ammonia (63), whereas 14.02 Da can be explained by meth-
ylation of the K373 residue (64). Although loss of ammonia is
produced from the peptide at elevated collision energies,
methylation of the peptide was observed already in the pep-
tide mixture of the tryptic digest of rhactin (supplemental
Table S7). Obviously, epitope peptides that contain modified
residues because of post-translational modifications or as a
result of chemical conversions during sample preparation are
still identified by ITEM-THREE, provided that the modification
not affects recognition of the epitope by the antibodys
paratope. This stands in agreement with findings of methio-
nine oxidized His-tag containing peptides, where oxidation
did not prevent recognition of the epitope by the antibody
under investigation or with partially carbamylated epitope
peptides, where the chemical modification of a lysine residue
was tolerated by the antibody as well (34). Such results illus-
trate the importance of ITEM-THREE as a method that can
study amino acid modification-related effects on antigen-an-
tibody binding.
Once an epitope peptides sequence has been determined,
one becomes able to search for amino acid sequence simi-
larities on other proteins, thereby allowing to estimate cross-
reactivities of the investigated antibody, or even to predict
which unrelated proteins might bind to an antibody of interest
in addition to its specific antigen. Such information becomes
particularly relevant when one aims at using antibodies to
identify proteins in species for which an antibody has not
been produced or specified. When the amino acid sequence
of the protein of interest is known, one can predict whether a
given antibody might be a good binder, i.e. suitable for im-
mune assays within a research project of a different species.
Based on epitope peptide sequence similarities, the applica-
bility of a precious antibody was securely broadened (8, 65).
Practicality of this approach is illustrated by NCBI BLAST
searches using the here identified epitope peptide sequences
without taxonomy restrictions. The obtained lists of proteins
that shared amino acid sequences that were like the query
sequences from the identified epitope peptides, for instance,
provided lists with more than 250 entries, each. Within the top
50 listed proteins in the report from the BLAST search apply-
ing the RA33 epitope peptide, only the top 6 proteins con-
tained amino acid sequence stretches that were 100% iden-
tical to the query sequence. The next 16 proteins in the list
had 100% identity to shorter query sequence stretches (Table
I). The following amino acid sequences in the list were from
unrelated proteins that possessed partial amino acid se-
quences with still high homologies to the original epitope
peptide sequence.
The same type of results, which match with reports from
cross-reactivity-studies with diagnostic heart muscle troponin
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T antibodies (65), can be obtained with any epitope peptide
amino acid sequence (Table I). Because of amino acid se-
quence similarities it is likely that the antibody of interest was
able to recognize binding motifs on unrelated proteins, as
long as the targeted amino acid sequence was surface ex-
posed and the partial peptide assumed a somewhat similar
three dimensional structure compared with that of the original
epitope peptide, even when the respective antibody was not
raised against the unrelated protein.
ITEM-THREE is an electrospray mass spectrometry-based
method that determines an utmost important antibody fea-
ture, its molecular recognition code. Except for mixing the
antibody of interest with a peptide mixture that contains the
epitope peptide, all experimental steps, such as epitope ex-
traction and epitope peptide sequencing are performed in a
single mass spectrometry experiment. Followed by an in-
silico search, which starts with subjecting the experimentally
determined mass lists to unsupervised data base search, the
epitopes peptide amino acid sequences are defined, and the
originating antigens thereby unequivocally determined while
homologues are retrievable and cross-reactivities estimated
using BLAST search tools.
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Table S1: Amino acid sequences and molecular masses of synthetic peptides a).  
 
peptide name amino acid sequence [p] c) [M+pH]p+ (calcd) m/z (exp) 
RA33 MAARPHSIDGRVVEP-NH2 
2 817.43 817.49 
3 545.29 545.32 
TRIM21 A LQELEKDEREQLRILGE 
2 1049.56 1049.64 
3 700.04 700.09 
TRIM21 B LQPLEKDEREQLRILGE 2 1033.57 1033.64 
TRIM21 C LQELEKDEPEQLRILGE 2 1020.04 1020.11 
FLAG DYKDDDDK 1 1013.41 1013.49 
FLAG (3-8) b) KDDDDK 1 735.32 735.36 
FLAG (4-8) b) DDDDK 1 607.22 607.26 
FLAG (5-8) b) DDDK 1 492.19 492.22 
angiotensin II DRVYIHPF 1 1046.54 1046.61 
GPI ALKPYSPGGPR 
1 1142.63 1142.72 
2 571.82 571.85 
GPI (4-11) b) PYSPGGPR 1 830.42 830.48 
GPI (6-11) b) SPGGPR 1 570.30 570.34 
GPI (7-11) b) PGGPR 1 483.27 483.30 
 
a) solution 1 (cf. Figures 1 and 2) 
b) sequence range of fragments observed at higher collision energies 






Table S2: MS/MS fragmentation of MAARPHSIDGRVVEP showing matches used for scoring a,b) 
 
no. b b++ b* b*++ b0 b0++ seq c,d,e). y y++ y* y*++ y0 y0++ no. 
1 132.0478 66.5275 
    
M 
      
15 
2 203.0849 102.0461 
    
A 1502.8186 751.9130 1485.7921 743.3997 1484.8081 742.9077 14 
3 274.1220 137.5646 
    
A 1431.7815 716.3944 1414.7550 707.8811 1413.7710 707.3891 13 
4 430.2231 215.6152 413.1966 207.1019 
  
R 1360.7444 680.8758 1343.7179 672.3626 1342.7338 671.8706 12 
5 527.2759 264.1416 510.2493 255.6283 
  
P 1204.6433 602.8253 1187.6167 594.3120 1186.6327 593.8200 11 
6 664.3348 332.6710 647.3082 324.1578 
  
H 1107.5905 554.2989 1090.5640 545.7856 1089.5800 545.2936 10 
7 751.3668 376.1870 734.3403 367.6738 733.3562 367.1818 S 970.5316 485.7694 953.5051 477.2562 952.5211 476.7642 9 
8 864.4509 432.7291 847.4243 424.2158 846.4403 423.7238 I 883.4996 442.2534 866.4730 433.7402 865.4890 433.2482 8 
9 979.4778 490.2425 962.4513 481.7293 961.4672 481.2373 D 770.4155 385.7114 753.3890 377.1981 752.4050 376.7061 7 
10 1036.4993 518.7533 1019.4727 510.2400 1018.4887 509.7480 G 655.3886 328.1979 638.3620 319.6847 637.3780 319.1926 6 
11 1192.6004 596.8038 1175.5738 588.2906 1174.5898 587.7985 R 598.3671 299.6872 581.3406 291.1739 580.3566 290.6819 5 
12 1291.6688 646.3380 1274.6423 637.8248 1273.6582 637.3328 V 442.2660 221.6366 
  
424.2554 212.6314 4 
13 1390.7372 695.8722 1373.7107 687.3590 1372.7266 686.8670 V 343.1976 172.1024 
  
325.1870 163.0972 3 
14 1519.7798 760.3935 1502.7533 751.8803 1501.7692 751.3883 E 244.1292 122.5682 
  
226.1186 113.5629 2 
15 
      
P 115.0866 58.0469 
    
1 
 
a) 21 of 140 fragment ion masses were assigned using 43 most intense peaks from the spectrum (c.f. Figure 1): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 43; random score (expectation value): 4.7 
c) monoisotopic mass of neutral peptide Mr: 1632.8518 
d) fixed modification: amidated C-terminus 






Figure S1: Mass spectrometric dissociation of the RA33 epitope peptide – antiRA33 antibody 
complex. Ion mobility arrival time plots of A: Solution 1, C: and E: Solution 3. Dashed lines mark 
the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the 
quadrupole are indicated at the right. B, D, and F: nanoESI mass spectra (high m/z range) of 
ions from selected arrival time ranges. Selected m/z values are given and charge states are 





Table S3: List of protein ion signals from antiRA33 antibody a).  
 
molecular species charge state d) exp. m/z exp. mass 
antibody  24 6235.51 149628.24 
 25 5988.58 149689.50 
 26 5760.03 149734.78 
 27 5548.13 149772.51 
 28 5351.02 149800.56 
 29 5167.67 149833.43 
 30 4997.90 149907.00 
antibody-peptide  25 6052.22 151280.50 
complex b) 26 5820.40 151304.40 
 27 5604.22 151286.94 
 28 5411.10 151482.80 
 29 5222.54 151424.66 
 30 5052.56 151546.80 
antibody fragments c) 12 2024.97 24287.64 
 13 1870.51 24303.63 
 14 1736.53 24297.42 
 7 1887.64 13206.48 
 8 1651.83 13206.64 
 9 1468.43 13206.87 
 
a) solutions 2 and 3; (cf. Figure S1) 
b) antibody bound to one peptide 
c) observed at high collision voltages 





Table S4: MS/MS fragmentation of LQELEKDEREQLRILGE showing matches used for scoring a,b) 
 
no. b b++ b* b*++ b0 b0++ seq c,d). y y++ y* y*++ y0 y0++ no. 
1 114.0913 57.5493 
    
L 
      
17 
2 242.1499 121.5786 225.1234 113.0653 
  
Q 1985.0298 993.0185 1968.0033 984.5053 1967.0192 984.0133 16 
3 371.1925 186.0999 354.1660 177.5866 353.1819 177.0946 E 1856.9712 928.9893 1839.9447 920.4760 1838.9607 919.9840 15 
4 484.2766 242.6419 467.2500 234.1287 466.2660 233.6366 L 1727.9286 864.4680 1710.9021 855.9547 1709.9181 855.4627 14 
5 613.3192 307.1632 596.2926 298.6499 595.3086 298.1579 E 1614.8446 807.9259 1597.8180 799.4127 1596.8340 798.9206 13 
6 741.4141 371.2107 724.3876 362.6974 723.4036 362.2054 K 1485.8020 743.4046 1468.7754 734.8914 1467.7914 734.3993 12 
7 856.4411 428.7242 839.4145 420.2109 838.4305 419.7189 D 1357.7070 679.3571 1340.6805 670.8439 1339.6965 670.3519 11 
8 985.4837 493.2455 968.4571 484.7322 967.4731 484.2402 E 1242.6801 621.8437 1225.6535 613.3304 1224.6695 612.8384 10 
9 1141.5848 571.2960 1124.5582 562.7828 1123.5742 562.2907 R 1113.6375 557.3224 1096.6109 548.8091 1095.6269 548.3171 9 
10 1270.6274 635.8173 1253.6008 627.3040 1252.6168 626.8120 E 957.5364 479.2718 940.5098 470.7585 939.5258 470.2665 8 
11 1398.6859 699.8466 1381.6594 691.3333 1380.6754 690.8413 Q 828.4938 414.7505 811.4672 406.2373 810.4832 405.7452 7 
12 1511.7700 756.3886 1494.7435 747.8754 1493.7594 747.3834 L 700.4352 350.7212 683.4087 342.2080 682.4246 341.7160 6 
13 1667.8711 834.4392 1650.8446 825.9259 1649.8606 825.4339 R 587.3511 294.1792 570.3246 285.6659 569.3406 285.1739 5 
14 1780.9552 890.9812 1763.9286 882.4680 1762.9446 881.9759 I 431.2500 216.1287 
  
413.2395 207.1234 4 
15 1894.0393 947.5233 1877.0127 939.0100 1876.0287 938.5180 L 318.1660 159.5866 
  
300.1554 150.5813 3 
16 1951.0607 976.0340 1934.0342 967.5207 1933.0502 967.0287 G 205.0819 103.0446 
  
187.0713 94.0393 2 
17 
      
E 148.0604 74.5339 
  
130.0499 65.5286 1 
 
a) 53 of 178 fragment ion masses were assigned using 140 most intense peaks from the spectrum (c.f. Figure 2): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 46; random score (expectation value): 1.6 
c) monoisotopic mass of neutral peptide Mr: 2098.1065 





Table S5: MS/MS fragmentation of LQPLEKDEREQLRILGE showing matches used for scoring a,b) 
 
no. b b++ b* b*++ b0 b0++ seq c,d) y y++ y* y*++ y0 y0++ no. 
1 114.0913 57.5493 
    
L 
      
17 
2 242.1499 121.5786 225.1234 113.0653 
  
Q 1953.0400 977.0236 1936.0134 968.5104 1935.0294 968.0183 16 
3 339.2027 170.1050 322.1761 161.5917 
  
P 1824.9814 912.9943 1807.9549 904.4811 1806.9708 903.9891 15 
4 452.2867 226.6470 435.2602 218.1337 
  
L 1727.9286 864.4680 1710.9021 855.9547 1709.9181 855.4627 14 
5 581.3293 291.1683 564.3028 282.6550 563.3188 282.1630 E 1614.8446 807.9259 1597.8180 799.4127 1596.8340 798.9206 13 
6 709.4243 355.2158 692.3978 346.7025 691.4137 346.2105 K 1485.8020 743.4046 1468.7754 734.8914 1467.7914 734.3993 12 
7 824.4512 412.7293 807.4247 404.2160 806.4407 403.7240 D 1357.7070 679.3571 1340.6805 670.8439 1339.6965 670.3519 11 
8 953.4938 477.2506 936.4673 468.7373 935.4833 468.2453 E 1242.6801 621.8437 1225.6535 613.3304 1224.6695 612.8384 10 
9 1109.5949 555.3011 1092.5684 546.7878 1091.5844 546.2958 R 1113.6375 557.3224 1096.6109 548.8091 1095.6269 548.3171 9 
10 1238.6375 619.8224 1221.6110 611.3091 1220.6270 610.8171 E 957.5364 479.2718 940.5098 470.7585 939.5258 470.2665 8 
11 1366.6961 683.8517 1349.6696 675.3384 1348.6856 674.8464 Q 828.4938 414.7505 811.4672 406.2373 810.4832 405.7452 7 
12 1479.7802 740.3937 1462.7536 731.8805 1461.7696 731.3884 L 700.4352 350.7212 683.4087 342.2080 682.4246 341.7160 6 
13 1635.8813 818.4443 1618.8547 809.9310 1617.8707 809.4390 R 587.3511 294.1792 570.3246 285.6659 569.3406 285.1739 5 
14 1748.9654 874.9863 1731.9388 866.4730 1730.9548 865.9810 I 431.2500 216.1287 
  
413.2395 207.1234 4 
15 1862.0494 931.5283 1845.0229 923.0151 1844.0389 922.5231 L 318.1660 159.5866 
  
300.1554 150.5813 3 
16 1919.0709 960.0391 1902.0443 951.5258 1901.0603 951.0338 G 205.0819 103.0446 
  
187.0713 94.0393 2 
17 
      
E 148.0604 74.5339 
  
130.0499 65.5286 1 
 
a) 34 of 174 fragment ion masses were assigned using 127 most intense peaks from the spectrum (c.f. Figure 2): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 27; random score (expectation value): 96) 
c) monoisotopic mass of neutral peptide Mr: 2065.1167 







Figure S2: Mass spectrometric dissociation of the TRIM21 epitope peptide – TRIM21 antibody 
complex. Ion mobility arrival time plots of A: Solution 1, C: and E: Solution 3. Dashed lines mark 
the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the 
quadrupole are indicated at the right. B, D, and F: nanoESI mass spectra (high m/z range) of 
ions from selected arrival time ranges. Selected m/z values are given and charge states are 





Table S6: List of protein ion signals from antiTRIM21 antibody a). 
 
molecular species charge state d) exp. m/z exp. mass 
antibody-peptide 23 6544.84 150508.32 
complex b) 24 6266.54 150372.96 
 25 6005.92 150123.00 
 26 5772.73 150064.98 
 27 5554.79 149952.33 
 28 5351.85 149823.80 
antibody fragmentsc) 12 3805.92 45659.04 
 13 3514.33 45673.29 
 14 3248.82 45469.48 
 8 2834.63 22669.04 
 9 2512.70 22605.30 
 4 2706.05 10820.20 
 5 2165.23 10821.15 
 6 1804.61 10821.66 
 
a) solutions 2 and 3 (cf. Figure S2) 
b) antibody bound to peptide not resolved from antibody ion signals 
c) observed at high collision voltages 





Table S7: List of peptide ion signals upon tryptic digestion of rhβactin a). 
 
sequence range charge state b) m/z (exp) peptide mass (Mr) 
19-28 2 488.75 975.44 
19-28 1 976.48 975.44 
29-39 2 599.82 1197.70 
40-50 2 586.31 1170.56 
51-61 2 599.82 1197.51 
51-61 1 1198.56 1197.70 
51-62 2 677.84 1353.62 
51-62 1 1354.67 1353.62 
63-68 1 644.43 643.43 
69-84 2 973.99 1945.89 
85-95 1 1515.75 1514.74 
96-113 3 652.05 1953.06 
96-113 2 977.57 1953.06 
114-116 1 360.21 359.19 
117-118 1 276.17 275.15 
178-183 1 644.40 643.37 
184-191 2 499.73 997.48 
184-191 1 998.52 997.48 
192-196 1 631.40 630.37 
197-206 2 566.79 1131.52 
197-206 1 1132.56 1131.52 
207-210 1 516.33 515.31 
207-213 2 436.78 871.51 
207-215 2 565.35 1128.65 
211-213 1 375.24 374.22 
211-215 2 316.69 631.35 
239-254 2 895.98 1789.88 
255-256 1 322.20 321.18 
285-291 2 453.24 904.44 
285-291 1 905.48 904.44 
313-315 1 406.22 405.20 
316-326 2 581.34 1160.61 
316-326 1 1161.65 1160.61 
327-328 1 260.21 259.19 
327-335 2 518.73 1035.64 
327-335 1 1036.46 1035.64 
329-335 1 795.50 794.50 
329-336 2 462.30 922.56 
360-372 2 758.88 1515.70 
360-372 1 1516.72 1515.70 
360-373 2 822.93 1643.79 
360-373 c) 2 829.93 1657.81 
373-381 d) 3 464.23 1389.60 
373-381 e) 3 468.89 1403.62 
373-381 d) 2 695.82 1389.60 
373-381 e) 2 702.83 1403.62 
a) solution 1 (cf. Figure 3 and Figure S5) 
b) positively charged ions 
c) singly methylated peptide 
d) triply carbamidomethylated peptide containing the epitope  




Table S8: MS/MS fragmentation of MAPIHHHYEKK showing matches used for scoring a,b) 
 
no. b b++ b* b*++ b0 b0++ seq c,d,e) y y++ y* y*++ y0 y0++ no. 
1 132.0478 66.5275 
    
M 
      
11 
2 203.0849 102.0461 
    
A 1259.6644 630.3358 1242.6378 621.8225 1241.6538 621.3305 10 
3 300.1376 150.5725 
    
P 1188.6273 594.8173 1171.6007 586.3040 1170.6167 585.8120 9 
4 413.2217 207.1145 
    
I 1091.5745 546.2909 1074.5479 537.7776 1073.5639 537.2856 8 
5 550.2806 275.6439 
    
H 978.4904 489.7489 961.4639 481.2356 960.4799 480.7436 7 
6 687.3395 344.1734 
    
H 841.4315 421.2194 824.4050 412.7061 823.4209 412.2141 6 
7 824.3984 412.7029 
    
H 704.3726 352.6899 687.3461 344.1767 686.3620 343.6847 5 
8 987.4618 494.2345 
    
Y 567.3137 284.1605 550.2871 275.6472 549.3031 275.1552 4 
9 1116.5044 558.7558 
  
1098.4938 549.7505 E 404.2504 202.6288 387.2238 194.1155 386.2398 193.6235 3 




      




a) 8 of 80 fragment ion masses were assigned using 12 most intense peaks from the spectrum (c.f. Figure 3): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 18; random score (expectation value): 11 
c) monoisotopic mass of neutral peptide Mr: 1389.6975 
d) fixed modification: carbamidomethyl 






Figure S3: Mass spectrometric dissociation of the His-tag epitope peptide – antiHis-tag 
antibody complex and amino acid sequence determination of the complex-released peptide by 
mass spectrometric fragmentation. Ion mobility arrival time plots of A: Solution 1, C: and E: 
Solution 3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP 
cell, the TRANSFER cell, and the quadrupole are indicated at the right. B, D, and F: nanoESI 
mass spectra (low m/z range) of ions from selected arrival time ranges. Selected m/z values are 
given and charge states are indicated in parentheses. For ion signal assignments see Table S7. 
G: Amino acid sequence of the complex-released peptide (single letter code) as determined by 
the matched mass spectrometric fragment ions (fragment ion types and numbers are indicated). 
Carbamidomethylation is indicated by *. The amended Uniprot protein id of the peptide source 
protein (first hit) is shown. H: Pseudo mass spectrum (after charge deconvolution and de-
isotoping) of fragment ions derived by selecting arrival time of the complex-released peptide 






Table S9: MS/MS fragmentation of KCFHHHHHH showing matches used for scoring a,b) 
 
no. b b++ b* b*++ seq c,d,e) y y++ y*++ no. 
1 243.1452 122.0762 226.1186 113.5629 K 
   
9 
2 403.1758 202.0915 386.1493 193.5783 C 1148.4704 574.7388 
 
8 
3 550.2442 275.6258 533.2177 267.1125 F 988.4397 494.7235 
 
7 
4 687.3031 344.1552 670.2766 335.6419 H 841.3713 421.1893 
 
6 
5 824.3621 412.6847 807.3355 404.1714 H 704.3124 352.6598 
 
5 
6 961.4210 481.2141 944.3944 472.7008 H 567.2535 284.1304 
 
4 
7 1098.4799 549.7436 1081.4533 541.2303 H 430.1946 215.6009 
 
3 




    




a) 7 of 48 fragment ion masses were assigned using 12 most intense peaks from the spectrum (c.f. Figure S3): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 22; random score (expectation value): 7.8 
c) monoisotopic mass of neutral peptide Mr: 1389.6010 
d) fixed modification: carbamidomethyl;  variable modification: dicarbamidomethyl 








Figure S4: Mass spectrometric dissociation of the His-tag epitope peptide – antiHis-tag 
antibody complex. Ion mobility arrival time plots of A: Solution 1, C: and E: Solution 3. Dashed 
lines mark the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER 
cell, and the quadrupole are indicated at the right. B, D, and F: nanoESI mass spectra (high m/z 
range) of ions from selected arrival time ranges. Selected m/z values are given and charge 






Table S10: List of protein ion signals from antiHis-tag antibody a). 
 
molecular species charge state d) exp. m/z exp. mass 
antibody-peptide 22 6803.40 149652.80 
complex b) 23 6509.17 149687.91 
 24 6233.08 149569.92 
 25 5978.56 149439.00 
 26 5748.62 149438.12 
 27 5534.18 149395.86 
antibody fragments c) 11 3472.98 38191.78 
 12 3176.01 38100.12 
 7 2141.62 14984.34 
 8 1874.07 14984.56 
 9 1665.97 14984.73 
 
a) solutions 2 and 3 (cf. Figure S4) 
b) antibody bound to peptide not resolved from antibody ion signals 
c) observed at high collision voltages 









Figure S5: Amino acid sequence of recombinant human β-actin protein with C-terminal His-tag 
in single letter code. Partial amino acid sequences that were matched to ion signals from the 
nanoESI mass spectra (cf. Figure 3) are printed in bold. The amino acid sequence of the 






Table S11: List of peptide ion signals upon tryptic digestion of rhTNFα a). 
 
sequence range charge state b) m/z (exp) peptide mass (Mr) 
1-28 5 631.73 3153.65 
2-27 5 583.14 2910.52 
2-27 4 728.63 2910.52 
2-28 6 512.11 3066.62 
2-28 5 614.33 3066.62 
2-28 4 767.66 3066.62 
3-27 4 689.61 2754.42 
3-27 3 919.15 2754.42 
3-28 5 583.14 2910.52 
3-28 4 728.63 2910.52 
28-40 3 466.28 1395.79 
29-40 2 620.86 1239.69 
29-61 3 1216.32 3645.98 
31-40 2 528.31 1054,61 
31-61 3 1154.63 3460.90 
33-40 1 871.48 870.49 
34-40 2 379.72 757.41 
34-40 1 758.45 757.41 
34-61 3 1055.57 3163.69 
41-61 3 809.10 2424.29 
41-61 2 1213.15 2424.29 
62-78 4 452.49 1805.92 
62-78 3 602.98 1805.92 
79-86 c) 2 455.26 908.50 
79-86 c) 1 909.54 908.50 
87-94 d) 2 429.29 856.54 
87-94 d) 1 857.56 856.54 
87-99 3 476.94 1427.79 
100-124 3 951.14 2850.41 
100-124 2 1426.19 2850.41 
100-127 4 795.64 3178.56 
100-127 3 1060.52 3178.56 
125-153 3 1077.2 3228.61 
128-153 3 967.82 2900.46 
128-153 2 1451.22 2900.46 
 
a) solution 1 (cf. Figure 4 and Figure S8) 
b) positively charged ions 
c) peptide containing the epitope 




Table S12: MS/MS fragmentation of IAVSYQTK showing matches used for scoring a,b) 
 



























Y 539.2824 522.2558 4 
6 634.3559 617.3293 662.3508 645.3243 Q 376.2191 359.1925 3 
7 735.4036 718.3770 763.3985 746.3719 T 248.1605 231.1339 2 
8 
    
K 147.1128 130.0863 1 
 
a) 7 of 32 fragment ion masses using 16 most intense peaks from the spectrum (c.f. Figure 4): bold italic print means the series contributed to the 
score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that the ion series is 
present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by chance, so that the 
matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal in the mass 
spectrum. 
b) ions score: 35; random score (expectation value): 0.25 
c) monoisotopic mass of neutral peptide Mr: 909.4967 






Figure S6: Mass spectrometric dissociation of the TNFα epitope peptide – anti TNFα antibody 
complex and amino acid sequence determination of the complex-released peptide by mass 
spectrometric fragmentation. Ion mobility arrival time plots of A: Solution 1, C: and E: Solution 
3. Dashed lines mark the regions for mass spectra selections. Settings of the TRAP cell, the 
TRANSFER cell, and the quadrupole are indicated at the right. B, D, and F: nanoESI mass 
spectra (low m/z range) of ions from selected arrival time ranges. Selected m/z values are given 
and charge states are indicated in parentheses. For ion signal assignments see Table S11. G: 
Amino acid sequence of the complex-released peptide (single letter code) as determined by the 
matched mass spectrometric fragment ions (fragment ion types and numbers are indicated). 
The Uniprot protein id of the peptide source protein (first hit) is shown. H: Pseudo mass 
spectrum (after charge deconvolution and de-isotoping) of fragment ions derived by selecting 





Table S13: MS/MS fragmentation of VNLLSAIK showing matches used for scoring a,b) 
 








2 186.1237 169.0972 214.1186 197.0921 N 758.4771 741.4505 7 
3 299.2078 282.1812 327.2027 310.1761 L 644.4341 627.4076 6 
4 412.2918 395.2653 440.2867 423.2602 L 531.3501 514.3235 5 
5 499.3239 482.2973 527.3188 510.2922 S 418.2660 401.2395 4 
6 570.3610 553.3344 598.3559 581.3293 A 331.2340 314.2074 3 
7 683.4450 666.4185 711.4400 694.4134 I 260.1969 243.1703 2 
8 
    
K 147.1128 130.0863 1 
 
a) 15 of 40 fragment ion masses were assigned using 63 most intense peaks from the spectrum (c.f. Figure S6): bold italic print means the series 
contributed to the score; bold print means that the number of matches in the ion series is greater than would be expected by chance, indicating that 
the ion series is present; non-bold underlined print means that the number of matches in the ion series is no greater than would be expected by 
chance, so that the matches themselves may be by chance; non-bold non-underlined print means that this mass was not represented by an ion signal 
in the mass spectrum. 
b) ions score: 14; random score (expectation value): 41 
c) monoisotopic mass of neutral peptide Mr: 856.5382 







Figure S7: Mass spectrometric dissociation of the TNFα epitope peptide – anti TNFα antibody 
complex. Ion mobility arrival time plots of A: Solution 1, C: and E: Solution 3. Dashed lines mark 
the regions for mass spectra selections. Settings of the TRAP cell, the TRANSFER cell, and the 
quadrupole are indicated at the right. B, D, and F: nanoESI mass spectra (high m/z range) of 
ions from selected arrival time ranges. Selected m/z values are given and charge states are 






Table S14: List of protein ion signals from antiTNFα antibody a). 
 
molecular species charge state d) exp. m/z exp. mass 
antibody-peptide 22 6779.89 149135.58 
complex b) 23 6483.18 149090.14 
 24 6203.56 148861.44 
 25 5954.48 148837.00 
 26 5720.10 148696.60 
 27 5506.67 148653.09 
antibody fragments c) 10 2363.79 23627.90 
 11 2148.90 23626.90 
 12 1969.85 23626.20 
 13 1818.49 23627.37 
 7 2059.88 14412.16 
 8 1802.59 14412.72 
 9 1603.87 14425.83 
 
a) solutions 2 and 3 (cf. Figure S7) 
b) antibody bound to peptide not resolved from antibody ion signals 
c) observed at high collision voltages 








Figure S8: Amino acid sequence of recombinant human TNFα protein monomer with N-terminal 
His-tag in single letter code. Partial amino acid sequences that were matched to ion signals 
from the nanoESI mass spectra (cf. Figure 4) are printed in bold. The amino acid sequence of 
the epitope peptide (aa79 – aa86) is underlined. The adjacent peptide (aa87 – aa94) is dotted 








Figure S9: Physico-chemical properties of recombinant human TNFα protein. A: Hydrophobicity 
plot. The epitope peptide (aa79 – aa86) is hydrophilic. The adjacent peptide (aa87 – aa94) is 
hydrophobic. B: Partial amino acid surface areas of the amino acids of the epitope peptide 
(aa79 – aa86). C: Partial amino acid surface areas of the amino acids of the adjacent peptide 
(aa87 – aa94). Values for monomers (filled dots and solid line) and of the trimer (filled squares 
and dotted line) represent means and standard deviations are shown. Amino acid residues are 







2.3 Apparent activation energies of protein-protein complex dissociation in the 
gas phase determined by electrospray mass spectrometry 
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Abstract We have developed a method to determine apparent
activation energies of dissociation for ionized protein–protein
complexes in the gas phase using electrospray ionization mass
spectrometry following the Rice-Ramsperger-Kassel-Marcus
quasi-equilibrium theory. Protein–protein complexes were
formed in solution, transferred into the gas phase, and sepa-
rated from excess free protein by ion mobility filtering.
Afterwards, complex disassembly was initiated by collision-
induced dissociation with step-wise increasing energies.
Relative intensities of ion signals were used to calculate ap-
parent activation energies of dissociation in the gas phase by
applying linear free energy relations. The method was devel-
oped using streptavidin tetramers. Experimentally determined
apparent gas-phase activation energies for dissociation
(E#A m0g ) of complexes consisting of Fc parts from immuno-
globulins (IgG-Fc) and three closely related protein G' vari-
ants (IgG-Fc•protein G'e, IgG-Fc•protein G'f, and IgG-
Fc•protein G'g) show the same order of stabilities as can be
inferred from their in-solution binding constants. Differences
in stabilities between the protein–protein complexes corre-
spond to single amino acid residue exchanges in the IgG-
binding regions of the protein G' variants.
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E#A m0g EA: energy of activation, #: apparent (with merged
temperature term), m: mean of charge states, 0: at
Ecom = 0 eV, g: gas phase
Fc part fragment crystallizable part
IgG immunoglobulin G
IVIG intravenous immunoglobulin
KD s dissociation constant in solution
K#D m0g KD: dissociation constant, #: apparent (with merged
temperature term), m: mean of charge states, 0: at
Ecom = 0 eV, g: gas phase
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Introduction
Already in the mid-90s of the last century, the possibility to
characterize non-covalent bio-macromolecular complexes
using electrospray mass spectrometry became evident [1, 2].
More recent studies provided strong indications that upon
transfer into the gas-phase proteins retained compact confor-
mations [3] that could be investigated by so-called Bnative
ESI-MS^ and ion mobility MS (IM-MS) [4–6]. These
methods are now widely applied for determining qualitative
properties of protein complexes, such as topology, size, sub-
unit organization, and stoichiometry [7–9].
In solution, protein–protein interactions are charac-
terized quantitatively by dissociation constants (KD s)
and Gibbs free binding energies (ΔG0s ) at equilibrium
[10], which are typically determined using calorimetric
or spectroscopic methods [11]. In some cases, mass
spectrometry-based methods have been applied as read-
outs for determining in-solution KD values of protein–pro-
tein complexes by comparing ion signal intensities of free
and complexed proteins at different solution concentra-
tions of the complex components [12–15]. Introducing
correction factors for differences of surface activities of
analytes in the droplet as well as for additional gas-phase
ion suppression effects [16] yielded satisfactory correla-
tion with results from conventional methods.
There are, however, currently no universally accepted gas-
phase equivalents to typical thermodynamic and/or kinetic
methods for evaluating protein–protein complex properties. In
one case, activation energies of thermal protein–protein complex
dissociation in the gas phase were deduced by observing com-
plex dissociation kinetics upon blackbody infrared radiation
using Fourier-transform ion cyclotron resonancemass spectrom-
etry [17]. In another study, factors that affected gas-phase stabil-
ities of non-covalent protein–peptide complexes were interro-
gated but without determining strengths of interactions [18].
Here, we describe a method to estimate apparent activation
energies of dissociation of charged protein–protein complexes in
the gas phase (E#A m0g) directly under quasi-equilibrium condi-
tions. After protein–protein complexes have been formed in so-
lution, electrospraymass spectrometry is used to ionize and trans-
fer them into the gas phase intact. Upon ion mobility separation
of the ionized intact complexes from excess non-complexed con-
stituents, dissociation of the complexes is initiated. Relative
intensities of ion signals were used to calculate apparent activa-
tion energies of dissociation in the gas phase according to the
Rice-Ramsperger-Kassel-Marcus quasi-equilibrium theory
(RRKM–QET), which assumes that dissociation of molecular
complexes in the gas phase is unidirectional and irreversible,
i.e., not reaching equilibrium conditions. The energy that is ap-
plied to dissociate a protein–protein complex in the mass spec-
trometer is, thus, in correlationwith its activation energy [19–21].
To develop our method, we investigated dissociation of the
streptavidin tetramer and applied the procedure to three closely
related protein–protein complexes consisting of Fc parts of im-
munoglobulins (IgG) and protein G' isoforms (IgG-Fc•protein
G'e, IgG-Fc•protein G'f, and IgG-Fc•protein G'g). Apparent ac-
tivation energies of dissociation in the gas phase were compared
with thermodynamic data from in-solution measurements.
Materials and methods
Materials
Protein G'e was obtained from Sigma-Aldrich, Steinheim,
Germany (catalog no. P4689-5MG; lot no.SLBB8536V).
Protein G'f was produced by the University of Applied
Sciences Bonn-Rhein-Sieg (Bonn, Germany). Protein G'g was
a gift from Rainin Corp. (Oakland, CA, USA). Active human
IgG-Fc fragment was fromAbcam, Cambridge, UK (product no.
ab90285, lot no. GR149467–12). All stock solutions contained
50 μg of protein. Polyclonal intravenous immunoglobulins
(IVIG) were obtained from Omrix Biopharmaceuticals (Nes-
Ziona, Israel). 16-Mercaptohexadecanoic acid, phosphate buff-
ered saline powder, ethanolamine, N-hydroxysuccinimide, 2-[N-
morpholino] ethanesulfonic acid, 1-ethyl-3-[3-dimethylamino-
propyl] carbodiimide were from Sigma-Aldrich. Details on
streptavidin can be found in the Electronic Supplementary
Material (ESM).
IgG-Fc and protein G'-containing solutions
Solutions of active human IgG-Fc and protein G' isoforms (pro-
tein G'e, protein G'f, and protein G'g) were buffer-exchanged
using Amicon ultra centrifugal filters with 10 K cutoff
(Millipore Corporation, Ireland) according to the manufacturer’s
protocol. Protein concentrations (aliquots of ca. 2μg in 5μl, each)
were determined with the fluorescence-based Qubit™
assay (Invitrogen, Carlsbad, USA). For calibration, Qubit™
working solution (Qubit™ reagent diluted 1/100 in Qubit™ buff-
er) and three calibration standards (0, 200, and 400 ng/μl) were
mixed (190 and 10 μl, respectively), incubated for 15 min, and
measured in theQubit®2.0 Fluorimeter. Raw fluorescence values
were used to calculate the concentrations of the similarly treated
proteins in the assay tubes and in the original stocks. Typical
protein concentrations were between 0.2 and 0.6 μg/μl. Sample
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solutions were either directly used for preparation of complexes
consisting of protein G' isoforms and IgG-Fc or stored at −20 °C.
Protein G'–IgG-Fc complex preparations
IgG-Fc (3.6 μM; ca. 20–35 μl) in 200 mM ammonium acetate
buffer, pH 7.1, was mixed with one of the buffer-exchanged
protein G' isoforms at a time (ca. 6.5–13 μl) to yield a molar
ratio of 1:1.3 (protein G' isoform: IgG-Fc). Small excess of
protein G' was found to be optimal for both, generating an in-
solution complex with 1:1 stoichiometry and avoiding precipi-
tation. All protein G' isoform–IgG-Fc complexes were prepared
in this manner at room temperature. Solutions with protein–
protein complexes were either directly used for nano-ESI-
IMS-MS/MS analysis or kept at +4 °C for maximally 1 week.
Nano-ESI-IMS-MS/MS acquisition conditions
Capillaries for nano-ESI-IMS-MS/MS measurements were
prepared in-house [22] from borosilicate glass tubes of
1 mm outer and 0.5 mm inner diameters using a P-1000
Flaming / Brown™ Micropipette Puller System (all Sutter
Instrument, Novato, CA, USA) and gold-coated using a
BalTec SCD 004 sputter coater (Bal-Tech, Balzers,
Liechtenstein). For each measurement, 3 μl of sample was
loaded using a micro-loader pipette tip (Eppendorf,
Hamburg, Germany). Measurements were performed on a
Synapt G2-S mass spectrometer (Waters MS-Technologies,
Manchester, UK) equippedwith a traveling-wave ion mobility
cell (TW-IMS). The instrumental parameters were optimized
as follows: source temperature, 50 °C; sample cone, 150 V;
source offset, 150 V; trap collision energy, 4 V; trap DC bias,
45 V; trap gas flow, 10 ml/min; helium cell gas flow, 180 ml/
min; IMS gas flow, 80 ml/min; wave velocity, 700 m/s; wave
amplitude, 35 V. The capillary voltage was adjusted individ-
ually for each measurement (1.3–2 kV). The transfer collision
energy (TCE) was raised from 2 to 220Vin a stepwise manner
(20–30 V steps) to induce protein–protein complex dissocia-
tion. Mass spectra were acquired in positive-ion mode apply-
ing a mass window ofm/z 200–10,000. External mass calibra-
tion was performed with 1 mg/ml sodium iodide dissolved in
an isopropanol/water solution (50:50, v/v). Data acquisition
and processing were performed with the MassLynx software
version 4.1 (Waters MS-Technologies, Manchester, UK) [22].
Data analysis and calculation of gas-phase activation energy
are outlined in the ESM.
In-solution KD value determinations
Real time bio-affinity analyses were performed with the
K5S-Sens® SAW biosensor (SAW Instruments, Bonn,
Germany). The chip surface was cleaned by a 45-min sonica-
tion in 20-ml piranha solution (30% H2O2/H2SO4 1:1) and
subsequent 15 min washing steps with ca. 20 ml deionized
water and with ca. 20 ml ethanol, respectively. When dried,
the plain gold surface of the chip was functionalized by incu-
bating the chip in 30 ml 10 μM 16-mercaptohexadecanoic
acid in CHCl3 at 25 °C for 12–16 h to generate the self-a-
ssembled monolayer (SAM). Afterwards, the SAM was
washed with ca. 5-ml ethanol and the chip was allowed to
dry. The functionalized chip was inserted into the sensor unit
of the instrument, and immobilization of the antibody (ligand)
was performed online in the microfluidic cell of the biosensor
as follows. After washing with immobilization buffer (10 mM
acetate buffer, pH 5) for 30 min, 250 μl of 30 mg/ml EDC
(dissolved in a mixture of 100 mM NHS: 50 mM MES,
pH 6.3) was injected to activate the free carboxyl groups on
the SAM. Ligand molecules were immobilized by injecting
250 μl of IVIG (2.5μg/μl in 10mM acetate buffer, pH 5). The
remaining active sites were quenched by injecting 250 μl of
aqueous 1 M ethanolamine (pH 8.5). A flow rate of 20 μl/min
was maintained throughout the immobilization procedure.
Binding experiments were performed at 22 °C using 10 mM
PBS (pH 7.4) running buffer in a two frequency mode (opti-
mum frequency 150.8 MHz). Serial dilutions of analytes were
prepared after determining stock solution concentrations
(1200 nM, each) using the Qubit® 2.0 Fluorometer
(Invitrogen, Carlsbad, USA) as described above. Sample con-
centrations of 25, 50, 100, 400, and 500 nM (protein G'e); 50,
200, 300, 400, and 500 nM (protein G'f); and 100, 300, 400,
600, and 800 nM (protein G'g) all in 10 mM PBS (pH 7.4)
were used. The measurements (binding curves) were recorded
as changes in the phases of the acoustic waves (in degree) due
to binding as functions of time (in seconds). Data analysis
procedures are described in the ESM.
Results
Method development
To develop a mass spectrometry-based method by which ap-
parent dissociation energies of ionized protein–protein com-
plexes could be investigated in the gas phase, we analyzed the
dissociation behavior of streptavidin tetramer complexes.
Both theoretical considerations as well as details of our
development-oriented investigations are provided in the
ESM (Figs. S1 to S6). The main findings of our studies with
streptavidin are that the RRKM–QE theory can be applied to
describe the dissociation behavior of protein–protein com-
plexes in the gas phase semi-quantitatively and that there is
no need to investigate the dissociation behavior of each indi-
vidual charge state of the protein–protein complex ions sepa-
rately in order to deduce the apparent activation energy of
complex dissociation. Instead, it is easier to perform and well
suitable for calculating dissociation energies when all multiply
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charged ions of a protein–protein complex are simultaneously
submitted to dissociation. The abundance-weighted mean of
charge states of a protein–protein complex (i) can easily be
determined as the maximum position of its precursor ion peak
ensemble and (ii) is subsequently applied for all thermody-
namic calculations.
Analysis of individual proteins and formation of protein
G' complexes with IgG-Fc in-solution
Having established the procedure, we focused on the analysis
of gas-phase dissociation of protein–protein complexes
consisting of the Fc parts of immunoglobulins (IgG-Fc) and
one of three closely related protein G' variants (proteins G'e,
G'f, and G'g). Each protein G' molecule contains three inde-
pendent IgG-binding domains, which according to X-ray crys-
tallography data [23] form part of the binding interface.
Amino acid sequence alignment of the three protein G' vari-
ants (ESM Fig. S7) shows that protein G'e and protein G'g
have identical sequences of the so-called IgG-binding do-
mains I, II, and III as well as of the in-between spacer se-
quences. They differ only in their flanking sequences that
are located on either the N-terminus (protein G'e; FSN) or
on the C-terminus (protein G'g; FSC). By contrast, proteins
G'f and G'e possess similar N-terminal flanking sequences
(FSN), but differ markedly by single amino acid exchanges
in the IgG-binding domains (four of them in the relevant re-
gion). The introduced single amino acid exchanges of protein
G'f have been suggested to increase the overall stability of
protein G'f under basic conditions as compared to that of
protein G'e [24]. All in all, the parts of proteins G'e and G'g
relevant for IgG-binding are identical as opposed to protein
G'f. Comparable IgG binding properties are therefore expect-
ed for proteins G'e and G'g, but a different one for protein G'f.
When the free proteins G' were sprayed from neutral solu-
tions, multiply charged ion series of high intensities with the
highest signals at +10 (G'e) and +9 (G'f and G'g) were ob-
served. Occasionally highly charged, i.e., unfolded proteins
were detected as well with, however, only low signal intensi-
ties (ESM Fig. S8A-C). Protein G'e and protein G'f are known
to be partially gluconoylated [25], yielding satellite ion signals
of these protein species which are not always well resolved
when sprayed under native ESI conditions (ESMFig. S8A-B).
For the non-gluconoylated proteins, we determined molecular
masses, which closely agree with the calculated average
masses of these proteins that were obtained from their amino
acid sequences (Table 1).
When IgG-Fc was analyzed by nano-ESI-MS under neutral
pH conditions, only a few rather broad protein ion signals
were observed in the higherm/z range corresponding to charge
states between 12+ and 15+ with a maximum intensity be-
tween the 13+ and the 14+ signal (ESMFig. S8D). From these
ions, the average molecular mass of ca. 53.4 kDa was
experimentally determined. We had used IgG-Fc from a pool
of polyclonal human IgGs, so several IgG-Fc species were
present with amino acid sequence differences and heteroge-
neous glycosylation, explaining the broad ion signals in the
ESI-MS spectra.
Protein G' isoforms were mixed with IgG-Fc at neutral pH
(7.1), and the resulting protein–protein complexes were ana-
lyzed by nano-ESI-MS (Table 1). All three IgG-Fc•Protein G'
complexes adopted a 1:1 stoichiometry, and their charge state
distributions followed the same trends as did the free protein
G' variants (Fig. 1). Because of slight excess of protein G' in
the mixtures, multiply charged ion signals of free protein G'
variants were seen in the mass spectra as well.
Dissociation of protein G'–IgG-Fc complexes in the gas
phase
The presence of potentially interfering free protein G' ion
signals led us to introduce a filtering step prior to inducing
dissociation of the IgG-Fc•protein G' complexes. We filtered
out ion signals of the unbound protein G' isoforms by ion
mobility separation. The specific arrival time windows in
which the IgG-Fc•protein G' complex ion signals were found
exclusively were determined when collision energy in the
transfer cell was turned off. For dissociation analyses without
interference of either ion signals of unbound protein G' or of
free IgG-Fc, the respective arrival time windows were kept
constant and acceleration voltage in the transfer cell (Vacc)
was raised stepwise from 50 to 220 V. For the IgG-
Fc•protein G'e complex, exclusively ion signals of the com-
plex with charge states from 16+ to 19+ were found until a
transfer cell energy voltage (Vacc) of 70 V (Fig. 2a). The
abundance-weighted mean charge state (m) of this complex
was 17.40+ (Table 1).
Upon further increase of Vacc, the signal intensities of the
complex ions decreased, while those of dissociated constitu-
ents appeared and increased (Fig. 2b–d). Protein G'e, which is
the complex constituent with lower molecular mass, retained
relatively more charges than the larger IgG-Fc. Released pro-
tein G'e carried 13+ to 11+ charges, whereas IgG-Fc retained
6+ or 7+ charges with low intensities. It should be mentioned
that at very high transfer cell energies (Vacc 220 V; cf. Fig. 2e)
substantial peptide backbone cleavage occurred, producing
poorly resolved fragment ions. All gas-phase dissociation ex-
periments were performed in triplicate for each of the three
complexes. Abundance-weighted mean charge states (m) of
17.71+ and 16.33+ were calculated from the charge-state dis-
tributions of IgG-Fc•protein G'f and IgG-Fc•protein G'g com-
plexes, respectively (Table 1).
Using the series of mass spectra that were recorded with
different transfer cell energies, i.e., different center-of-mass
energies of the protein–protein complexes, we next deter-
mined all areas under the ion signals in a given spectrum that
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were present with decent intensities. After summing up all
these areas under the ion signals, e.g., of protein G'e, the
IgG-Fc•protein G'e complex, and their fragments, the ion sig-
nal intensities were normalized to the sum of all peak areas.
The same procedure was applied with the IgG-Fc•protein G'f
and IgG-Fc•protein G'g complex dissociation analyses (ESM
Figs. S9 and S10). Normalized and averaged areas under the
signals (norm. AUS) corresponding to the IgG-Fc•protein G'e
complex and its dissociation products were plotted against
center-of-mass collision energy values (Ecom) (Fig. 3). The
data points were fitted to a sigmoidal curve and showed the
disappearance of the IgG-Fc•protein G'e complex with in-
creasing energy, while the intensities of the ion signals for
the dissociated protein G'e went up to reach a maximum at
around Ecom = 1.5 eV. At higher Ecom, the ion signal intensities
of the backbone fragments increased at the expense of the
intact proteins. Dissociation analysis was performed for IgG-
Fc•protein G'g and IgG-Fc•protein G'f complexes following
the same procedure as described above.
The overlaid normalized AUS curves of all three IgG-
Fc•protein G' complexes (Figure 4a) showed similar
sigmoidal characteristics of complex disappearance with in-
creasing Ecom values. The center-of-mass energy at which
50% of the IgG-Fc•protein G'e and IgG-Fc•protein G'g com-
plexes were dissociated was 1.3 eV. However, in case of the
IgG-Fc•protein G'f complex, 50% dissociation was achieved
already at 1.2 eV (Table 2).
Using the normalized AUS values, we calculated the ap-
parent Gibbs free energy,ΔG#g , in the gas phase for individual
complex dissociation events and plotted them vs. Ecom (Fig.
4b). Interestingly, the slopes (Bn values^) of all three fitted
lines were very similar. A linear free energy (LFE) evaluation,
i.e., linear extrapolation of the lines from the ΔG#g values
provided the apparent activation energy (E#A m0g) of protein–
protein complex dissociation at the intercepts with the y-axis
(Ecom = 0 eV), at which the external energy component is
negligible.
It is apparent that the IgG-Fc•protein G'f complex requires
less activation energy for dissociation than the IgG-Fc•protein
G'e and IgG-Fc•protein G'g complexes, respectively. They
both dissociate at comparable activation energies (Table 2).
Fig. 2 Nano-ESI mass spectra of IgG-Fc•proteinG'e after ion mobility
separation and exposure to different transfer cell energies (TCE; given as
acceleration voltages Vacc). A: 70 V. B: 120 V. C: 150 V. D: 170 V. E:
200 V. Charge states and m/z values for selected ion signals are given for
the complexes (center ion series) and for the respective released protein
G'e (left ion series) and IgG-Fc (right ion series). Solvent: 200 mM
NH4OAc. Ranges with 10-fold or 5-fold magnification are marked; m/z
values of ion signal apexes are labeled. At 200 V, TCE protein ion signals
are superimposed by ion signals from fragments
Fig. 1 NanoESI mass spectra of protein complexes derived from protein
G' isoforms and IgG-Fc. A IgG-Fc•proteinG'e. B IgG-Fc•proteinG'f. C
IgG-Fc•proteinG'g. Charge states and m/z values for selected ion signals
are given for the complexes (right ion series) and for the respective
uncomplexed protein G' isoforms (left ion series). Solvent: 200 mM
NH4OAc
Table 1 Average molecular masses of starting materials and protein–protein complexes
Protein IgG-Fc•proteinG' complex
No. of aa Mr Exp. mass ± stdv., Da Exp. mass ± stdv., Da m
G'e 241 25,999.55 25,999.60 ± 0.09 79,380.20 ± 53.94 17.40
G'f 228 24,415.92 24,415.05 ± 0.16 77,818.48 ± 55.52 17.71
G'g 209 22,809.09 22,809.43 ± 0.10 76,016.77 ± 20.73 16.33
IgG-Fc n.d. n.d. 53,392.70 ± 0.83 n.a. n.d.
aa amino acid residues, m abundance-weighted mean charge state, n.d. not determined, n.a. not applicable
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Since the IgG-Fc•protein G'f complex was found to be less
stable in the gas phase than the complexes with the two other
protein G' isoforms, we conclude that amino acid sequence
differences in the IgG-binding domains playedmore dominant
roles for complex stability as opposed to the flanking se-
quences which seemed to be of lesser importance.
Structural analysis of IgG-Fc complex formation
by protein G'
From X-ray data of protein G', it is known that IgG-binding
domain III is involved in binding to IgG-Fc to a larger degree
than the other two domains. Since mixing of protein G' and
IgG-Fc in solution resulted in a 1:1 stoichiometry, we con-
clude that the 3rd domain of protein G' variants made the most
important contacts to IgG-Fc. Consequently, the differences in
amino acid sequences of the 3rd domains (Fig. 5) between
protein G'e or protein G'g and protein G'f were mostly to be
made responsible for the observed protein–protein complex
stability differences.
As outlined above, the amino acid sequences of the
IgG-binding relevant regions of protein G'e and protein
G'g are identical (Fig. 5, the two upper and lowermost
lines, respectively). Significant deviations within the ac-
tually binding-relevant regions only occur in the third
Fig. 4 A Normalized areas under signals (AUS) plotted as functions of
center-of-mass collision energy for IgG-Fc•proteinG'e (dashed line; filled
squares), IgG-Fc•proteinG'g (dotted line; filled circles), and IgG-
Fc•proteinG'f (solid line; empty squares). Curves are fitted using
Boltzmann functions. B Differences of apparent Gibbs free energies in
the gas phase (ΔG#g ) plotted as functions of center-of-mass collision
energy for IgG-Fc•proteinG'e (dashed line; filled squares), IgG-
Fc•proteinG'g (dotted line; filled circles), and IgG-Fc•proteinG'f (solid
line; empty squares). The intercepts with the y-axis (zoomed insert) give
E#A m0g values
Fig. 3 Normalized areas under signals (AUS) plotted as a function of center-
of-mass energy. AUS of IgG-Fc•proteinG'e (filled pentagons), intact
protein G'e (filled triangles), and fragments (open pentagons) are shown.
Each data point is the mean of three independent measurements, and
standard deviations are shown by vertical bars. A Boltzmann function was
used to fit the curve for the IgG-Fc•proteinG'e complex, a Gaussian function
was used to fit the curve for intact protein G'e, and a logistic function was
used to fit the curve for the protein fragment abundances
Table 2 Comparison of gas phase and in-solution parameters of protein
G' isoforms complexed with IgG(Fc)
Protein Solution Gas phase










G'e 54.8 ± 8.3 1.3 135.7 81.6
G'f 133.0 ± 17.5 1.2 127.2 226.7
G'g 56.0 ± 2.8 1.3 133.1 111.5
a Center-of-mass energies at which 50% of the IgG-Fc•protein G' com-
plexes were dissociated
Fig. 5 Partial amino acid sequences of protein G'e, protein G'g, and
protein G'f regions that are involved in contacts with IgG-Fc. Amino
acid exchanges in the 3rd domains are boxed and numbered
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IgG-binding domain of protein G'f as compared to the
other two protein G'variants (Fig. 5, the two innermost
lines). Out of the four amino acid residues which differ
in the IgG-binding regions of protein G'e or protein G'g as
compared to protein G'f, residue E24 (boxes marked 1 and
1′ in Fig. 5) has been suggested to cause the largest dif-
ference. E24 is involved in hydrogen bonds with residues
R255 and/or K248 of IgG-Fc. Disrupting these hydrogen
bonds, the E24A exchange results in decreased binding
strength of protein G'f to IgG-Fc. By contrast, amino acid
exchanges A29V and N37A (boxes marked 2 and 2′ as
well as 3 and 3′ in Fig. 5) do not affect binding because
the concerned amino acid residues are too remote from
the interface region between the two proteins. Finally,
the carboxyl group of E42 (boxes marked 4 and 4′ in
Fig. 5) is involved in hydrogen bonding with the side
chain of Q311 on the Fc part. However, it was reasoned
that the E42V exchange neither favored nor disfavored
binding, as upon this exchange remote conformational
changes occurred and led to new hydrophobic interactions
between protein G' and IgG-Fc [23].
In-solution dissociation constants of protein G'–IgG
complexes and comparison to gas phase activation
energies
To test whether the differences in gas phase binding be-
tween protein G' isoforms and IgG-Fc are mirroring in-
solution behavior, we determined the dissociation con-
stants (KD s) of the interactions between polyclonal intra-
venous immunoglobulins (IVIG) and the three protein G'
isoforms using a Surface Acoustic Wave Biosensor assay.
The average KD s for IgG–protein G'e binding obtained
from four independent measurements in two measurement
series was 54.8 ± 8.3 nM. For IgG interaction of protein
G'f, an average KD s value of 133.0 ± 17.5 nM and for
protein G'g an average KD s value of 56.0 ± 2.8 nM were
obtained from two independent measurements, each
(Table 2). While the KD s values for protein G'e and pro-
tein G'g were identical within experimental error, that of
protein G'f was roughly twice as high.
The experimentally determined apparent gas-phase acti-
vation energy values (E#A m0gÞ were mathematically trans-
formed into apparent gas-phase dissociation constants
(K#D m0g ). Interestingly, the trends of the gas-phase values
pretty much resembled those from the in-solution analyses.
The K#D m0g values of IgG-Fc•protein G'e and IgG-Fc•G'g
were more or less equal and half of that of IgG-Fc•protein
G'f (Table 2), again indicating the differences in the binding
strengths of the IgG-Fc•protein G'f complex as compared to
the other two complexes.
Discussion
The current study opens the field for rapidly and reliably inves-
tigating protein–protein complex stabilities in the gas phase
using mass spectrometry. Non-covalent complex dissociation
under CID conditions requires an energy input above a critical
threshold and proceeds irreversibly, but (comparatively) slow-
ly. This concerns the fraction of particles, which, according to
the energy-dependent Boltzmann distribution, contain suffi-
cient energy for crossing the dissociation energy barrier.
Hence, within this Btransition energy region^ dissociated com-
plex constituent ions (products) and protein–protein complex
ions (educts) are detectable simultaneously with their respec-
tive relative abundances. Hence, despite the de facto irrevers-
ible character of the dissociation reaction, an apparent equilib-
rium exists (RRKM-QET).
Of note, Ecom50 values do not represent pure internal ener-
gies of protein–protein complexes, as they still contain the
ions’ kinetic energy and charge-related energy increments.
This may explain why in previous reports [26, 27] experimen-
tally determined gas-phase binding strengths did not match
with in-solution binding forces. Hence, for semi-quantitative
evaluation of gas-phase protein–protein complex dissociation,
we emphasize to subtract the ions’ charge-related and kinetic
energy contributions to the dissociation reaction, i.e., correct
for Bexternal^ energy increments, by extrapolation to Ecom = 0.
The linear fit errors by which the intercepts with the y-axis are
determined are within the 10% accuracy of the extrapolation
procedure [28, 29]. Increasing the number of repetitions ren-
ders the method more robust. To limit the inherent effort,
abundance-weighted mean charge states (m) were successfully
applied instead of individual charge-state analyses.
As shown here, dissociation energies of protein–protein
complexes in the gas phase that have been corrected for
Bexternal energy^ contributions seem to represent in-solution
properties of protein–protein complexes well. As was pointed
out in a recent review [30], surface-induced dissociation (SID)
seems to be an alternative to CID breakage of non-covalent
bonds in the gas phase [31, 32]. However, in SID experiments,
charges are distributed proportionally to the masses of
dissociated constituents [33]. Dissociation reactions of any
kind traverse at least one transition state with its associated
energy barrier. This principle applies to both solution [28, 34,
35] and gas-phase reactions [36, 37], thus providing a
common thermodynamic background. In solution, the back-
ward reaction ensures that under equilibrium the system is
limited by the Gibb’s free energy, i.e., the internal energy
difference between product and educt. However, in the gas
phase, since there is no backward reaction, this role is
fulfilled by the Gibb’s free activation energy (here E#A m0gÞ,
representing the energy barrier between ground state and tran-
sition state. Both gas phase and in-solution reactions assume,
with first approximation, linear responses of product
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formation with changing complex energies; thus, nominal sta-
bility values can be obtained by linear extrapolation [38, 39].
This model assumes that dissociation is mostly enthalpy driv-
en and not requiring substantial entropy energy terms (hard
spheres model), and that transition states are comparable, if
not independent, of the ions’ charge states. However, applying
well-established in-solution equilibrium description (i.e.,
LFE; see ESM) to inherently irreversible gas-phase dissocia-
tion processes needs to take into account typical gas phase
reaction features, such as asymmetric charge partitioning
[40–43] and simultaneous (partial) unfolding of the dissociat-
ed complex components [26, 44].
Applying the LFE concept to describe gas-phase dissocia-
tion of protein–protein complexes, i.e., nominal complex sta-
bility values (E#A m0gÞ, we were able to add experimental evi-
dence to the assumption that particular amino acid residues of
the IgG-binding domains of protein G' variants play decisive
roles in high affinity binding to IgG-Fc. Our gas-phase results
not only confirmed what was expected from previous knowl-
edge but also matched the results from in-solution measure-
ments. Only, since desolvation occurs in the source of the
mass spectrometer, hydrophobic interactions that contribute
significantly to non-covalent binding in the liquid phase are
(partially) lost in the gas phase. The (partial) loss of these
hydrophobic forces could be the reason for lower binding
constants observed in the gas phase (K#D m0g) as opposed to
the KD s values (cf. Table 2). However, since this is the first
report on the issue, we do not exclude exceptions to the ob-
servations that have come out from our experiments. With
respect to in-solution data, one should keep in mind that avail-
able software programs typically assume a 1:1 binding stoi-
chiometry [45, 46]. By contrast, our analyses of protein com-
plexes by mass spectrometry provide definite protein–protein
complex stoichiometries.
The method for experimental determination of gas-phase
stabilities of protein–protein complexes, as presented here,
could, e.g., be used for checking whether or not non-
synonymous coding single nucleotide polymorphisms
(nsSNPs) affect protein–protein interactions by comparing
E#A m0g values of wild-type and mutated proteins. Altering
protein function, particularly protein–protein interaction prop-
erties, ultimately may lead to disease [47, 48]. The effects of
nsSNPs, i.e., genomic mutations that cause specific amino
acid substitutions [49], on binding strengths between two pro-
teins can now be analyzed by ESI-MS in detail. To emphasize
the importance, it has been found that a nsSNP variant of
integrin β-2 (CD18) caused a P178L exchange which affects
binding to integrin α-X (CD11) [50]. Patients who carry this
mutation in their genomes suffer from leukocyte adherence
deficiency (LAD) [51, 52]. LAD is clinically characterized
by chronic neutrophilia, impaired wound healing, and severe
life-threatening infections [53]. The huge amount of up to
200,000 nsSNPs in the human population shows the dimen-
sion of the task that awaits to be tackled, and therefore, any
method that helps to characterize stabilities of protein–protein
interactions that is less time-consuming and less expensive as
conventional methodology clearly is of importance to charac-
terize these effects on protein functions [14].
In sum, determination of gas phase stabilities, i.e., apparent
activation energies of dissociation (E#A m0g ) of protein–protein
complexes in the gas phase is a rapid method to obtain useful
information for characterizing protein–protein, protein–me-
tabolite, protein–drug, or protein–nucleic acid interactions
with only little sample consumption.
Acknowledgements We express our thanks to Dr. Stephan Mikkat for
providing expertise on mass spectrometry and to Ms Ursula Glocker for
preliminary technical assistance. We also thank Dr. Marcus Frank for
providing access to the capillary sputter. We acknowledge the German
Academic Exchange Service (DAAD) for providing scholarships for YY
(no. 91523785), BD (no. 91566064), and KO (no. 91548123). The
WATERS Synapt G2S mass spectrometer has been bought through an
EU grant (EFRE-UHROM 9) made available to MOG.
Compliance with ethical standards
Conflict of interest The authors have no conflict of interest to declare.
References
1. Przybylski M, Glocker MO. Electrospray mass spectrometry of
biomacromolecular complexes with noncovalent interactions—
new analytical perspectives for supramolecular chemistry and mo-
lecular recognition processes. Angew Chem Int Ed. 1996;35(8):
807–26. https://doi.org/10.1002/anie.199608061.
2. Loo JA. Studying noncovalent protein complexes by electrospray
ionization mass spectrometry. Mass Spectrom Rev. 1997;16(1):1–
23. https://doi.org/10.1002/(SICI)1098-2787(1997)16.
3. Pagel K, Natan E, Hall Z, Fersht AR, Robinson CV. Intrinsically
disordered p53 and its complexes populate compact conformations
in the gas phase. Angew Chem Int Ed. 2013;52(1):361–5. https://
doi.org/10.1002/anie.201203047.
4. Bornschein RE, Ruotolo BT. Ion mobility-mass spectrometry of
charge-reduced protein complexes reveals general trends in the col-
lisional ejection of compact subunits. Analyst. 2015;14(20):7020–
9. https://doi.org/10.1039/c5an01242b.
5. Chen F, Gulbakan B, Weidmann S, Fagerer SR, Ibanez AJ, Zenobi
R. Applying mass spectrometry to study non-covalent biomolecule
complexes. Mass Spectrom Rev. 2016;35(1):48–70. https://doi.org/
10.1002/mas.21462.
6. Hoaglund CS, Valentine SJ, Sporleder CR, Reilly JP, Clemmer DE.
Three-dimensional ion mobility/TOFMS analysis of electrosprayed
biomolecules. Anal Chem. 1998;70(11):2236–42. https://doi.org/
10.1021/ac980059c.
7. Konijnenberg A, Butterer A, Sobott F. Native ion mobility-mass
spectrometry and related methods in structural biology. Biochim
Biophys Acta. 2013;1834(6):1239–56. https://doi.org/10.1016/j.
bbapap.2012.11.013.
8. Sobott F, Benesch JL, Vierling E, Robinson CV. Subunit exchange
of multimeric protein complexes. Real-time monitoring of subunit
exchange between small heat shock proteins by using electrospray
6556 Yefremova Y. et al.
mass spectrometry. J Biol Chem. 2002;277(41):38921–9. https://
doi.org/10.1074/jbc.M206060200.
9. ZhongYY, Hyung SJ, Ruotolo BT. Ionmobility-mass spectrometry
for structural proteomics. Expert Rev Proteomics. 2012;9(1):47–58.
https://doi.org/10.1586/Epr.11.75.
10. Cooper A (1999) Thermodynamic analysis of biomolecular inter-
actions. Curr Opin Chem biol 3 (5):557-563. https://doi.org/10.
1016/S1367-5931(99)00008-3.
11. Robertson AD, Murphy KP. Protein structure and the energetics of
protein stability. Chem Rev. 1997;97(5):1251–67. https://doi.org/
10.1021/Cr960383c.
12. Erba EB, Barylyuk K, Yang Y, Zenobi R. Quantifying protein-
protein interactions within noncovalent complexes using
electrospray ionization mass spectrometry. Anal Chem.
2011;83(24):9251–9. https://doi.org/10.1021/ac201576e.
13. Jorgensen TJD, Roepstorff P, Heck AJR. Direct determination of
solution binding constants for noncovalent complexes between bac-
terial cell wall peptide analogues and vancomycin group antibiotics
by electrospray ionization mass spectrometry. Anal Chem.
1998;70(20):4427–32. https://doi.org/10.1021/Ac980563h.
14. Krishnaswamy SR, Williams ER, Kirsch JF. Free energies of
protein-protein association determined by electrospray ionization
mass spectrometry correlate accurately with values obtained by
solution methods. Prot Sci. 2006;15(6):1465–75. https://doi.org/
10.1110/ps.062083406.
15. West GM, Tang L, FitzgeraldMC. Thermodynamic analysis of protein
stability and ligand binding using a chemical modification- and mass-
spectrometry based strategy. Anal Chem. 2008;80(11):4175–85.
https://doi.org/10.1021/ac702610a.
16. Cech NB, Enke CG. Practical implications of some recent studies in
electrospray ionization fundamentals. Mass Spectrom Rev.
2001;20(6):362–87. https://doi.org/10.1002/mas.10008.
17. Sinelnikov I, Kitova EN, Klassen JS. Influence of Coulombic re-
pulsion on the dissociation pathways and energetics of multiprotein
complexes in the gas phase. J Am Soc Mass Spectrom. 2007;18(4):
617–31. https://doi.org/10.1016/j.jasms.2006.11.006.
18. Catalina MI, de Mol NJ, Fischer MJE, Heck AJR. Probing factors
affecting the gas phase stabilities of noncovalent complexes formed
by peptides bound to the Grb2 SH2 domain protein. Phys Chem
Chem Phys. 2004;6(10):2572–9. https://doi.org/10.1039/
b315435a.
19. Baer T, Mayer PM. Statistical Rice-Ramsperger-Kassel-Marcus
quasiequilibrium theory calculations in mass spectrometry. J Am
Soc Mass Spectrom. 1997;8(2):103–15. https://doi.org/10.1016/
S1044-0305(96)00212-7.
20. Rosenstock HM, Wallenstein MB, Wahrhaftig AL, Eyring H.
Absolute rate theory for isolated systems and the mass spectra of
polyatomic molecules. Proc Natl Acad Sci U S A. 1952;38(8):667–
78. https://doi.org/10.1073/pnas.38.8.667.
21. Vekey K. Internal energy effects in mass spectrometry. J Mass
Spectrom. 1996;31(5):445–63. https://doi.org/10.1002/(Sici)1096-
9888(199605)31:5<445::Aid-Jms354>3.0.Co;2-G.
22. Yefremova Y, Al-Majdoub M, Opuni KFM, Koy C, Yan Y, Gross
ML, et al. A dynamic model of pH-induced protein G' e higher
order structure changes derived from mass spectrometric analyses.
Anal Chem. 2016;88(1):890–7. https://doi.org/10.1021/acs.
analchem.5b03536.
23. Sauer-Eriksson AE, Kleywegt GJ, Uhlen M, Jones TA. Crystal
structure of the C2 fragment of streptococcal protein G in complex
with the Fc domain of human IgG. Structure. 1995;3(3):265–78.
https://doi.org/10.1016/S0969-2126(01)00157-5.
24. Gulich S, Linhult M, Stahl S, Hober S. Engineering streptococcal
protein G for increased alkaline stability. Protein Eng. 2002;15(10):
835–42. https://doi.org/10.1093/protein/15.10.835.
25. Yefremova Y, Al-Majdoub M, Opuni KFM, Koy C, Cui WD, Yan
YT, et al. "De-novo" amino acid sequence elucidation of protein G'e
by combined "top-down" and "bottom-up" mass spectrometry. J
Am Soc Mass Spectrom. 2015;26(3):482–92. https://doi.org/10.
1007/s13361-014-1053-2.
26. Nesatyy VJ. Gas-phase binding of non-covalent protein complexes
between bovine pancreatic trypsin inhibitor and its target enzymes
studied by electrospray ionization tandem mass spectrometry. J
Mass Spectrom. 2001;36:950–9. https://doi.org/10.1002/jms.199.
27. Nesatyy VJ. Mass spectrometry evaluation of the solution and gas-
phase binding properties of noncovalent protein complexes. Int J
Mass Spectrom. 2002;221:147–61. https://doi.org/10.1016/S1387-
3806(02)00956-9.
28. Pace CN, Shaw KL. Linear extrapolation method of analyzing sol-
vent denaturation curves. Proteins Suppl. 2000;4:1–7. https://doi.
org/10.1002/1097-0134(2000)41:4+3.3.
29. Bolen DW, Santoro MM. Unfolding free energy changes deter-
mined by the linear extrapolation method. 2. Incorporation of delta
G degrees N-U values in a thermodynamic cycle. Biochemistry.
1988;27(21):8069–74. https://doi.org/10.1021/bi00421a014.
30. Yefremova Y, Danquah BD, Opuni KFM, El-Kased RF, Koy C,
Glocker MO (2017) Mass spectrometric characterization of protein
structures and protein complexes in condensed and gas phase. Eur J
Mass Spectrom 23. https://doi.org/10.1177/1469066717722256.
31. Harvey SR, Yan J, Brown JM, Hoyes E, Wysocki VH. Extended
gas-phase trapping followed by surface-induced dissociation of
noncovalent protein complexes. Anal Chem. 2016;88:1218–21.
https://doi.org/10.1021/acs.analchem.5b03479.
32. Quintyn RS, Zhou MW, Yan J, Wysocki VH. Surface-induced dis-
sociation mass spectra as a tool for distinguishing different struc-
tural forms of gas-phasemultimeric protein complexes. Anal Chem.
2015;87:11879–86. https://doi.org/10.1021/ar400223t.
33. Zhou M, Dagan S, Wysocki VH. Protein subunits released by sur-
face collisions of noncovalent complexes: native-like compact
structures revealed by ion mobility mass spectrometry. Angew
Chem Int Ed Engl. 2012;51:4336–9. https://doi.org/10.1002/anie.
201108700.
34. Myers JK, Pace CN, Scholtz JM. Denaturant m values and heat
capacity changes: relation to changes in accessible surface areas
of protein unfolding. Protein Sci. 1995;4(10):2138–48. https://doi.
org/10.1002/pro.5560041020.
35. Pace CN. Determination and analysis of urea and guanidine hydro-
chloride denaturation curves. Methods Enzymol. 1986;131:266–
80. https://doi.org/10.1016/0076-6879(86)31045-0.
36. Drahos L, Vekey K. Entropy evaluation using the kinetic method: is
it feasible? JMass Spectrom. 2003;38(10):1025–42. https://doi.org/
10.1002/jms.538.
37. Wu L, Lemr K, Aggerholm T, Cooks RG. Recognition and quanti-
fication of binary and ternary mixtures of isomeric peptides by the
kinetic method: metal ion and ligand effects on the dissociation of
metal-bound complexes. J Am Soc Mass Spectrom. 2003;14(2):
152–60. https://doi.org/10.1016/S1044-0305(02)00868-1.
38. Parker MJ, Spencer J, Clarke AR. An integrated kinetic analysis of
intermediates and transition states in protein folding reactions. J Mol
Biol. 1995;253(5):771–86. https://doi.org/10.1006/jmbi.1995.0590.
39. Staniforth RA, Burston SG, Smith CJ, Jackson GS, Badcoe IG,
Atkinson T, et al. The energetics and cooperativity of protein fold-
ing: a simple experimental analysis based upon the solvation of
internal residues. Biochemistry. 1993;32(15):3842–51. https://doi.
org/10.1021/bi00066a003.
40. Benesch JL, Ruotolo BT, Simmons DA, Robinson CV. Protein
complexes in the gas phase: technology for structural genomics
and proteomics. Chem Rev. 2007;107(8):3544–67. https://doi.org/
10.1021/cr068289b.
41. Jurchen JC, Williams ER. Origin of asymmetric charge partitioning
in the dissociation of gas-phase protein homodimers. J Am Chem
Soc. 2003;125(9):2817–26. https://doi.org/10.1021/ja0211508.
Apparent activation energies of protein-protein complex dissociation in the gas phase determined by... 6557
42. Sciuto SV, Liu JJ, Konermann L. An electrostatic charge partitioning
model for the dissociation of protein complexes in the gas phase. J
Am Soc Mass Spectrom. 2011;22(10):1679–89. https://doi.org/10.
1007/s13361-011-0205-x.
43. Sobott F, Robinson CV. Characterising electrosprayed biomole-
cules using tandem-MS—the noncovalent GroEL chaperonin as-
sembly. Int J Mass Spectrom. 2004;236(1–3):25–32. https://doi.
org/10.1016/j.ijms.2004.05.010.
44. Benesch JL. Collisional activation of protein complexes: picking up
the pieces. J Am Soc Mass Spectrom. 2009;20(3):341–8. https://
doi.org/10.1016/j.jasms.2008.11.014.
45. Dragusanu M, Petre BA, Slamnoiu S, Vlad C, Tu TT, Przybylski
M. On-line bioaffinity-electrospray mass spectrometry for simulta-
neous detection, identification, and quantification of protein-ligand
interactions. J Am Soc Mass Spectrom. 2010;21(10):1643–8.
https://doi.org/10.1016/j.jasms.2010.06.011.
46. Gronewold TMA. Surface acoustic wave sensors in the
bioanalytical field: recent trends and challenges. Anal Chim Acta.
2007;603(2):119–28. https://doi.org/10.1016/j.aca.2007.09.056.
47. Thomas PD, Kejariwal A. Coding single-nucleotide polymor-
phisms associated with complex vs. Mendelian disease: evolution-
ary evidence for differences in molecular effects. Proc Natl Acad
Sci U S A. 2004;101(43):15398–403. https://doi.org/10.1073/pnas.
0404380101.
48. Zhao N, Han JG, Shyu CR, Korkin D. Determining effects of non-
synonymous SNPs on protein-protein interactions using supervised
and semi-supervised learning. PLoS Comput Biol. 2014;10(5).
ARTN):e1003592. https://doi.org/10.1371/journal.pcbi.1003592.
49. Stunnenberg HG, Hubner NC. Genomics meets proteomics: iden-
tifying the culprits in disease. Hum Genet. 2014;133(6):689–700.
https://doi.org/10.1007/s00439-013-1376-2.
50. David A, Razali R, Wass MN, Sternberg MJ. Protein-protein interac-
tion sites are hot spots for disease-associated nonsynonymous SNPs.
Hum Mutat. 2012;33(2):359–63. https://doi.org/10.1002/humu.21656.
51. Back AL, Kwok WW, Hickstein DD. Identification of two molec-
ular defects in a child with leukocyte adherence deficiency. J Biol
Chem. 1992;267(8):5482–7.
52. Ohashi Y, Yambe T, Tsuchiya S, Kikuchi H, Konno T. Familial
genetic-defect in a case of leukocyte adhesion deficiency. Hum
Mutat. 1993;2(6):458–67. https://doi.org/10.1002/humu.
1380020606.
53. Etzioni A. Adhesion molecules—their role in health and disease.
Pediatr Res. 1996;39(2):191–8. https://doi.org/10.1203/00006450-
199602000-00001.







Analytical and Bioanalytical Chemistry 
 
Electronic Supplementary Material 
 
 
Apparent activation energies of protein-protein complex dissociation  
in the gas-phase determined by electrospray mass spectrometry 
 
Yelena Yefremova, F. Teresa I. Melder, Bright D. Danquah, Kwabena F.M. Opuni,  
Cornelia Koy, Alexandra Ehrens, David Frommholz, Harald Illges, Knut Koelbel, Frank Sobott,  




I) Theoretical background and method development 
 Basic considerations         S3 
 Ion mobility separation of protein complexes    S4 
 Evaluation of CID data of ion mobility-selected streptavidin complexes S6 
 
II) Protein G´ • IgG-Fc 
 Amino acid sequences of protein G´ variants    S9 
 Data on individual complex constituents    S10 
 Collision induced protein-protein complex dissociation   S11 




I) Theoretical background and method development 
Basic considerations 
Thermodynamic evaluation of gas-phase dissociation reactions of protein-protein complexes along well 
established laws for in-solution reactions, such as linear free energy relationships, is derived from 
considering the following facts and simplifications [17-21, 26, 27, 29, 30]: 
1. Both, the protein-protein complex dissociation reaction itself (because of entropy gain of the products) 
and concomitant complex constituent unfolding reactions (due to lack of the hydrophobic effect which 
could drive refolding) are irreversible. 
2. Within the energy “transition region” of the protein-protein complex dissociation reaction, the time 
required for recording single spectra is shorter than that which was needed for reaching complete 
unfolding/dissociation of protein-protein complexes.  
3. Consequently, educt (protein-protein complex) and product (complex constituent) ion signals are 
simultaneously recorded in the corresponding mass spectra with elevated collision energies as 
opposed to the exclusive presence of educt ions in the “baseline region” as well as of only product ions 
in the maximum energy regime (disregarding potential fragmentation).  
These considerations permit application of “Linear Free Energy relations” (LFE).  
 
In-solution thermodynamic methods [10-16] were adapted to gas-phase experiments using the following 
conventions and definitions: 
(1) Normalized area under signal norm. AUS =  
Σ !"# ∗ %%' ()*+,- (1) 
(2) The charge contribution to the kinetic energy was accounted for by converting acceleration voltage 
(Vacc) into center of mass (Ecom) energy: 
 ./01 2!03 = 40 ∗ 5 (2) 
 ."3 = 6 73879 ∗ ./01 2!03 (3) 
(N = mass of the neutral collision gas (here Ar, Mr = 39.95); mp = mass of the protein-protein 
complex ion; z = charge) 
(3) An “in-solution-like” LFE was applied to the “apparent equilibrium”: 
 :;<# = −? ∗ @A BCC%DE"!3.FGHE"!3.FGH # = :;3C<# − n ∗ %."3' (4) 
R = gas constant, n = slope, m = mean of charge state, 0 = at Ecom=0, g = gas phase.  
Principally, the absolute temperature, T, should be a factor in this equation, too, but since it 
cannot be determined with certainty, it was merged with the free enthalpy term. :;3C<#  must, 
therefore, be regarded as apparent.  
(4) Extrapolation towards “zero activation”, at Ecom=0, yields the nominal stability (as opposed to 
observed parameters as threshold values) of complexes. However, because of the de facto 
irreversibility of the dissociation reaction (see above considerations), this value describes not a 
S4 
thermodynamic (equilibrium) stability, but has to be regarded as being proportional to the 
activation energy (.F 3C<# : :; 3C<# C = .F 3C<#  (5) 
 
Plotting normalized AUS curves as functions of the respective lab frame or center-of-mass energies in order 
to obtain valid threshold energies has been accepted standard. But, Coulomb repulsion affects the 
unfolding and dissociation processes (“interface separation”) of protein-protein complex ions in the gas 
phase. This dissociation process comprises two different aspects which need to be considered separately. 
1) the charge impact on kinetic energy itself is conveniently corrected for by plotting the peak areas of 
complex ions and constituent ions, respectively, vs. lab frame or, as in our case, center-of-mass energies 
(Ecom).  
2) charge repulsion - as driving force for separation - is covered by our analysis by extrapolation towards 
Ecom = 0.  
Further correction is not necessary, since we used the respective educt and product abundances (in the 
transition region) at energies that limit formation of charge repulsed products. Principally, this 
simplification is correct as long as the procedure is applied to each charge state separately. Of note, our 
experiments with streptavidin have shown that extrapolation lines from the different charge states are well 
represented by the line that is obtained by the data from the mean of the charge states. 
Therefore, we determined the activation energy (.F 3C<#  at Ecom=0 eV of protein-protein complexes by 
applying “Linear Free Energy relations” (LFE; cf. Figure S6B).  
 
Ion mobility separation of protein complex ions 
Our method was tested by dissociating the streptavidin tetramer (S4) with and without ion mobility 
selection of individual charge states using a Synapt mass spectrometer as described in the Materials and 
Methods section. A streptavidin tetramer (S4) stock solution was prepared by dissolving the commercial 
product (Carl-Roth, Karlsruhe, Germany, article no. 6073, lot no. 025218507; Mr (avg.): 56,116) in 50 mM 
NH4OAc, pH 6.9 (final streptavidin (S4) concentration 1 mg/ml). Buffer exchange, using 50 mM NH4OAc, pH 
6.9 for all steps, protein concentration determination, and spectrum acquisition are described in the 
materials and methods section for IgG-Fc and protein G´-containing solutions. 
Despite the fact that the 16+ streptavidin tetramer ion signal is located at the same m/z position as the 4+ 
streptavidin monomer ion signal, there is no risk of ambiguity in the assignment, since the latter appears at 
clearly different TCE / Ecom values as opposed to that of the first one. When dissociating the individual 






Fig. S1 Ion mobility selection of tetrameric streptavidin ions. A: Precursor ion mass spectrum of the intact streptavidin 
tetramer recorded with 30 V acceleration voltage (TCE). Individual charge states are indicated above the respective 
peaks. B: Arrival time distributions corresponding to the complete spectrum (red) or to the individual charge states 
(same color code as in A). Drift time windows as used for abundance-weighted mean of charge states (m) and charge 
state-specific ion mobility selections (see Fig. S2-S5) are indicated by vertical ticked lines 
 
 
Fig. S2 Collision induced dissociation of 16+ tetrameric streptavidin ion. NanoESI mass spectra of intact and 
dissociated streptavidin tetramers after ion mobility selection of the 16+ charge state and its subsequent collision 




Fig. S3 Collision induced dissociation of 15+ tetrameric streptavidin ion. NanoESI mass spectra of intact and 
dissociated streptavidin tetramers after ion mobility selection of the 15+ charge state and its subsequent collision 
induced dissociation by stepwise increasing transfer cell collision energies (TCE, from bottom to top) 
 
 
Fig. S4 Collision induced dissociation of 14+ tetrameric streptavidin ion. NanoESI mass spectra of intact and 
dissociated streptavidin tetramers after ion mobility selection of the 14+ charge state and its subsequent collision 




Fig. S5 Collision induced dissociation of n+ tetrameric streptavidin ions. NanoESI mass spectra of intact and dissociated 
streptavidin tetramers after ion mobility selection of the abundance-weighted mean of charge states (m) and their 




Evaluation of CID data of ion mobility-selected streptavidin complexes 
From Fig. S2-S5 the unaltered pattern of the highly charged monomeric product ions is apparent – 
regardless of precursor ion charge. Contrarily, the charge states of the respective precursor and dominant 
trimeric product ions correlate strictly. Since the classical asymmetric charge distribution pattern is adhered 
to, ion mobility selection can be conveniently used as surrogate of conventional MS/MS. 
The unfolding/dissociation transitions of tetrameric streptavidin are steep (Fig. S6A), leaving only four to 
five data points for LFE evaluation. The potential error margin depends from either keeping or dropping the 
extreme points from analysis (Fig. S6B). Sufficient numbers of repetitions are therefore required. These, in 
turn, are more conveniently achieved for the complete sets of precursor ion peaks (m) than for each 
individual charge state. So, we widened the drift time window to encompass the complete tetrameric 
ensemble (+16 to +13, m; see Fig. S1) and measured dissociation of tetrameric streptavidin (S4) in triplicate 
(Fig. S5). An abundance-weighted mean of charge state (m) of 14.6+ was calculated using equation 6: 
 m = ∑ 5E ∗ JKL∑ J# (6) 
m = abundance weighted mean of charge state of the tetramer ion series 
Zn = individual charge states of the tetramer ion series 
IZn = individual ion intensities of the tetramer ion series 
∑I = sum of the intensities of the tetramer ion series 
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Fig. S6 Evaluation of streptavidin complex gas-phase stabilities by LFE. A: Series of CID measurements using ion 
mobility-selected (see Fig. S1 for the respective drift time windows) tetrameric streptavidin (S4) were conducted and 
normalized areas under ion signals (normalized AUS) were determined as described. B: LFE evaluation was applied to 
the normalized AUS data. Selected data points were deliberately dropped from analysis to test for their effects on 
resulting deviations (maximum effects are within error bars).  
 
Quite reasonably – as the mean of charge states inherently represents the most intense signal within the 
considered ensemble (+14 and +15 for S4) – LFE evaluation of these data closely resembles the 
corresponding results of the individual charge state-specific measurements. And, since the most intense 
native-MS peaks of a given protein are usually adjacent to each other, LFE evaluation of abundance-
weighted mean of charge states will yield fairly representative .F 3C<#  values for the complete charge state 




II) Protein G´ • IgG-Fc 
Amino acid sequences of protein G´ variants 
 
 
Fig. S7 Amino acid alignment of the three protein G’ variants. The amino acid sequences of proteins G’e, G’g and G’f 
(from top to bottom in each single panel) are aligned with the N- and C-termini shown in italics. Kinked arrows 
encompass the complete IgG binding domains, whereas boxes indicate regions known to be actually involved in IgG 
binding. Distinct domains and linkers of the proteins are labeled individually above the sequences: the N- and C-
terminal flanking sequences (FSN and FSC, respectively), the three IgG binding domains (I-III) and the spacer regions in 






Data on individual complex constituents  
 
 
Fig. S8 NanoESI mass spectra of protein G´ isoforms and IgG-Fc. A: protein G´e. B: protein G´f. C: protein G´g. D: IgG-Fc. 




Collision induced protein-protein complex dissociation 
 
Fig. S9 Collision induced dissociation of the ion mobility-separated IgG-Fc protein G’f complex. The complex was 
prepared and sprayed from 200 mM NH4OAc and measurement series with increasing transfer cell collision energies 
(TCE) were acquired as described. Example spectra recorded at (A) 70 V, (B) 120 V, (C) 150 V, (D) 170 V, and (E) 200 V 
are presented. Charge states and m/z values (from the apex of each peak in question) of released protein G’f product 
ions, IgG-Fc G’f precursor ions as, well as of retained IgG-Fc product ions are labeled. Note: At 200 V TCE signals of 





Fig. S10 Collision induced dissociation of the ion mobility-separated IgG-Fc protein G’g complex. The complex was 
prepared and sprayed from 200 mM NH4OAc and measurement series with increasing transfer cell collision energies 
(TCE) were acquired as described. Example spectra recorded at (A) 70 V, (B) 120 V, (C) 150 V, (D) 170 V, and (E) 200 V 
are presented. Charge states and m/z values (from the apex of each peak in question) of released protein G’g product 
ions, IgG-Fc G’g precursor ions, as well as of retained IgG-Fc product ions are labeled. Note: At 200 V TCE signals of 
intact protein G’g are superimposed by backbone fragment ion signals 
  
S13 
In-solution KD value determinations 
The obtained in-solution data (see Materials and Methods) were stored in the SensMaster software. For 
evaluation of the sensograms the software FitMaster (Rev. 2.0; SAW Instruments, Bonn, Germany) coupled 
with Origin 8.1G (OriginLab corporation, Massachusetts, USA) was used. Fitting of the binding curves was 
done by applying the “1:1 Binding + Residue model” which assumes a permanently bound residue [45, 46]. 
Since the concentration of immobilised antibodies (IVIG) is in excess and remains almost unchanged during 
the interactions, the time course of phase changes that occurred during binding was fitted to a pseudo first 
order kinetics. The pseudo first order kinetic constant (kobs) was determined for the different 
concentrations of analytes using equation (7), where A is the number of bound sites at any given time point 
(t) and Aeq is the number of bound sites at equilibrium between absorption and desorption. 
M, = MN ∗ %1 − expR−S"1 ∗ ,T' (7) 
Next, kobs(n) values determined for different concentrations (c1, c2, … cn) were subjected to linear regression 
described by equation (8). 
S"1E = S"E ∗ +E + S"22 (8) 
A linear regression of concentration of analyte vs kobs(n) was subsequently used to obtain kon and koff values, 
where kon is the slope of the graph, koff is the intercept on the kobs(n) axis, and cn is the concentration of 
analytes. From these, KD s values were calculated according to equation (9). 
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